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The objective of this thesis was to investigate the activity of functionalized 
aminoacridines in neurodegenerative conditions. To this end, a library of forty acridine 
derivatives and several related tetrahydroacridine and quinoline analogues were 
synthesized and evaluated for (i) antiprion activities against different prion strains 
including two mouse strains (RML and 22L) and one human strain (Fukuoka-1) (ii) 
neuroprotection against glutamate-induced oxytosis (iii) anti-acetylcholinesterase and 
anti-butyrylcholinesterase activities. The compounds were classified into seven groups 
based on nature of side chain and ring template. 
Almost all the compounds demonstrated activity on the murine RML strain-
infected neuroblastoma (ScN2a) model, with EC50 values ranging from 0.03 µM to 4 µM. 
A number of compounds were active on the 22L strain-infected cells (N167) model as 
well as cells overexpressing cellular prion (Ch2) model. Most importantly, some Group 2 
and Group 3 compounds were more potent than quinacrine on PrPC-overexpressed 
neuroblastoma cells infected with a human prion strain (F3 model) with EC50 values at a 
low micromolar range. They were also able to clear aggregates of abnormal prion 
proteins (PrPSc) completely at a concentration less than 3 µM. Surface plasmon resonance 
revealed that the compounds bind to PrPC. The high lipophilicity of the 9-aminoacridined 
contributes to its potential to cross the blood brain barrier as demonstrated from the 
PAMPA-BBB assay. One analog which was active on all four tested prion models had a 
lower susceptibility to be a Pgp substrate when tested on a cell monolayer overexpressing 
Pgp. Thus, the 9-aminoacridine template was found to be a promising template from 
 xi
which potential antiprion agents with good in vitro potencies and drug-like properties for 
BBB permeability may be derived.  
      An –NH– group flanked by a phenyl and an acridine is crucial for 
neuroprotection against glutamate-induced oxytosis. The compounds were able to 
“rescue” cells exposed to 5mM glutamate for up to 12 hours. All 9-
(phenylamino)acridines were able to quench ROS level as seen from the TEAC assay. 
These compounds effectively reduced the mitochondrial ROS levels and the intracellular 
Ca2+ level. Both these mechanisms were late-stage events linked to glutamate-induced 
cell death and were proposed to contribute to the latent protective effects of the active 
compounds. 
The optimal ring scaffold for AChE inhibition was the 6-chlorotetrahydroacridine 
ring which had low nanomolar IC50 values. The side chain determined potency and 
selectivity for AChE versus BChE inhibition. The 1-benzyl-4-piperidinyl side chain was 
associated with the most potent activity. Most of the compounds were mixed inhibitors of 
AChE and competitive inhibitors of BChE. Compounds with the 6-
chlorotetrahydroacridine template (Group 6) and those that had 1-benzyl-4-piperidinyl 
side chains attached to the 6-chloro-2-methoxyacridine ring (Group 3) were more 
selective inhibitors of AChE compared to BChE. Docking of active compounds onto the 
crystal structures of AChE and BChE shed light on the binding mode of these 
compounds.  
In conclusion, this thesis had shown that functionalized aminoacridines were 
attractive starting points for the design of compounds for antiprion activity, inhibition of 
 xii
oxytosis and inhibition of AChE.  While structural requirements for these activities were 
different, they are found in compounds that bear a common template. 
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Chapter 1:  Introduction 
Acridine is a nitrogen heteroaromatic compound that is structurally related to 
anthracene (Figure 1.1). In acridine, the –CH= in the central ring of anthracene is 
replaced by an azomethine nitrogen (-N=), the presence of which imparts basicity to the 











Figure 1.1:  Structure and numbering of acridine (also known as dibenzo(b,e)pyridine, 
2,3,5,6-dibenzopyridine, 2,3-benzoquinoline, 10-azaanthracene) 
 
Acridine itself has no therapeutic utility but functionalized acridines like 
aminoacridines, and reduced acridines like tetrahydroacridines are represented in several 
important drugs. This has boosted the reputation of acridine as a privileged scaffold and 
explains the sustained interest in this template for drug design, particularly for agents 
targeted against microbial infection, cancer, neurodegeneration and inflammation.   
 
1.1 Antimicrobial activity 
The first antimicrobial acridines were dyestuffs, namely acriflavine which was 
found to possess activity against the parasitic disease trypanosomiasis by Ehrlich and 
Benda in 1912 and proflavine whose antibacterial activity was reported by Browning in 
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1913.1 Acriflavin was subsequently found to have antibacterial activity, which led to 
widespread use of acriflavin and proflavin as wound antiseptics during the First World 
War. Interest in the antimicrobial activitiy of acridines continued unabated after the War 
and resulted in the development of cyanine and styryl derivatives of quaternary acridines, 
quinolines and phenazines,1 as well as quinacrine which was widely employed as an 
antimalarial substitute for quinine during the ensuing Second World War.2  The post-war 
period of the 1940s and 1950s saw a decline in research interest in the antibacterial 
properties of acridines due to the discovery of the highly efficacious penicillins as 
antibiotics in the 1950s. Nonetheless, antibacterial acridines like proflavin and acriflavin 
are remembered to this day for plugging the “antibacterial gap” between Ehrlich’s 
Salvarsan and Fleming’s penicillin. The research of Steck et al.3 on anti-rickettsial 
acridines and Elslager et al.4 on anti-bacterial acridine N-oxides were the last major 
investigations on the antimicrobial properties of acridines.5 Ironically, it was a better 
understanding of the antibacterial activity of the acridines that caused the waning of 
interest.  
 
Figure 1.2: Structures of early acridine-based antimicrobials.  
 
Nucleic acids are the established sites of action of aminoacridine derivatives in 
bacteria. The planar tricyclic acridine nucleus intercalates perfectly between nucleotide 
base pairs in the DNA helix, with the positively charged acridinium moiety directed 
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towards the negatively-charged phosphate groups. The principal driving forces for 
intercalation are stacking and charge-transfer interactions, with hydrogen bonding and 
electrostatic forces playing stabilization roles. Intercalation destroys the regular helical 
structure of DNA, causing it to unwind at the site of binding and consequently interfering 
with the action of the DNA-binding enzymes (DNA topoisomerases, DNA polymerases). 
In fact, the targeting of nucleic acids by acridines open a new front for their deployment 
as anticancer agents as described in Section 1.2.  However, it also raised misgivings over 
the widespread use of acridines as main stream antibacterials for fear that its intercalating 
properties would result in undesirable frameshift mutagenesis in mammalian cells. These 
fears had since been challenged by investigations demonstrating that simple intercalators 
like acridines were weak clastogens and not associated with widespread mutagenic 
properties.6,7   
The intercalating propensity of the acridine template is influenced by the type of 
substituents on the ring. Introducing bulky substituents such as propyl and tertiary butyl 
groups resulted in analogues that were significantly weak intercalators.8 The presence of 
a methyl group at C2 of 9-aminoacridine was also reported to diminish both DNA 
intercalative ability and mutagenicity.9 
The past decade had seen a modest resurgence in the research on antimicrobial 
acridines, prompted in part by the growing resistance to available drugs. Denny and co-
workers described structure-activity relationships for the antileishmanial and 
antitrypanosomal activities of 1’-substituted-9-anilinoacridines.10 Guetzoyan et al. 
reported new 9-substituted acridyl derivatives that were active against chloroquine-
resistant strains of Plasmodium falciparum.11 Biagini and co-workers designed 
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dihydroacridinediones as potent antimalarials with nanomolar IC50 values and greater 
selectivity for the parasite (and not host) mitochondrial bc1 complex.12 More recently, 
hybrid molecules designed from 4-aminoquinoline and clotrimazole resulted in potent 
and selective antimalarials with promising pharmacokinetic profiles.13 
  
1.2 Anticancer activity 
The ability of the acridine ring to intercalate within the double-stranded DNA 
structure forms the basis of its anticancer activity. For most of these acridines, their 
cytotoxicity is determined not only by its affinity for DNA but the ability to form a 
relatively stable complex with DNA that can inhibit the topoisomerase enzymes. Briefly, 
topoisomerases play a crucial role in the control of the structural organization of DNA in 
cells and in the release of negative and positive constraints generated by DNA 
replication, transcription and repair processes. To release the constraints on the global 
structure of DNA, topoisomerase I makes transient cleavages on one strand of the DNA 
double helix14 while topoisomerase II breaks both strands of the duplex.15,16 This leads to 
the formation of a covalent topoisomerase-DNA complex (“cleavable complex”) which 
in normal cells will break down to restore a native relaxed DNA strand and the free 
functional enzyme. This process can be inhibited at various levels such as the DNA 
binding or DNA cleavage step, but the most potent inhibitory process in terms of cellular 
toxicity is the stabilization of the cleavable complex through inhibition of the re-ligation 
step. Two major families of acridines were identified to act in this manner, namely the 9-
anilinoacidines represented by amsacrine (m-AMSA) and carboxamidoacridines of which 

















Figure 1.3: Structures of representative topoisomerase inhibitors. 
 
Amsacrine (m-AMSA) has been used as an antileukaemic agent since 1976. Its 
mode of action involves the stabilization of the topoisomerase II - DNA complex17 by 
intercalation of the acridine ring18 and specific interactions between the substituted 
aniline ring and the enzyme.19  Modification of substituents on the acridine core and 9-
anilino moiety had resulted in interesting novel AMSA-like derivatives like 3-(9-
acridinylamino)-5-(hydroxymethyl)anilines (AHMA),3 5-(9-acridinylamino) toluidines20  
and anisidines21 which were more potent as anticancer agents and less toxic to the host. 
 While most topoisomerase inhibitors were selective towards either topoisomerase 
I or II, DACA was unusual in its ability to inhibit both enzymes. DACA was evaluated in 
phase II clinical trials for efficacy against non-small cell lung cancer and advanced 
ovarian cancer22,23 but further trials were discontinued in the face of poor results.   
Quadruplex nucleic acids are four-stranded structures comprising short tracts of 
guanine (G)-rich sequences that are held together by intervening sequences (loops).24  
Their occurrence has been extensively characterized at the telomeric ends of eurkaryotic 
chromosomes, whose DNA consists of tandem repeats of the sequence d[(TTAGGG)n] 
and where the extreme 3’ ends are single stranded.25 These guanine-rich single strands 
can adopt higher–ordered and functionally useful G-quadruplexes.26 The induction and 
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stabilization of telomeric G-quadruplexes by small molecules interfere with telomere 
function, inhibit telomerase activity and eventually alter telomere maintenance.27-29  
Telomere maintenance is necessary if cancer cells are to retain their unlimited 
proliferative potential,30,31 thus the design of drugs targeting the telomeric G-quadruplex 
is a rational and promising approach for cancer chemotherapy.32 Several acridines were 
identified as selective ligands for the telomeric G-quadruplex DNA.  These were the 3,6,9 
-trisubstituted analog BRACO-19,33,34 the pentacyclic acridinium RHPS435-37 and 
aminoglycoside-quinacridine conjugates.38 Aminoglycosides were known for their ability 
to recognize RNA residues and this property was exploited to good advantage in the 
conjugates which targeted the RNA element of telomerase.  
 
Figure 1.4: Structures of representative telomerase inhibitors. 
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Acridine derivatives were reported to inhibit cyclin-dependent kinases (CDK) that 
were frequently over-expressed in cancer cells. For example, 3-amino-9-thio(10H)-
acridone (3-ATA) was a selective inhibitor of CDK4. 10-Benzyl-1-hydroxy-3-
morpholinoacridin-9(10H)-one sensitized cancer cells and caused DNA lesions by 












Figure 1.5: Structures of representative acridine-based kinase inhibitors. 
 
Besides amsacrine, the only other acridine derivative in clinical use as an 
anticancer agent is nitracrine [1-nitro-9-(3’,3’–dimethylaminopropylamino)acridine] 
(Figure 1.6). The reduction of the nitro group in nitracrine is one of the activation steps 
leading to covalent binding to DNA and other proteins.40 This process predominated in 




Figure 1.6: Structure of nitracrine (Ledarin ) 
 
1.3 Efficacy in neurodegenerative conditions 
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Only two acridine derivatives have been used for neurodegenerative disorders. 
They are quinacrine for Cruetzfeldt-Jakob disease (CJD) and tacrine for Alzheimer’s 
disease (AD). Quinacrine was found to be effective in a cell-based model of prion 
infection at submicromolar EC50 values.41-43  Although it failed to demonstrate activity in 
scrapie-infected mice,44-46 it was used on compassionate grounds in a few patients with 
CJD. The decision was prompted mainly by the absence of a therapeutic agent for prion 
diseases as well as the relatively good safety record of quinacrine as an antimalarial 
agent.47 Tacrine is an inhibitor of the acetylcholinesterase (AChE) enzyme and the first 
centrally acting AChE inhibitor to be approved for AD. It was used to treat the symptoms 
of the disease but did not offer a curative solution. Tacrine has been largely replaced by 
safer and more effective AChE inhibitors like rivastigmine for Alzheimer’s disease48 but 
it still remains an interesting template for the design of hybrid agents for cognitive 
disorders.49-52 
 
1.3.1. Prion Diseases 
Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), 
belong to a class of neurodegenerative disorders that arise from the misprocessing and 
aggregation of normally benign soluble proteins. The causative agent is the prion protein 
originally defined by Prusiner as “a small proteinaceous infectious particle that is 
resistant to inactivation by most procedures that modify nucleic acid.”53  The only known 
component of the prion is a modified form of the cellular prion protein PrPC, a cell 
surface glycoprotein54 of unknown function that is found in all mammals examined to 
date. The central event in prion pathogenesis is the conformational conversion of PrPC 
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into PrPSc, an insoluble and partially protease resistant isoform that propagates itself by 
imposing its abnormal conformation onto PrPC molecules. The precise molecular 
mechanism of the PrPC to PrPSc conversion is unknown. Two models have been proposed 
to explain this phenomenon. 
 
Figure 1.7: Theoretical models for the formation of PrPSc amyloid from PrPC 
 
 10
Figure 1.7-A shows the template-assisted model which proposed an interaction 
between exogenously introduced PrPSc and endogenous PrPC. PrPSc induced the 
conversion of PrPC to PrPSc, which then aggregated to form the amyloid. Without a PrPSc 
template, spontaneous conversion from PrPC to PrPSc was energetically unfavorable 
because of the presence of a kinetic barrier that favored the thermodynamically more 
stable PrPSc.55 A role for putative heat shock protein (Protein X), presumably as a 
molecular chaperone that binds PrPC  and assists in the change of conformation has been 
proposed.55    
Figure 1.7-B illustrates the “seeding” or nucleation-polymerization model which 
proposed that PrPC and PrPSc existed in a reversible thermodynamic equilibrium.56 In the 
non-disease state, the equilibrium favored PrPC and only small amounts of non-infective 
monomeric PrPSc were present. The monomeric PrPSc slowly assembled to form a highly 
ordered “seed” which recruited more monomeric PrPSc to form large aggregates 
(amyloid). The latter fragmented into smaller infectious seeds which were able to initiate 
further aggregate formation. This model may also apply to amyloid formation in other 
protein misfolding disorders (PMDs) like Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease. Protein conformational changes associated with the pathogenesis of 
most PMDs resulted in the formation of abnormal proteins that were rich in β-sheet 
structures, partially resistant to proteolysis and had a propensity to form larger-order self-
propagating aggregates. 
While the conversion of PrPC to PrPSc is central to the pathogenesis of TSEs, the 
question as to whether PrPSc is directly responsible for the neurodegenerative process 
remains unanswered. More likely, its toxicity depends on some PrPC-dependent process 
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that contributes to neuronal dysfunctions.57,58 The role of PrPC in this context has been 
reviewed59 and is summarized in the following paragraphs. 
(i) Alteration of PrPC mediated signaling: It is noteworthy that depletion of PrPC 
per se did not trigger scrapie pathology. However, when depleted in mice with an 
established prion infection, disease progression was slowed down, even in the presence of 
high levels of extraneuronal PrPSc. The implication was that PrPSc might not be directly 
responsible for neurodegeneration. Rather its toxicity was related to some PrPC-
dependent process that led to neuronal dysfunction and death. PrPC may function as a 
signaling molecule with an important cytoprotective role. Its conversion to PrPSc could 
abrogate this function, thus inducing neurodegeneration. Alternatively, the binding of 
PrPSc to PrPC may trigger a signal transduction pathway leading to neuronal damage.  
  (ii) PrPC mislocalization: PrPC is synthesized, folded and glycosylated in the 
endoplasmic reticulum (ER) where its glycosyl phosphatidylinositol (GPI) anchor is 
added, followed by further modification in the Golgi complex. PrPC was found to assume 
at least two unusual transmembrane topologies in the ER: CtmPrP and NtmPrP which were 
distinguished by having either the COOH or NH2 terminus in the endoplasmic reticulum 
lumen respectively. These misfolded and aberrantly processed PrP forms normally 
comprise a small proportion of cellular PrPC but may increase in some PrP mutations. 
Such an increase could lead to neurotoxicity even without PrPSc formation. Under normal 
circumstances, misfolded (and wild type) forms of PrPC underwent retrograde transport to 
the cytosol where they were ubiquitinylated and degraded by the proteasome through a 
process called ER-associated degradation pathway. When this pathway was overwhelmed 
(as would happen during proteosomal inhibition or malfunction during prion disease), the 
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excess PrP molecules were routed to the cytoplasm where they accumulated and caused 
neurotoxicity. Therefore aberrant PrPC trafficking leading to mislocalization may 
contribute to PrPSc associated neurotoxicity.  
(iii) PrP-derived oligomeric species: The currently accepted view of the causative 
agents of prion disease are not the highly organized amyloidal aggregates but the smaller 
oligomeric species of approximately 20 molecules.60 The toxicity of small aggregates has 
also been proposed for Alzheimer’s disease61,62 and Parkinson’s disease.63 The disease 
potential of small aggregates may exceed that of large aggregates because small 
aggregates expose a higher proportion of residues on their surfaces. These residues may 
be normally buried within the core of the protein but are uncovered during the misfolding 
process and can participate in improper interactions with cellular components such as cell 
membranes, metabolites, proteins or other macromolecules that would ultimately lead to 
the malfunctioning of the cellular machinery.64 
 
1.3.2. Oxidative stress and protein misfolding diseases 
Although each protein misfolding disorder has its own molecular mechanisms and 
clinical symptoms, some general pathways are recognized in the different pathogenic 
cascades. Protein misfolding and aggregation is one common feature. Yet another is the 
role of oxidative stress and free radical formation as either a cause or consequence of the 
neurodegenerative cascade.65 The brain is highly susceptible to oxidative stress-related 
degeneration for many reasons. Neural cells are rich in mitochondrial content and possess 
a high level of aerobic metabolism. Invariably a proportion of the consumed oxygen will 
end up as incompletely reduced reactive oxygen species (ROS). Brain tissue is also very 
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sensitive to oxidative stress due to low levels of some antioxidant enzymes, susceptibility 
of brain membranes to peroxidation and high content of iron.66 There is mounting 
evidence that neurodegenerative disorders further increase the oxidant load and thus 
subject the brain to further oxidative stress.  Pappolla et al. presented in vitro and in vivo 
models in support of the hypothesis that the neurotoxicity of the Aβ protein in 
Alzheimer’s disease was mediated by free radicals.67 Antioxidant enzymes such as 
catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase were 
elevated, an indication that oxidative stress plays a significant but as yet undefined role in 
this disorder.68,69 Oxidative biomarkers such as cholesterol hydroperoxide, 
malondialdehyde, protein adducts of 4-hydroxy-2-nonenal and 8-hydroxy-2-
deoxyguanosine were detected in higher levels in Parkinson’s disease.70,71 Analysis of the 
dopaminergic neurons in patients with Parkinson’s disease revealed a significant decline 
in reduced glutathione (>60%) and a moderate increase in oxidized glutathione (29%) 
levels.72,73 Oxidative stress markers such as malondialdehyde and heme oxygenase-1, as 
well as superoxide radicals were markedly elevated in the brains of scrapie-infected mice. 
The mitochondrial manganese-superoxide dismutase was substantially decreased in these 
mice.74 Analysis of the brains of CJD patients and scrapie-infected Syrian hamsters 
revealed elevated levels of products of oxidation, lipoxidation, and glycoxidation.75 
However, the administration of one or a few antioxidants to address the problem of 
neurodegeneration would be naïve and several clinical studies had shown limited benefits 
with this approach.76  In view of the multifactorial nature of neurodegenerative diseases 
and the fact that cells can often exploit the redundancy of the system to compensate for a 
protein whose activity was moderated by a drug, Melchiorre and co-workers proposed 
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multi-targeting drugs against neurodegenerative disorders instead of the current practice 
of deploying “one-molecule, one-target”-type of therapeutics.77 
 
1.3.3 Prion diseases and other protein misfolding conditions 
Prion diseases share similar underlying pathogenic conditions with other 
neurodegenerative diseases like Alzheimer’s, Huntington’s, Parkinson’s diseases, Lewy 
Body dementia. The underlying pathogenesis is the conversion of a soluble protein into 
an insoluble isoform, leading to an accumulation of abnormal protein mass78. In 
Huntington’s disease, fragments of the Huntingtin proteins aggregate to form toxic 
inclusion bodies within brain cells.79 The hallmark in Parkinson’s disease and Lewy 
Body dementia is an abnormal accumulation of the α-synuclein protein bound to 
ubiquitin forming Lewy bodies. In Alzheimer’s disease, normal soluble amyloid-β 
peptide (sAβ) is converted to Aβ plaques, forming neuritic plaques. In prion diseases, the 
central event is conversion of soluble cellular prion protein (PrPC) to insoluble scrapie 
prion protein (PrPSc). Both Aβ and PrPSc are rich in β-sheet content. Common early 
neurologic symptoms are memory loss, speech impairment, jerky movements, balance 
and coordination dysfunction. These diseases are all caused by formation of insoluble 
misfolded proteins. All of these disorders except prion diseases are not infectious.78 
There are evidences of interconnection between AD and prion pathologies. AD 
and CJD share a common spatial pattern of protein deposition.80 Recently, there are fresh 
findings that link PrPC to the culprit of Alzheimer’s disease, amyloid-β (Aβ) peptides. 
Aβ-positive senile plaques in AD brains commonly contain PrP deposit81 while they are 
also identified in brains of CJD and GSS patients.82 Lauren et al.83 have found out that 
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PrPC has greater affinity for Aβ oligomers than for monomeric and non-toxic Aβ. Aβ 
oligomers inhibit long-term potentiation, which is a measure of synaptic plasticity related 
to learning and memory, in hippocampal slices from normal mice, but not in slices from 
mice lacking PrPC.83 Thus PrPC seems to be a main receptor for Aβ oligomers and 
mediates synaptic dysfunction. On the other hand, Pera et al.84 showed that AChE, well-
known for triggering amyloid plaques formation in Alzheimer’s disease, also accelerated 
the fibrillization of amyloid plaques in brains of patients with GSS. In contrast, PrPC was 
reported to promote β-amyloid plaque formation in mice.81 
 
1.3.4. The antiprion activity of quinacrine and other acridine derivatives  
Quinacrine is a potent antiprion compound in cell culture models of prion 
disease85,86 but failed to demonstrate efficacy in infected animals9,87,88 and human clinical 
trials.89 Besides quinacrine, other acridines have been explored for antiprion activity. 
May and co-workers90 found bis-acridines like compound A (Figure 1.8) to have more 
potent in vitro antiprion activity than quinacrine. Csuk et al. found that replacing the 2-
methoxy-6-chloro substituents on the two acridine rings with 3-nitro-5-methoxy 
improved antiprion activity.91  Klingenstein and co-workers13  observed the synergistic 
antiprion effects of quinacrine and iminodibenzyl-derived antidepressants, and this led to 
the synthesis of potent hybrid molecules like quinpramine (corresponding to fused 
quinacrine and imipramine moieties) and compound B (EC50 of 20 nM in cell based 
assay).92 Investigations into the structure-activity relationships of quinacrine showed that 
antiprion activity was influenced by several structural features, namely, the length of the 
alkyl linker attached to the 9-amino functionality, the groups attached to the distal tertiary 
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amino group of the alkyl side chain and the substitution pattern on the acridine ring.42,93  
The latter feature was also identified as an important determinant of cellular cytotoxicity. 
For example, 3-fluoro-6-methoxy-4-methyl groups were associated with greater 
cytotoxicity than 2-methoxy-6-chloro groups on the acridine ring of quinacrine.93 Cope 
and co-workers synthesized several substituted N-phenylacridin-9-amines and found 
electron withdrawing groups on the N-phenyl ring to be particularly favorable for 
activity. The most promising compound in their series (Compound C, Figure 1.8) had an 
EC50 of 1.0-2.5 µM on the scrapie mouse brain (SMB) cell model.94 
 








Pharmacokinetic factors have often been cited for the failure of quinacrine 
therapy in prion infected animals and human subjects.95,96 The insufficient accumulation 
of quinacrine in the infected brain was attributed to its active efflux by ABCB1 (p-
glycoprotein)95 which is found in the blood brain barrier and widely linked to multidrug 
resistance.97,98 Indeed, it was shown that when administered orally to mice that had mdr 
genes deleted (MDRo/o), brain levels of quinacrine exceeded 100 µM.99 Despite this high 
concentration in the brain, it still failed to extend the survival times of prion inoculated 
MDRo/o mice.99 These results suggested that the failure of quinacrine in vivo was not 
solely due to its pharmacokinetic properties. The authors proposed that chronic 
quinacrine treatment eliminated a specific subset of PrPSc conformers, resulting in the 
survival of drug-resistant prion conformations that could not be removed by continued 
drug treatment.99 Interestingly, the quinacrine-resistant conformers could not propagate in 
the absence of quinacrine and thus should not be considered as a stably propagating 
strain. The formation of quinacrine-resistant prions was evident only in cells that were 
not actively dividing, possibly because the probability of a partially resistant 
conformation surviving drug treatment would be increased in quiescent but not actively 
dividing cells. If this was the case, then screening for antiprion compounds in quiescent 
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cells rather would offer a better chance of identifying compounds that were effective in 
vivo.99 
The suggestion that continuous quinacrine treatment is associated with the 
emergence of drug-resistant prions should not diminish interest in the antiprion potential 
of quinacrine/acridine analogs. It should be noted that drug-resistant prions emerged only 
on chronic dosing of quinacrine (40 mg/kg/day) for up to 60 days (given at 10-day 
intervals). The fact that untreated control mice could tolerate this regimen confirmed the 
remarkable safety profile of quinacrine, a property that may be shared by other 
structurally-related acridine analogs. It results in the need of compounds that combine 
greater antiprion potency with a better pharmacokinetic profile than quinacrine, which 
would make high dosing regimens unnecessary and possibly diminish the probability of 
resistance. In due course, the co-administration of multiple antiprion compounds may be 
a necessary step to keep resistance at bay.  
 The mechanism of action of quinacrine in prion disease remains unknown. A 
direct interaction with PrPC was unlikely as demonstrated from investigations employing 
surface plasmon resonance100 and NMR spectroscopy.101 Phuan et al. suggested that the 
9-aminoacridines like quinacrine bind to PrPSc and inhibited its replication by occluding 
necessary epitopes for templating PrPC conversion or by altering the stability of PrPSc 
oligomers.102 A site on PrPC (alpha helix 2) located near the “protein X” epitope, a 
hypothetical factor that participates in the conformational transformation of cellular prion 
proteins (PrPC) into the scrapie form was proposed based on NMR spectroscopy.103 
Turnbull et al.104 proposed that quinacrine was an antioxidant and that this property was 
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linked to the ability of quinacrine to reduce the toxicity of the prion peptide PrP106-126 
which shared several similarities to PrPSc. 
 
1.4. Statement of purpose 
The acridine template is a privileged scaffold that is associated with antimicrobial, 
anticancer and neuroprotective activities. The objective of this thesis was to investigate 
functionalized aminoacridines for their activity against prion diseases, a class of protein 
misfolding disorders associated with severe neurodegeneration and death. Quinacrine is 
the prototype aminoacridine derivative that has been widely investigated for its antiprion 
properties. Not withstanding its limitations as a CNS targeting agent for prion disease 
(Pgp substrate, moderate potency, poor in vivo properties, likelihood of resistance), the 
literature has shown that it is a fruitful lead structure which on structural modification had 
yielded promising analogues with improved antiprion potencies. The bis-acridine 
(Compound A) and the quinacrine-imipramine hybrid molecules quinpramine and 
compound B are examples (Figure 1.8). Despite their improved potencies, the limited 
follow up on the antiprion activities of these compounds in the literature did not bode 
well. A likely deterrent to clinical application may be the accessibility of these agents to 
the brain which is the site of action of antiprion agents. The above mentioned compounds 
had molecular weights that exceeded 500D (quinacrine 399D), lipophilicities (estimated 
by ClogP) that were greater than that of quinacrine and with more hydrogen (H) bond 
donor and acceptor atoms. These features would deter penetration across the blood brain 
barrier.105 It is proposed that a more profitable approach would be to focus on smaller and 
less lipophilic mono-acridines and to carry out modifications that would not lead to overt 
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increases in size, lipophilicity and H bonding ability as these features would disqualify 
the resulting compound from further pharmaceutical development. To examine this 
proposal, modifications were made to (i) the side chain at the 9-amino position and (ii) 
the acridine ring, namely to replace it with the bicyclic quinoline and the partially 
reduced tetrahydroacridine template. The objective was to establish how these 
modifications affected antiprion activity and access across the blood brain barrier. 
There is broad agreement in the scientific community that the multi-factorial 
nature of neurodegenerative disorders would benefit from a multi-target therapeutic 
approach and that structural scaffolds with this property would be valuable starting 
templates for drug design. Thus, a related aspect of this thesis was to investigate the 
ability of the synthesized acridine derivatives to exert neuroprotective activity. Here the 
ability to protect against glutamate-induced oxytosis (a process that depletes cells of 
glutathione, the major intracellular antioxidant) and inhibit acetylcholinesterase activity 
(a recognized target for cognitive and movement disorders) would be explored. The 
purpose was to establish the potential of the aminoacridine analogs to act on one or more 
targets linked to neurodegenerative conditions. 
To achieve these objectives, the following work was planned: 
(i) Design and synthesize acridine analogues based on the lead compounds 
reported in literature, e.g. quinacrine and tacrine, with the aim to fulfill the structure-
activity relationships for the three biological activities including antiprion, 
neuroprotective, and anticholinesterase activities (Chapter 2). 
(ii) Screen compounds for antiprion activities using several cell lines infected 
with different prion strains and investigate compounds’ effects on expression of total 
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PrPC and cell surface PrPC levels as well as their binding affinities to PrPC using surface 
plasmon resonance. The blood brain barrier permeabilities of these compounds were also 
investigated in a cell free system as well as a cell-based assay. (Chapter 3). 
(iii) Screen compounds for neuroprotective activity using a murine 
hippocampal cells challenged with a high concentration of glutamate to induce oxytosis. 
Mechanisms of action of these compounds investigated include ROS scavenging, 
inhibition of calcium influx, and effect on glutathione synthesis (Chapter 4). 
(iv) Screen compounds for acetylcholinesterase and butyrylcholinesterase 
inhibition and investigate binding poses of these compounds with the two above enzymes 
using molecular docking simulation. (Chapter 5). 
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Chapter 2: Design and synthesis of 9-aminoacridine analogs 
 
2.1 Introduction 
The design and synthesis of target compounds evaluated for antiprion and 
neuroprotective activities are described in this chapter.  The compounds were structurally 
related to quinacrine (Figure 2.1) and were assigned to 7 groups based on their structural 
features. A search on the SciFinder Scholar (March 2010) showed that 29 of the 60 target 
compounds were novel. Some of the compounds presented in this chapter were 
synthesized by other members of the laboratory. Compounds 1-6, and 9 were prepared by 
Dr Lee Chong Yew; compounds 8, 10, 11, and 46 by Dr Liu Jianchao; compound 48 by 






Figure 2.1. Structure of quinacrine. 
Compounds were designed at two stages. The first batch included compounds 1-
16, 32, 44, 46-48. Inspired by their antiprion actitivies and neuroprotective activity, the 
rest of the compounds were designed to further explore the potential of emerging 
templates. 
 
2.2 Design Approach 
In keeping with the design approach which was based on quinacrine as the lead 
structure, nearly ¾ of the compounds retained the 2-methoxy-6-chloro-9-aminoacridinyl 
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motif of quinacrine. Variations were made to the side chain attached to the 9-amino 
functionality. 
 
2.2.1. Group 1  
Table 2.1: Structures of compounds in Group 1 
Compound Substituent (R) 
1# n=2, R=C2H5 
2# n=3, R=CH3 








4# n=4, R=C2H5 
 
The compounds in Group 1 (1-4) retained the dialkylaminoalkyl side chain of 
quinacrine (Table 2.1). The alkyl chain separating the two nitrogen atoms varied from 2 
to 4 carbon atoms and the substitution state of the distal tertiary nitrogen was similar to 
quinacrine (N,N-diethylamino), except for 3 where it was N,N-dimethylamino. A notable 
modification was the absence of branching in the side chain of Group 1 compounds, 
unlike quinacrine. Hence, the compounds were achiral in contrast to quinacrine which is 
chiral. It was reported that the (S)-quinacrine had more in vitro antiprion activity than 
(R)-quinacrine.106 No stereoselectivity was reported for the antimalarial activity of 
quinacrine.107  The decision to synthesize Group 1 compounds without the chiral centre 
was based on the following reasons: (i) to facilitate synthesis and purification; (ii) to 
investigate the importance of a chiral side chain for antiprion activity.  
                                                 
# Compound was synthesized by other lab members. 
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2.2.2. Group 2  
An aliphatic side chain attached to the 9-amino group of the 9-aminoacridine 
template was reported to be essential for the inhibition of PrPC to PrPSc conversion.108  
Less is known of how an aromatic or heterocyclic ring at this position would affect 
activity. For this reason, a series of functionalized 9-N-phenylaminoacridines (Group 2, 
Table 2.2) and 9-N-(4-piperidinyl)aminoacridines (Group 3, Table 2.3) were prepared. 
The first batch of compounds that were synthesized and evaluated was those that had 
basic functionalities attached to the phenyl ring (5-16). Only tertiary amines 
(dimethylamino, diethylamino, various heterocyclic amines like pyrrolidine, piperidine, 
morpholine, 4-methylpiperazine) attached (mostly) to the meta (3’) and para (4’) 
positions of the aromatic ring were examined, in part to mimic the distal tertiary amino 
function of quinacrine. The analog with the 4’-(4-methylpiperazin-1-yl) side chain (16) 
was found to possess promising in vitro antiprion activity and this prompted further 
structural variation of the 4-methylpiperazinyl moiety. These variations were (i) replacing 
the methyl group with its ethyl homolog (17) and the more hydrophilic 3-hydroxypropyl 
sidechain (18), (ii) converting the distal basic nitrogen of piperazine into a non-basic 
amide by attaching a methylcarbonyl (19), cyclohexylcarbonyl (20) or phenylcarbonyl 
(21) moiety, and (iii) inserting an additional methylene (22) or carbonyl (20) group 
between the phenyl and piperazine rings. A piperidyl analogue of 22 was also prepared 
(24). A small number of compounds (25-31) in Group 2 have non-basic groups (H, 
OCH3, OH, F, CN) on the phenyl ring. These compounds were not evaluated for 
antiprion activity but were tested for neuroprotective and antioxidant properties. The 
substituents were selected to ensure adequate coverage of Hansch σ (electron donating / 
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withdrawing) and Hammett π (lipophilicity) values as guided by the Craig Plot.109  Mono 
and dihydroxy substituents (30, 31) are included in view of their free radical quenching 
potential. 









Compound Substituent (R) Compound Substituent (R) 
5# 2’-N(CH3)2 6# 3’-N(CH3)2 
7 4’-N(CH3)2 8# 3’-N(C2H5)2 






























                                                 
# Compound was synthesized by other lab members. 















25 H 26 4’-CN 
27* 4’-F 28* 3’,4’-diF 
29 4’-OCH3 30* 3’-OH 
31* 3’,4’-diOH   
 
2.2.3. Group 3 
The Group 3 compounds had an N-substituted piperidine attached to the 9-amino 
group. The first compound to be synthesized was 32 which had a N-(1-benzylpiperidin-4-
yl) sidechain. 32 was found to have outstanding in vitro antiprion activity and this 
prompted further variation of the benzyl side chain to give the other compounds (33-41) 
in Group 3. The variations included: (i) preparing homologs of the benzyl ring (n=1 to 
n=3) and (ii) introducing representative groups with different Hansch σ and Hammett π 
values on the phenyl ring. Attention is drawn to compounds 24 and 32 which differed in 






                                                 
* Novel compound 
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Table 2.3: Structures of compounds in Group 3 
Compound Substituent 
32 n=1, R=H 
33* n=1, R=CH3 
34* n=1, R=Cl 
35* n=1, R=OCH3 
36* n=1, R=CN 
37* n=2, R=H 
38* n=2, R=CH3 
39* n=2, R=Cl 








41* n=3, R=H 
 
2.2.4. Group 4 
Group 4 comprise miscellaneous compounds that were synthesized to address 
specific structure-activity relationship (SAR) issues (Table 2.4). To determine the 
importance of the N-substituted secondary amino function at position 9 of the acridine 
ring, compounds 44-46 were proposed. 44 was a common intermediate in the synthesis of 
Group 1 and 2 compounds and had a phenoxy group in place of the amino functionality. 
To assess the importance of a secondary amino function at position 9, 46 (primary amino) 
and 45 (tertiary amino) were synthesized. The remaining two compounds (42, 43) were 
structurally related to 16 and 32 respectively. In 42, the phenyl ring was replaced by 
butenyl-2,3, a moiety often considered as an aromatic ring equivalent because it is 
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electron rich, can participate in π-π stacking interactions and is structurally constrained 
like the aromatic ring.110 43 and 32 were structurally related in that the flexible piperidine 
ring of 32 was replaced by the conformationally more rigid 8-azabicyclo[3.2.1]oct-8-yl 
ring. With two additional methylene groups, 43 is also bulkier and more lipophilic than 
32.    





















46# NH2   
 
2.2.5. Group 5 
To evaluate the importance of the 2-methoxy and 6-chloro substituents on the 
acridine template, compounds without these two substituents were synthesized (Table 
2.5) Only two compounds (47, 48) were synthesized in this Group in spite of several 
attempts to prepare more analogs.85  This template appears to have limited stability.111  
 
                                                 
∗ Novel compound 
# Compound was synthesized by other lab members. 
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Table 2.5: Structures of compounds in Group 5 









2.2.6. Groups 6 and 7 
In Groups 6 and 7, the acridine ring was replaced by 3-chloro-5,6,7,8-
tetrahydroacridine and 7-chloroquinoline respectively (Tables 2.6 and 2.7). The 
tetrahydroacridine ring is less planar than acridine but just as lipophilic while the 
quinoline ring will be as planar but less bulky compared to acridine. These ring structures 
may have diminished DNA-intercalating properties. Like the compounds in the other 
groups, the 9-amino (of Group 6) and 4-amino (of Group 7) were substituted with 
representative aliphatic, phenyl and piperidine side chains. Notable inclusions were the 
N-[4’-(4-methylpiperazin-1-yl)phenyl and N- (1-benzylpiperidin-4-yl)  side chains found 
in the promising compounds 16 and 32 respectively.   
 
 




                                                 
+ Compound was purchased from Sigma Aldrich. 
# Compound was synthesized by other lab members. 
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Compound Substituent (R) Compound Substituent (R) 




























Compound Substituent (R) Compound Substituent (R) 
























2.3. Chemical Considerations 
                                                 
* Novel compound 
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2.3.1. N-substituted 9-aminoacridines 
As most of the compounds synthesized in this thesis were 9-aminoacridines, the 
physicochemical properties and reactivities of this structure are briefly discussed in this 
section. 9-Aminoacridine is a stronger base (pKa ca 10) than acridine (pKa ca 5).112 In the 
present series of compounds, the 9-aminoacridine ring was substituted with 2-methoxy 
(electron donating) and 6-chloro (electron withdrawing) groups. These groups were not 













Figure 2.2: Canonical structures of 9-aminoacridine. 
In the aromatic 9-aminoacridine system, the attached amino group is sp2-
hybridized, and in conjugation with the ring nitrogen (Figure 2.2). This renders the ring 
nitrogen basic, and protonation occurs preferentially at this site. However, when bulky 
groups are attached to the amine nitrogen, these force the N atom out of coplanarity, and 
disrupt the conjugation. When this happened, the 9-amino group would be susceptible to 
displacement by nucleophiles, like water (Figure 2.3).112 
 
Figure 2.3: Formation of 9-acridone due to nucleophilic attack by water on the 9-
substituted amino acridine (R1 and R2 are bulky groups). 
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Goodell and co-workers investigated the effect of steric bulk at the 9-substituted 
amino group on the rate of hydrolysis of the resulting compound.111 Their findings are 
summarized as follows: 
(i) 9-Aminoacridines with dimethylaminoethyl or dimethylaminopropyl side 
chains attached to the 9-amino group were susceptible to hydrolysis at a pH that was 
close to the pKa value of the distal tertiary amino groups (ca 8-10) and higher. At acidic 
pH, the compounds were stable because the distal tertiary amino group was protonated 
and assumed an extended conformation to minimize charge repulsion with the positively 
charged 9-amino group. In contrast, at higher pH, more of the non-protonated side chain 
was present and intramolecular H bonding occurred (Figure 2.4). As a result, steric bulk 
at the vicinity of the 9-amino group was increased, co-planarity was compromised and 
hydrolysis was accelerated. This finding is relevant to the Group 1 compounds and serves 
to highlight the importance of avoiding high pH values (>7.5) when evaluating biological 
activity. 
 
Figure 2.4: Illustration of the proposed intramolecular hydrogen bond in Group 1 
compounds. 
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(ii) The 9-aminoacridine with a benzylpiperidinyl side chain (like 32 in Group 3) 
was found to be remarkably stable over pH 5-10. The inflexibility of the side chain would 
make intramolecular H bonding highly improbable. Thus there is minimal steric bulk at 
the 9-amino group and this permits electron delocalization to occur unimpeded. 
(iii) The 9-aminoacridine with an N-(4-methylpiperazin-1-yl) side chain (Figure 
2.5) was found to be unstable over the pH range of 5-10. The added constraint of the 
piperazine ring is likely to force the ring out of plane, resulting in hydrolysis at C9-N 
bond.   
 
Figure 2.5 : 9-aminoacridine analog with N-(4-methylpiperazin-1-yl) side chain.111 
9-Aminoacridines have been reported to undergo partial amine exchange 
reactions in organic solvents.113 The mechanism of reaction was proposed to proceed 



























Scheme 2.1: Proposed mechanism for reversible amine exchange reaction on 9-
aminoacridine.113 
 34
This reaction was influenced by the strength of the C9-N11 bond. Thus, as steric 
interactions around the C9 position increased, the C9-N11 bond was weakened making it 
susceptible to amine displacement. The occurrence of amine exchange was unlikely to 
pose as a complicating factor in the synthetic reactions explored in this report because 
only one amine was present at any one time in the reaction mixture. However, the 
likelihood of displacement of the 9-substituted amino function of the functionalized 
acridine under physiological conditions should not be discounted. Paul and Ladame113 
proposed that the telomerase inhibitor BRACO-19 participated in an amine exchange 
reaction in vivo and that this may have implications on its mode of action.  
 
2.3.2. General approach to the synthesis of the 9-aminoacridines of Group 1-5.  
The Group 1-5 aminoacridines were synthesized by reacting 6,9-dichloro-2-
methoxyacridine or 6-chloroacridine (in the case of Group 5) with the corresponding 
amine in the presence of catalytic HCl in ethanol as solvent (Scheme 2.2)43,114 or via the 
formation of phenoxy intermediates (Scheme 2.3).43,92 
 
Scheme 2.2: Ethanol, cat. HCl, reflux, 24 hours. 
 
Scheme 2.3: a) 1h, 100oC b) 4-5 h, 100oC. 
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In both instances, the mechanism of reaction involved the displacement of the 9-
chloro atom by the nucleophilic amine or phenol. The C9-Cl was selectively displaced in 
preference to the C6-Cl because of its proximity to the electron withdrawing N of the ring 
and the stability of the resulting intermediate. When the reaction was carried out in 
presence of HCl/ethanol, the acridine N was protonated and this served to further increase 
the electrophilicity of C9 (Figure 2.5). However, the attacking amine would also be 



















Figure 2.5: Nucleophilic substitution of 9-Cl  by amine. 
 
When the reaction was carried out in phenol as solvent, a phenoxide intermediate 
was formed in situ and subsequently displaced by the reacting amine.111 As the reaction 
was not carried out under acidic conditions, C9 would be activated by the non-protonated 
acridine N (weaker electron withdrawing effect compared to its protonated state) but the 
attacking amine would be more nucleophilic because of the larger number of non-
protonated species. As a leaving group, the phenol was more readily displaced than 
chloride (Figure 2.5) by the attacking amine. The formation of acridones as a byproduct 
of hydrolysis of 9-chloroacridines was also minimized.88  The phenoxide intermediate 44 
was isolated and characterized (Appendix 1). 
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Scheme 2.4: Nucleophilic substitution of 9-Cl to give phenoxide 44, followed by 
displacement of phenol by amines. 
 
It was generally found that both approaches gave comparable yields but workup 
procedures were more favorable when ethanol was used as solvent. In cases where yields 
in ethanol were unsatisfactory, the reaction was repeated in phenol.  Most of the amines 
involved in the condensation reactions were purchased. However there were some amines 
that were not commercially available and these were synthesized as described in the 
following sections. 
  
2.3.3. Synthesis of substituted anilines for Groups 2, 6, and 7 by Hartwig-Buchwald 
amination reaction 
3-Morpholinoaniline, 3-(4-methylpiperazin-1-yl)aniline,  4-(4-methylpiperazin-1-
yl)aniline, 4-(4-ethylpiperazin-1-yl)aniline, 3-[4-(4-aminophenyl)piperazin-1-yl] propan-
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1-ol, 1-(4-(4-aminophenyl)piperazin-1-yl)ethanone, (4-(4-aminophenyl)piperazin-1-yl) 
(cyclohexyl)methanone and [4-(4-aminophenyl)piperazin-1-yl]phenylmethanone were 
required for the synthesis of 12-21 in Group 2 and 54, 60 in Groups 6 and 7. These 
amines were synthesized by the Hartwig-Buchwald amination of iodobenzene by a 
palladium coupling reaction, followed by catalytic reduction of the aromatic nitro group 










Scheme 2.5: a) Pd(OAc)2, BINAP, Cs2CO3, anhydrous toluene, 120oC  b) H2, Pd/C. 
 
The mechanism of the Buchwald-Hartwig reaction 89, 90 is illustrated in Figure 2.6. 
The Pd/BINAP catalyst system was used to establish the C-N bond. BINAP (rac-2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl) formed a complex with palladium diacetate 
Pd(II), [PdL2](OAc)2, which was possibly reduced by BINAP  to the activated Pd(0) 
species PdL2 which then lost one ligand to form PdL. Iodonitrobenzene (ArX) 
coordinated to palladium by oxidative addition to form an intermediate which was in 
equilibrium with its dimeric species. The iodine atom was displaced by the nitrogen atom 
of the attacking amine in the presence of cesium carbonate which functioned as a base to 
abstract a proton from the amine to form the intermediate PdL(Ar)NR2. The latter 
underwent reductive amination to give the desired aryl amine. β-Hydride elimination 
could occur to give an arene and imine but this competing pathway was not found to be 
significant. Aryl amines were obtained with good yields (>90%). The Pd/BINAP catalyst 
was regenerated at the end of the cycle. 
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Figure 2.6: Mechanism of Buchwald-Hartwig amination115  (X = iodine and L = BINAP).  
 
2.3.4. Synthesis of N1,N1-dimethylbenzene-1,2-diamine  
N1,N1-Dimethylbenzene-1,2-diamine was required for the synthesis of 5 in Group 2.  
It was synthesized by reacting 1-chloro-2-nitrobenzene with hexamethylphosphoramide 
(HMPA) to give the 1-dimethylamino-2-nitrobenzene. The aromatic nitro group was 







Scheme 2.6: a) HMPA 6eq, 150oC, 24h b) H2, Pd/C, 12h 
2.3.5. Synthesis of N1,N1-diethylbenzene-1,3-diamine  
N1,N1-Diethylbenzene-1,3-diamine was required for 8 in Group 2. It was prepared 
from the acid hydrolysis of commercially available N-(3-diethylamino)phenylacetamide 








Scheme 2.7: conc. HCl, reflux 2h 
2.3.6. Synthesis of 4-[(4-methylpiperazin-1-yl)methyl] aniline, 4-(piperidin-1-
ylmethyl)aniline and  (4-aminophenyl)(4-methylpiperazin-1-yl)methanone]  
These amines were required for the synthesis of 22-24 (Group 2).  The synthesis 
of 4-[(4-methylpiperazin-1-yl)methyl] aniline and 4-(piperidin-1-ylmethyl)aniline is 









X= NCH3 in 22
  = CH2 in 24  
Scheme 2.8: a) Amine, TEA, THF, 70oC, 24h b) H2, PtO2, 50 psi, overnight. 
Commercially available 1-(chloromethyl)-4-nitrobenzene was reacted with either 
1-methylpiperazine or piperidine in the presence of triethylamine in tetrahydrofuran as 
solvent. The chloride ion was displaced by the nucleophilic secondary amine. 
Triethylamine was used to remove HCl released during the course of reaction. The 
aromatic nitro functionality was reduced to the amino by low pressure hydrogenation 
with Adam’s catalyst. The latter was preferred to palladium/charcoal as it did not cause 
hydrogenolysis of the C-N bond. 
A similar method was employed for the preparation of (4-aminophenyl)(4-
methylpiperazin-1-yl)methanone (Scheme 2.9). Commercially available 4-nitrobenzoyl 
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chloride was stirred overnight (ca 12 h) with 1-methylpiperazine in dichloromethane at 
room temperature. The milder reaction conditions employed for this reaction was due to 
the greater susceptibility of the acid chloride to nucleophilic attack. The nitro group was 












Scheme 2.9: a) 1-methylpiperazine, TEA, anhydrous DCM, rt, overnight b) H2, Pd/C 
10%, 50psi, overnight. 
 
2.3.7 Synthesis of 1-benzyl-piperidin-4-ylamine, 1-phenethylpiperidin-4-ylamine, 1-
(3-phenylpropyl)piperidin-4-ylamine and their ring substituted analogs.   
 
n=1,2,3 
R=H, CH3, OCH3, CN, Cl 
Scheme 2.10: a) TEA, THF, reflux, overnight b) TFA, DCM, rt c) aq. NaHCO3 
Scheme 2.10 outlines the reaction route for the synthesis of 1-benzyl-piperidin-4-
ylamine, 1-phenethylpiperidin-4-ylamine, 1-(3-phenylpropyl)piperidin-4-ylamine and 
their ring substituted analogs. These amines were required for the synthesis of 33-41 
(Group 3). tert-Butyl piperidin-4-ylcarbamate reacted with the phenylalkyl halide with 
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release of the hydrogen halide (HCl or HBr) which was removed by triethylamine. The 
protective tert-butoxycarbonyl (Boc) moiety was subsequently removed in the presence 
of trifluoroacetic acid to give the desired primary amine.  






n=1 (for 34) and 2 (for 39) 
Scheme 2.11: a) SOCl2, anhydrous DCM, rt, 1h. 
4-Chlorobenzylchloride and 1-chloro-4-(2-chloroethyl)benzene were required for 
the synthesis of 34 and 39 respectively. They were prepared from the reaction of (4-
chlorophenyl)methanol and 2-(4-chlorophenyl)ethanol with thionyl chloride (Scheme 
2.11). Mechanistically, this was an SN2 substitution reaction with thionyl chloride as the 
source of the nucleophilic chloride. 



















42b 42c  
Scheme 2.12: a) 1,4-dichlorobut-2-yne, DMF, 100oC, 5h b) 1-methylpiperazine, TEA, 
DCM, rt, overnight c) NH2NH2, EtOH, reflux, 2h. 
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4-(4-Methyl-piperaziny-1-yl)-but-2-ynylamine was required for the synthesis of 
42 (Group 4). It was prepared by the Gabriel synthesis which involved the reaction of 
1,4-dichloro-2-butyne with potassium phthalimide (Scheme 2.12).116 Excess 1,4-
dichloro-2-butyne (2 equivalents) was employed to ensure that only the monosubstituted 
phthalimide (42a) was formed. The later was then reacted with 1-methylpiperazine in an 
SN2 substitution reaction in which the terminal halide was displaced by the nucleophilic 
piperazinyl nitrogen to give 42b. The phthalolyl group was then removed in the presence 
of hydrazine to give the desired amine (42c). 
An alternative route to give 42c was to react 1,4-dichloro-2-butyne with 
equivalent amounts of 1-methylpiperazine and ammonia in a stepwise manner (Scheme 
2.13).  However this approach gave 42c in lower yields, mainly because both chloride 





N b H2N N
N
42c  
Scheme 2.13: a) 1-Methylpiperazine, TEA, DMF, heat b) NH3, MeOH, sealed tube, heat. 
 











43c 43d  
Scheme 2.14: a) KOH, water, THF, 80oC, 10h b) PhCH2Cl, TEA, THF, reflux, overnight 
c) NH2OH.HCl, MeOH, Na2CO3, rt, 4h d) H2, PtO2, 50psi, rt, overnight. 
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8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-ylamine (43d) was required for the synthesis 
of 43 (Group 4). Its synthesis is shown in Scheme 2.14. Starting from the ethyl ester of 3-
oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid, the ethoxycarbonyl group was 
removed by alkaline hydrolysis to give the secondary amine 43a. The latter was reacted 
with benzyl chloride in an SN2 type reaction to give 8-benzyl-8-aza-bicyclo[3.2.1]oct-3-
one (43b).  The ketone carbonyl was derivatized to give the oxime 43c which was then 
reduced in the presence of Adam’s catalyst (PtO2) to give the desired amine 43d.  
 







Scheme 2.15: a) POCl3, reflux, 2h. 
While the starting materials for the acridine (6,9-dichloro-2-methoxyacridine) and 
quinoline (4,7-dichloroquinoline) templates were commercially available, this was not 
the case for the tetrahydroacridine template. The starting material (3,9-dichloro-5,6,7,8-
tetrahydroacridine) for the Group 6 compounds had to be synthesized and this was 
achieved by a three-step-one-pot reaction (Scheme 2.15).  
 
2.3.12. Synthesis of 6-chloro-2-methoxyacridin-9-amine monohydrochloride (46) 
Compound 46 was synthesized by reacting 6,9-dichloro-2-methoxyacridine with 
sodium methoxide in methanol. The 9-chloro group was displaced by methoxide to give 
6-chloro-2,9-dimethoxyacridine. In the next step, 6-chloro-2,9-dimethoxyacridine was 
reacted with NH4Cl to give the desired product (Scheme 2.16). However, this method did 
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not work for the synthesis of 49 and 55 which were prepared by displacing the chloro 
atoms of their respective starting materials with hydrazine, followed by reduction to give 











Scheme 2.16: a) CH3ONa, MeOH, reflux, 2h b) NH4Cl, MeOH, 70oC, 2h. 
 











Scheme 2.17: a) NH2NH2.H2O, mw, 150oC, 10min b) NiCl2, NaBH4, rt, 1h 
 
6-chloro-1,2,3,4-tetrahydro-acridin-9-ylamine (49) was synthesized by reacting 
6,9-dichloro-1,2,3,4-tetrahydro-acridine with hydrazine followed by reduction of the 
resulting hydrazide with nickel chloride and sodium borohydride to give the desired 
amine (Scheme 2.17).117  The same method was used for the synthesis of 55 which was 
synthesized from 4,7-dichloroquinoline. 
Another approach to 49 and 55 was to react 6,9-dichloro-1,2,3,4-tetrahydro-
acridine or 4,7-dichloroquinoline with ammonia by heating (170oC) in a close reaction 
vessel at high pressure.118 This method was not adopted because it involved the high 
pressure/temperature conditions.  
 45
2.4. Experimental methods 
2.4.1 General experimental methods 
1H-NMR and 13C-NMR spectra were recorded on a Bruker DPX 300MHz 
spectrometer and chemical shifts were reported in δ (ppm) relative to the internal 
standard TMS. Mass spectra (MS, nominal) were collected on a LCQ Finnigan MAT 
mass spectrometer. Atmospheric pressure ionization (APCI) or electron spray (ionization 
(ESI) were used as probes. Reactions were routinely monitored by thin layer 
chromatography using silica gel 60 F 254 plates from Merck, with UV light as a 
visualizing agent. Column chromatography was performed using silica gel G (0.04-
0.063mm) from Merck. Solvents were of analytical grade or distilled from technical 
grade. All chemicals were purchased from Sigma Aldrich Chemical Company (MO, 
USA), Tokyo Chemical Industry (Tokyo, Japan), and Alfa Aesar (MA, USA).   Purity 
analysis was verified by high pressure liquid chromatography (HPLC) or by combustion 
analysis. Combustion analyses (C, H) were determined by Perkin-Elmer PE 2400 
CHN/CHNS elemental analyzer by the Department of Chemistry, National University of 
Singapore. Spectroscopic data, melting points, yields and purities of individual 
compounds are listed in Appendix 1. 
 
2.4.2. General procedure for the reaction of 2-methoxy-6,9-dichloroacridine, 9-
chloroacridine and 4,7-dichloroquinoline with amines in ethanol as solvent (GP1). 
This method was applied to compounds 5-31, 45, 48, 58-60. The acridine or 
quinoline (2 mmol) and the amine (2 mmol) were dissolved in ethanol (30 to 50 ml) and 
2 drops of concentrated HCl was added. The reaction mixture was refluxed until the 
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reaction was completed (ca 24h or when starting materials were not detected on TLC). 
On cooling to room temperature, the workup process depended on the solubility of the 
product in ethanol. For those compounds that were insoluble in ethanol, they were 
precipitated from the reaction mixture by neutralizing with cold water and ammonia 
solution (25%), followed by recrystallization with methanol. Compounds which were 
soluble in ethanol were extracted with dichloromethane and brine after neutralization 
with either ammonia solution (25%) or NaOH (1M). The crude product was subjected to 
column chromatography (gradient elution from hexane: ethyl acetate (EA) 1:4 to EA 
100% to EA :methanol: NH3 90:10:1) and recrystallized with methanol to afford the 
desired compound. 
 
2.4.3. General procedure for the reaction of 2-methoxy-6,9-dichloroacridine, 3,9-
dichloro-5,6,7,8-tetrahydroacridine and 4,7-dichloroquinoline with amines in phenol 
as solvent (GP2). 
This method was applied to compounds 1-4. The acridine (1mmol) was added to 
melted phenol (10mmol) and stirred for 1 hour before adding 1-benzylpiperidin-4-amine 
(1.06 mmol) or related amines. The reaction was stirred at 120oC for 4 hours. On cooling 
to room temperature, diethylether was added to precipitate the crude product which was 
filtered and purified by column chromatography (EA :hexane 1:1, increasing to 100% 
EA).  
To synthesize compounds 32-43, 50-54, 56-57, the acridine or quinoline (1mmol) 
was added to melted phenol (10mmol) and stirred for 1 hour before adding 1-
benzylpiperidin-4-amine (1.06 mmol) or related amines. The reaction was stirred at 
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120oC for 4 hours. On cooling to room temperature, the mixture was neutralized with 5M 
NaOH, extracted with dichloromethane (20ml x 3). The organic fractions were pooled, 
concentrated in vacuo and purified by column chromatography (EA :hexane 1:1, 
increasing to 100% EA). 
 
2.4.4. Synthesis of the 3,9-dichloro-5,6,7,8-tetrahydroacridine119 
To a mixture of 2-amino-4-chlorobenzoic acid (5mmol, 0.858g) and 
cyclohexanone (5mmol, 0.52ml) was carefully added 5 ml of POCl3 at 0oC. The mixture 
was heated under reflux for 2 h, then cooled to room temperature, and concentrated to 
give a slurry. The residue was diluted with dichloromethane, neutralized with aqueous 
K2CO3, and washed with brine. The organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo to furnish 1.118g of the desired compound as a reddish brown 
solid (Yield 88%). 1H NMR (300MHz, CDCl3) δ 1.89 (m, 4H), 2.88 (t, J=5.3, 2H), 3.06 
9t, J=5.3, 2H), 7.34 (dd, J1=1.9, J2=8.9, 1H), 7.89 (m, 2H). 13C NMR (75MHz, CDCl3) δ 
22.1, 22.2, 27.1, 33.4, 123.3, 124.7, 126.8, 127.1, 128.9, 135.1, 141.4, 145.9, 160.5. 
MS(APCI) m/z [M+] 252.7. 
 
2.4.5. Synthesis of 6-chloro-1,2,3,4-tetrahydro-acridin-9-ylamine (49)  
A solution of hydrazine monohydrate (2mmol) was added to 3,9-dichloro-5,6,7,8-
tetrahydroacridine (1mmol) in ethanol (5ml). The solution was subjected to heating 
(150oC, 10min) on a microwave reactor (Biotage InitiatorTM, Biotage AB, Uppsala, 
Sweden). The hydrazine [1-(3-chloro-5,6,7,8-tetrahydroacridin-9-yl)hydrazine] was 
isolated by filtration as a red solid. 1H NMR (300MHz, CDCl3) δ 1.94 (m, 4H), 3.04 (m, 
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4H), 7.45 (dd, J1=1.9, J2=9.0, 1H), 7.96 (d, J=1.7, 1H), 8.06 9d, J=9.0, 1H). 13C NMR 
(75MHz, CDCl3) δ 22.2, 22.7, 23.8, 30.1, 111.2, 115.0, 120.3, 125.7, 126.9, 139.2, 140.6, 
154.5, 155.9. 
The hydrazine intermediate was transferred to a round bottom flask to which was 
added NiCl2.6H2O (1mmol) and NaBH4 (3mmol). The mixture was stirred at room 
temperature for 1 hour and then filtered through a Celite pad. The filtrate was 
concentrated under vacuum, dissolved in ethyl acetate and extracted with brine three 
times. The organic layers were combined, concentrated under vacuum and purified by 
column chromatography (EA/hexane) to give the final pure product (49). Spectroscopic 
details of 49 are given in Appendix 1. 
 
2.4.6. Synthesis of 4-amino-7-chloroquinoline (55) 
A solution of hydrazine monohydrate (2mmol) was added to 4,7-
dichloroquinoline (1mmol) in ethanol (5ml) and heated in a microwave reactor as 
described in Section 2.4.5. The hydrazine [1-(7-chloroquinolin-4-yl)hydrazine] was 
isolated and characterized:  1H NMR (300MHz, DMSO-d6) δ  7.10 (d, J=6.9, 1H), 7.69 
(d, J=9.0, 1H), 7.92 (9s, 1H), 8.44 (d=8.1, 2H). MS(APCI) m/z [M+H+] 194.6. 
The hydrazine was reduced by NiCl2.6H2O and NaBH4 (3mmol) and purified as 
described in Section 2.4.5 to give the final pure product (55). Spectroscopic details of 55 
are given in Appendix 1. 
 
2.4.7. 6-chloro-2-methoxyacridin-9-amine monohydrochloride (46) 
 49
6,9-Dichloro-2-methoxyacridine (0.1 mol) was dissolved in 200ml of methanol 
and refluxed for 2 hours with a solution of sodium methoxide, prepared by dissolving 
sodium (0.12 mol) in 50 ml of methanol. The precipitated sodium chloride was removed 
by filtration and the filtrate treated with water to precipitate out the 6-chloro-2,9-
dimethoxyacridine. This alkoxyacridine (0.01 mol) was dissolved in 20ml of alcohol and 
treated with ammonium chloride (0.012 mol) dissolved in 2ml of water. The mixture was 
maintained at 60-700C for 2 hours, during which the salt of the 6-chloro-9-amino-2-
methoxyacridine was crystallized from the reaction mixture. The desired compound was 
obtained as a yellow solid. Spectroscopic details of 46 are given in Appendix 1. 
 
2.4.8. Synthesis of substituted nitrobenzenes for Groups 2, 5, 6, and 7 by Hartwig-
Buchwald amination reaction (GP3) 
Cs2CO3 (25mmol) and BINAP (0.8 mmol) were added into a reaction flask under 
argon. 1-Iodo-3 (or 4) – nitrobenzene (10mmol) and amine (25mmol) were dissolved in 
dry toluene (30-50 ml) in another round bottom flask and purged with argon. The mixture 
was transferred to the reaction flask by a canula.  Pd(OAc)2 (0.6mmol) was added to the 
reaction flask quickly. The reaction mixture was heated (90oC) and the reaction mixture 
monitored on TLC. Heating was stopped when the iodobenzene, was not detected on 
TLC. On cooling to room temperature, the reaction mixture was filtered and concentrated 
to give the crude product which was then purified by column chromatography (50% ethyl 
acetate/hexane increasing to 100% ethyl acetate and then to 10% methanol in ethyl 
acetate + few drops of NH3) to give the desired product in good yield.  
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1-(3-Nitrophenyl)pyrrolidine as obtained from 1-iodo-3-nitrobenzene and 
pyrrolidine following GP3. Yellow solid. 1H-NMR (300MHz, CDCl3) δ 2.06 (m, 4H), 
3.34 (t, J=6.6, 4H), 6.80 (dd, J1=2.1, J2=8.0, 1H), 7.32 (m, 2H), 7.46 (dd, J1=1.7, 
J2=8.0, 1H). MS(ESI) m/z [M+H+] 193.4. 
1-(3-Nitrophenyl)piperidine was obtained from 1-iodo-3-nitrobenzene and 
piperidine following GP3. Yellow solid. 1H-NMR (300MHz, CDCl3) δ 1.63 (m, 2H), 
1.72 (m, 4H), 3.26 (m, 4H), 7.18 (dd, J1=2.3, J2=8.3, 1H), 7.34 (t, J=8.2, 1H), 7.60 (dd, 
J1=1.6, J2=8.0, 1H), 7.71 (t, J=2.1, 1H). MS(ESI) m/z [M+H+] 207.3. 
4-(3-Nitrophenyl)morpholine was obtained from 1-iodo-3-nitrobenzene and 
morpholine following GP3. Yellow solid. 1H-NMR (300MHz, CDCl3) δ 3.251 (t, 4H, 
J=5.3) 3.886 (t, 4H, J=5.3), 7.183 (dd, J1=1.92, J2=8.40, 1H), 7.399 (t, J=8.08, 1H), 
7.707 (m, 2H). MS(ESI) m/z [M+H+] 209.1. 
1-Methyl-4-(3-nitrophenyl)piperazine: was obtained from 1-iodo-3-
nitrobenzene and 1-methylpiperazine following GP3. Yellow solid. 1H-NMR (300MHz, 
CDCl3) δ 2.304 (s, 3H) 2.584 (t, J=5.3, 4H) 3.303 (t, J=5.3, 4H) 7.367 (m, 2H) 7.660 (m, 
2H). MS(ESI) m/z [M+H+] 222.3. 
1-Methyl-4-(4-nitrophenyl)piperazine: was obtained from 1-iodo-4-
nitrobenzene and 1-methylpiperazine following GP3. Yellow solid. 1H-NMR (300MHz, 
CDCl3) δ 2.36 (s, 3H), 2.56 (m, 4H), 3.44 (m, 4H), 6.83 (d, J=9.4, 2H), 8.13 (d, J=9.4, 
2H). MS(ESI) m/z [M+H+] 222.3. 
1-Ethyl-4-(4-nitrophenyl)piperazine was obtained from 1-iodo-4-nitrobenzene 
and 1-ethylpiperazine following GP3. Yellow solid. 1H-NMR (300MHz, CDCl3) δ 1.11 
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(t, J=7.2, 3H), 2.46 (q, J=7.2, 2H), 2.57 (m, 4H), 3.42 (m, 4H), 6.80 (d, J=9.4, 2H), 8.10 
(d, J=9.4, 2H). MS(ESI) m/z [M+H+] 236.2. 
3-(4-(4-Nitrophenyl)piperazin-1-yl)propan-1-ol was obtained from 1-iodo-4-
nitrobenzene and 3-(piperazin-1-yl)propan-1-ol. Yellow solid. 1H-NMR (300MHz, 
CDCl3) δ 1.79 (p, J=5.5, 2H), 2.68 (m, 6H), 3.44 (m, 4H), 3.84 (m, 2H), 6.83 (d, J=9.4, 
2H), 8.13 (d, J=9.4, 2H). MS(ESI) m/z [M+H+] 266.3. 
1-(4-(4-Nitrophenyl)piperazin-1-yl)ethanone was obtained from 1-iodo-4-
nitrobenzene and 1-(piperazin-1-yl)ethanone following GP3.. Red solid. Yield 92%. 1H-
NMR (300MHz, CDCl3) δ 2.16 (s, 3H), 3.47 (m, 4H), 3.68 (m, 2H), 3.80 (m, 2H), 6.82 
(d, J=9.4, 2H), 8.13 (d, J=9.3, 2H). MS(ESI) m/z [M+] 248.9. 
Cyclohexyl(4-(4-nitrophenyl)piperazin-1-yl)methanone was obtained from 1-
iodo-4-nitrobenzene and cyclohexyl(piperazin-1-yl)methanone following GP3.. Yellow 
solid. Yield 87%. 1H-NMR (300MHz, CDCl3) δ 1.26 (t, J=8.1, 3H), 1.68-1.85 (m, 6H), 
2.50 (m, 1H), 3.45 (m, 4H), 3.75 (m, 4H), 6.83 (d, J=9.4, 2H), 8.16 (d, J=9.4, 2H). (ESI) 
m/z [M+H+] 318.2. 
(4-(4-Nitrophenyl)piperazin-1-yl)(phenyl)methanone was obtained from 1-
iodo-4nitrobenzene and phenyl(piperazin-1-yl)methanone following GP3.. Orange solid. 
Yield 80%. 1H-NMR (300MHz, CDCl3) δ 3.44 (m, 4H), 3.81 (m, 4H), 6.85 (d, J=9.4, 
2H), 7.45 (s, 5H), 8.16 (d, J=9.3, 2H). (ESI) m/z [M+H+] 312.1. 
 
2.4.9. General procedure for catalytic reduction of substituted nitrobenzenes (GP4) 
To an ethanolic solution of the nitrobenzene obtained from the Hartwig-Buchwald 
reaction (section 2.3.3) was added 10% Pd/C (5%w/w) in the presence of nitrogen. The 
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mixture was hydrogenated at 50 psi overnight on a Parr hydrogenator. The catalyst was 
removed by filtration, the filtrate was concentrated in vacuo and the residue containing 
the aniline was used immediately for the next reaction step.  
 
2.4.10. Synthesis of N1,N1-dimethylbenzene-1,3-diamine  
N1,N1-Dimethylbenzene-1,3-diamine was required for the synthesis of 6. 0.4 g 
(2.5 mmol) ortho-nitrochlorobenzene was added into a flask which was then sealed and 
flushed with argon. Hexamethylphosphoramide (15 mmol, 2.5 ml) was added into the 
flask and the solution was heated at 150ºC, 24 hours in the presence of argon. It was then 
diluted with 20 ml water, extracted with ether, after which the ether fraction was 
extracted with 4 × 10 ml 4M HCl. The aqueous fractions were basified with 4M NaOH 
and extracted with 4 × 20 ml ether and dried with anhydrous Na2SO4. On evaporation in 
vacuo, the residue was recrystallised with absolute ethanol to yield yellow crystals. The 
residue was immediately reduced to an amine following GP4 to obtain the desired 
product. 1H-NMR (300MHz, CDCl3) δ 3.091 (s, 6H) 7.14 (d, J=1.5, 1H) 7.57 (d, J=1.5, 
1H) 7.88 (s, 1H). 
 
2.4.11. Synthesis of N1,N1-diethylbenzene-1,3-diamine  
N1,N1-Diethylbenzene-1,3-diamine was required for the synthesis of 8.  1.2 g (5.8 
mmol) 3-(N,N-diethylamino)acetanilide and 2.5 ml concentrated HCl was refluxed for 
two hours. After cooling, the pH of the solution was adjusted to 4 with 2M NaOH. The 
solution was added directly to an ethanolic solution of 4-methoxy-6,9-dichloroacridine 
following the general procedure described in Section 2.4.2 (GP1). 
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2.4.12. Synthesis of 4-[(4-methylpiperazin-1-yl)methyl] benzenamine 
4-[(4-Methylpiperazin-1-yl)methyl]benzenamine was required for the synthesis of 
22. To a solution of 4-nitrobenzylchloride (1mmol, 0.172g) in anhydrous THF (3ml) was 
added 1-methylpiperazine (1mmol, 0.11ml) and triethylamine (1.5mmol, 0.21ml). The 
solution was heated at 70oC overnight. The reaction mixture was then extracted with 
dichloromethane and water. The organic fractions were combined, dried over anhydrous 
Na2SO4, and concentrated under reduced pressure. The residue was purified by column 
chromatography (hexane/EA 1:4) to give 0.2 g of 1-(4-nitrobenzyl)-4-methylpiperazine 
yellow liquid (Yield 85%). 1H NMR ((300MHz, CDCl3) δ 2.29 (s, 3H), 2.48 (b, 8H), 3.59 
(s, 2H), 7.51 (d, J=8.7, 2H), 8.17 (d, J=8.7, 2H). MS(ESI) m/z [M+] 236.1. This 
intermediate was dissolved in 10ml ethanol, PtO2 (0.010g) was added under nitrogen. 
Hydrogenation was carried out on a Parr hydrogenator at 50psi for 16h. The catalyst was 
then removed by filtration and the filtrate was concentrated in vacuo to give the amine in 
quantitative yield. 1H NMR ((300MHz, CDCl3) δ 2.21 (s, 3H), 2.39 (b, 8H), 3.33 (s, 2H), 
3.55 (b, 2H), 6.56 (d, J=6.6, 2H), 7.02 (d, J=7.2, 2H). MS(ESI) m/z [M+H+] 206.1. 
 
2.4.13. Synthesis of 4-[(piperidin-1-yl)methyl]benzenamine 
4-[(Piperidin-1-yl)methyl]benzenamine was required for the synthesis of 24. 4-
Nitrobenzylchloride was reacted with piperidine as described in Section 2.4.12. 1-(4-
Nitrobenzyl)piperidine was obtained as a yellow oil (85%). 1H NMR (300MHz, CDCl3) δ 
1.47 (m, 2H), 1.67 (m, 4H), 2.48 (m, 4H), 3.65 (s, 2H), 7.59 (d, J=7.7, 2H), 8.19 (d, 
J=8.6, 2H). It was subjected to catalytic hydrogenation as described in Section 2.4.12 to 
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give the desired amine in quantitative yield. 1H NMR (300MHz, CDCl3) δ 1.43 (m, 2H), 
1.60 (m, 4H), 2.40 (t, J=5.3, 4H), 3.42 (s, 2H), 6.63 (d, J=8.6, 2H), 7.09 (d, J=8.4, 2H). 
13C NMR (75MHz, CDCl3) δ 34.2, 35.4 (2C), 58.3 (2C), 65.8, 107.6 (2C), 107.9 (2C), 
120.4, 132.4. MS(ESI) m/z [M+] 219.8. 
 
2.4.14. Synthesis of (4-aminophenyl)(4-methylpiperazin-1-yl)methanone 
(4-Aminophenyl)(4-methylpiperazin-1-yl)methanone was required for the 
synthesis of 23. To a solution of 4-nitrobenzoyl chloride (1 mmol, 0.186g) in anhydrous 
dichloromethane (5ml) was added 1-methylpiperazine (1mmol, 0.11ml) and triethylamine 
(1.5mmol, 0.21ml). The solution was stirred at room temperature. The reaction mixture 
was then extracted with DCM and saturated NaHCO3. The organic fractions were 
combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The 
residue was purified by column chromatography (silica gel, hexane/ EA 1:4) to give 
0.249g of (4-methylpiperazin-1-yl)(4-nitrophenyl)methanone as a yellow liquid. 1H NMR 
(300MHz, CDCl3) δ 2.33 (s, 3H), 2.40 (m, 2H), 2.51 (m, 2H), 3.39 (m, 2H), 3.82 (m, 
2H), 7.57 (d, J=8.6, 2H), 8.28 (d, J=8.6, 2H). MS(ESI) m/z [M+H+] 250.1. It was then 
subjected to catalytic hydrogenation as described in section 2.4.12 to give the desired 
amine in quantitative yield. 1H NMR (300MHz, CDCl3) δ 2.32 (s, 3H), 2.42 (m, 4H), 
3.65 (m, 4H), 3.92 (b, 2H), 6.63 (d, J=8.3, 2H), 7.24 (d, J=8.3, 2H). MS(ESI) m/z 
[M+H+] 220.1. 
 
2.4.15 Synthesis of amines for Group 3 
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A solution of tert-butyl piperidin-4-ylcarbamate (2mmol), phenylalkyl halide 
(2mmol), and triethylamine (6mmol) in tetrahydrofuran (THF, 5ml) was refluxed 
overnight. THF was evaporated under reduced pressure. Dichloromethane was added and 
the mixture was extracted with dilute NaHCO3. The organic fractions were combined, 
dried over anhydrous Na2SO4, concentrated in vacuo, and the residue purified by column 
chromatography (EA/hexane) to give the desired Boc-protected amine. The Boc-
protected amine was dissolved in dichloromethane (4ml) and tetrafluoroacetic acid (TFA, 
4 ml) was added dropwise. The reaction mixture was neutralized with saturated (5M) 
NaOH, extracted with dichloromethane and NaHCO3 solution to give the desired amine 
as an oil. It was reacted with 6,9-dichloro-2-methoxyacridine by the general procedure 2 
(GP2) without further characterization.  
tert-Butyl 1-(4-methylbenzyl)piperidin-4-ylcarbamate: Light orange solid. 
Yield 95%. 1H NMR (300MHz, CDCl3) δ 1.35 (m, 2H), 1.43 (s, 9H), 1.88 (d, J=11.5, 
2H), 2.06 (t, J=11.3, 2H), 2.32 (s, 3H), 2.78 (d, J=11.5, 2H), 3.43 (s, 2H), 4.53 (m, 1H), 
7.10 (d, J=7.8, 2H), 7.18 (d, J=7.9, 2H). 13C NMR (75MHz, CDCl3) δ 20.9, 28.3 (2C), 
32.4, 47.7, 52.1, 62.6, 80.0, 128.7 (2C), 129.0 (2C), 135.1, 136.4, 155.1. MS(APCI) m/z 
[M+] 305.2. 
tert-Butyl 1-(4-chlorobenzyl)piperidin-4-ylcarbamate: White solid. Yield 84%. 
1H NMR (300MHz, CDCl3) δ 1.44 (s, 11H), 1.90 (d, J=11.3, 2H), 2.08 (t, J=11.4, 2H), 
2.77 (d, J=11.6, 2H), 3.44 (s, 3H), 4.51 (s, 1H), 7.24 (d, J=8.7, 2H), 7.27 (d, J=8.6, 2H). 
13C NMR (75MHz, CDCl3) δ 28.3 (3C), 32.4, 47.6, 52.2, 62.1, 79.1, 128.3 (2C), 130.3 
(2C), 132.7, 136.7, 155.1. MS(APCI) m/z [M+] 325.2. 
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tert-Butyl 1-(4-methoxybenzyl)piperidin-4-ylcarbamate: White solid. Yield 
93%. 1H NMR (300MHz, CDCl3) δ 1.38 (m, 2H), 1.43 (s, 9H), 1.87 (d, J=11.0, 2H), 2.03 
(t, J=10.8, 2H), 2.77 (d, J=11.4, 2H), 3.39 (s, 2H), 3.76 (s, 3H), 4.71 (d, J=6.4, 1H), 6.83 
(d, J=8.5, 2H), 7.19 (d, J=8.5, 2H). 13C NMR (75MHz, CDCl3) δ 28.2 (3C), 32.3, 47.6, 
51.9 (2C), 54.9 (2C), 62.1, 78.7, 113.3 (2C), 130.0 (2C), 130.1, 154.9, 158.4. MS(APCI) 
m/z [M+] 320.0. 
tert-Butyl 1-(4-cyanobenzyl)piperidin-4-ylcarbamate: Orange solid 95%. 1H 
NMR (300MHz, CDCl3) δ 1.44 (s, 9H), 1.50 (m, 2H), 1.92 (d, J=11.3, 2H), 2.13 (t, 
J=10.6, 2H), 2.77 (d, J=11.6, 2H), 3.54 (s, 2H), 4.59 (d, J=5.2, 1H), 7.45 (d, J=8.1, 2H), 
7.60 (d, J=8.1, 2H). 13C NMR (75MHz, CDCl3) δ 28.2 (3C), 32.3, 47.4 (2C), 52.3, 62.2 
(2C), 79.1, 110.6, 118.8, 129.3 (2C), 131.9 (2C), 144.2, 155.0. MS(APCI) m/z [M+] 
315.7. 
tert-Butyl 1-phenethylpiperidin-4-ylcarbamate: White solid. Yield 74%. 1H 
NMR (300MHz, CDCl3) δ 1.45 (s, 9H), 1.49 (m, 2H), 1.95 (d, J=11.4, 2H), 2.15 (t, 
J=11.1, 2H), 2.58 (m, 2H), 2.80 (m, 2H), 2.93 (d, J=10.9, 2H), 3.47 (s, 1H), 4.58 (s, 1H), 
7.19 (d, J=5.3, 2H), 7.26 (d, J=6.6, 2H). 13C NMR (75MHz, CDCl3) δ 28.3 (3C), 32.4, 
33.6, 47.6, 52.2, 60.3, 79.0, 125.9, 128.2 (2C), 128.5 (2C), 140.0, 155.1. MS(APCI) m/z 
[M+] 304.7. 
tert-Butyl 1-(4-methylphenethyl)piperidin-4-ylcarbamate: White solid. Yield 
88%. 1H NMR (300MHz, CDCl3) δ 1.45 (s, 9H), 1.51 (m, 2H), 1.95 (d, J=11.6, 2H), 2.15 
(t, J=10.9, 2H), 2.30 (s, 3H), 2.57 (dd, J1=5.8, J2=10.4, 2H), 2.76 (dd, J1=5.8, J2=10.4, 
2H), 2.92 (d, J=11.5, 2H), 3.47 (s, 1H), 4.59 (s, 1H), 7.07 (s, 4H). 13C NMR (75MHz, 
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CDCl3) δ 20.8, 28.3 (3C), 32.3, 33.1, 47.6, 52.2, 60.4, 79.1, 128.4 (2C), 128.9 (2C), 
135.3, 136.9, 155.1. MS(APCI) m/z [M+] 318.4. 
tert-Butyl 1-(4-chlorophenethyl)piperidin-4-ylcarbamate: Light orange solid. 
Yield 82%. 1H NMR (300MHz, CDCl3) δ 1.45 (s, 11H), 1.94 (d, J=11.8, 2H), 2.12 (t, 
J=11.2, 2H), 2.53 (m, 2H), 2.74 (m, 2H), 2.89 (d, J=10.9, 2H), 3.46 (m, 1H), 4.61 (b, 
1H), 7.10 9d, J=8.0, 2H), 7.22 (d, J=8.0, 2H). 13C NMR (75MHz, CDCl3) δ 28.2 (3C), 
32.4, 32.9, 47.6, 52.2, 60.0, 79.0, 128.22 (2C), 129.8 (2C), 131.5, 138.6, 155.0. 
MS(APCI) m/z [M+] 338.4. 
tert-Butyl 1-(4-methoxyphenethyl)piperidin-4-ylcarbamate: White solid. Yield 
89%. 1H NMR (300MHz, CDCl3) δ 1.37 (s, 9H), 1.44 (m, 2H), 1.86 (d, J=10.9, 2H), 2.04 
(t, J=10.7, 2H), 2.45 (dd, J1=5.9, J2=9.6, 2H), 2.64 (m, 2H), 2.82 (d, J=10.7, 2H), 3.39 
(b, 1H), 3.66 (s, 3H), 4.71 (b, 1H), 6.73 (d, J=8.3, 2H), 7.01 (d, J=8.3, 2H). 13C NMR 
(75MHz, CDCl3) δ 28.1 (3C), 32.2, 32.5, 47.5, 52.1, 54.8, 60.4, 78.7, 113.5 (2C), 129.2 
(2C), 131.9, 154.9, 157.6. MS(APCI) m/z [M+] 334.2. 
tert-Butyl 1-(3-phenylpropyl)piperidin-4-ylcarbamate: White solid. Yield 
75%.1H NMR (300MHz, CDCl3) δ 1.44 (s, 11H), 1.81 (m, 2H), 1.93 (d, J=12.1, 2H), 
2.05 (t, J=10.4, 2H), 2.36 (m, 2H), 2.62 (t, J=7.7, 2H), 2.84 (d, J=9.3, 2H), 4.47 (m, 1H), 
7.17 (d, J=7.5, 2H), 7.26 (d, J=7.4, 2H). 13C NMR (75MHz, CDCl3) δ 28.4 (3C), 28.7, 
32.5, 33.7, 47.7, 52.3, 57.9, 79.2, 125.7, 128.2 (2C), 128.3 (2C), 142.0, 155.2. MS(APCI) 
m/z [M+] 318.7. 
 
2.4.16. Synthesis of 4-(4-methylpiperazin-1-yl)but-2-yn-1-amine  
4-(4-Methylpiperazin-1-yl)but-2-yn-1-amine was required for the synthesis of 42.  
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2-(4-Chlorobut-2-ynyl)isoindoline-1,3-dione (42a): 1,4-Dichloro-2-butyne 
(6mmol, 0.58ml) was added to the stirred suspension of potassium phthalimide (3mmol, 
0.556g) in DMF (5ml), and heated to 100oC for 5 h. After cooling, the reaction mixture 
was extracted with dichloromethane and water. The organic layers were pooled, dried, 
and concentrated in vacuo. The residue was purified by column chromatography 
(hexane/ethyl acetate 1:19) to furnish 0.35g of 42a (white solid, yield 50%). 1H NMR 
(300MHz, CDCl3) 4.11 (s, 2H), 4.51 (s, 2H), 7.75 (dd, J1=3.1, J2=5.5, 2H), 7.89 (dd, 
J1=3.1, J2=5.4, 2H). 13C NMR (75MHz, CDCl3) δ 27.1, 45.7, 46.9, 51.7 (2C), 54.7 (2C), 
78.1, 78.4, 123.4 (2C), 131.9 (2C), 134.0 (2C), 166.9 (2C). 
2-(4-(4-Methylpiperazin-1-yl)but-2-ynyl)isoindoline-1,3-dione (42b): 42a was 
reacted with 1-methylpiperazine in the presence of TEA and anhydrous THF as solvent 
as described in section 2.4.12. 42b was obtained as a yellow solid in 83% yield. 1H NMR 
(300MHz, CDCl3) δ 2.28 (s, 3H), 2.45 (m, 4H), 2.58 (m, 4H), 3.26 (s, 2H), 4.47 (s, 2H), 
7.73 (dd, J1=3.1, J2=5.4, 2H), 7.88 (dd, J1=3.1, J2=5.4, 2H). MS(APCI) m/z [M+H+] 
298.2. 
4-(4-Methylpiperazin-1-yl)but-2-yn-1-amine (42c): A solution of 42b 
(0.72mmol, 0.213g) and hydrazine (0.72mmol, 0.03ml) in 1ml of ethanol was heated at 
reflux for 2h. After cooling the mixture to 0oC, phthalhydrazide was removed by 
filtration. Evaporation of the filtrate gave the 42c (free base). 1H NMR (300MHz, CDCl3) 
δ 2.30 (s, 3H), 2.49-2.61 (m, 8H), 3.28 (t, J=1.8, 2H), 3.44 (t, J=1.8, 2H). 13C NMR 




2.4.17. Synthesis of 8-benzyl-8-aza-bicyclo[3.2.1]octan-3-amine  
8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-amine was required for the synthesis of 43.   
8-Aza-bicyclo[3.2.1]octan-3-one (43a): A solution of ethyl 3-oxo-8-
azabicylo[3.2.1]octane-8-carboxylic acid (2.3mmol, 0.46g) in ethanol (1ml) was mixed 
with KOH (0.353g) in water (5ml) and heated at 100oC for 3h. After cooling down to 
room temperature, the solution was diluted with 20ml of dichloromethane. The organic 
layer was dried and concentrated in vacuo to give crude 43a. 1H NMR (300MHz, CDCl3) 
δ 1.69 (m, 2H), 1.90 (dd, J1=4.1, J2=8.8, 2H), 2.31 (m, 1H), 2.36 (m, 2H), 2.56 (m, 2H), 
3.87 (m, 2H). 13C NMR (75MHz, CDCl3) δ 30.0 (2C), 50.8 (2C), 54.9 (2C), 209.7.  
8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-one (43b): 43a was reacted with benzyl 
chloride as described for 1-(4-nitrobenzyl)-4-methylpiperazine (Section 2.4.12). 1H NMR 
(300MHz, CDCl3) δ 1.63 (m, 2H), 2.16 (m, 4H), 2.72 (m, 2H), 3.50 (m, 2H), 3.76 (m, 
2H), 7.34 (m, 5H). 13C NMR (75MHz, CDCl3) δ 27.7 (2C), 48.1 (2C), 55.1, 58.6 (2C), 
127.2, 128.4 (2C), 128.5 (2C), 138.9, 210.1. MS(APCI) m/z [M+] 215.3. 
8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-one oxime (43c): Hydroxylamine 
hydrochloride (1.7mmol, 0.117g) was stirred in methanol (7ml) at 0oC.  The slurry was 
treated with Na2CO3 (0.09g) and stirred for 5min. A solution of 43b (1.36mmol, 0.2934g) 
in 1ml of methanol was added and the reaction mixture was allowed to reach room 
temperature. After stirring for 5h, methanol was removed in vacuo, the residue was 
treated with dichloromethane and brine, the organic fractions were combined, dried 
(anhydrous Na2SO4), and concentrated to give 0.2g of  the desired product as a white 
solid (Yield 65%). 1H NMR (300MHz, CDCl3) δ 1.52 (t, J=9.6, 1H), 1.63 (t, J=9.6, 1H), 
2.04 (m, 2H), 2.14 (d, J=14.7, 1H), 2.26 (dd, J1=2.7, J2=12.6), 2.62 (d, J=14.7, 1H), 2.99 
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(d, J=15.6, 1H), 3.36 (b, 2H), 3.66 (s, 2H), 7.25-7.42 (m, 5H). 13C NMR (75MHz, 
CDCl3) δ 26.6, 27.5, 31.3, 37.1, 55.5, 57.8, 58.4, 127.0, 128.2 (2C), 128.7 (2C), 138.9, 
156.3. MS(ESI) m/z [M+H+] 231.1. 
8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-amine (43d): The oxime (43c) was 
reduced with Adam’s catalyst as described for 4-[(4-methylpiperazin-1-
yl)methyl]benzenamine (Section 2.3.6). 43d was obtained as a yellow oil (Yield 76%) 
which was used immediately for the synthesis of compound 43. MS(ESI) m/z [M+H+] 
217.4. 
 
2.4.18. Synthesis of 1-chloro-4-(chloromethyl)benzene  
To a solution of 4-chlorobenzylhydroxy (5mmol, 0.713g) in anhydrous 
dichloromethane (5ml) was added SOCl2 (15mmol, 1.1ml) dropwise at 0oC. The reaction 
mixture was allowed to reach room temperature, stirred for 1h, and then cooled down to 
0oC again.  It was then carefully diluted with water, and neutralized with saturated 
NaHCO3. The reaction mixture was extracted with dichloromethane and washed with 
water to afford the product as a yellow oil (0.64g, 80%) 1H NMR (300MHz, CDCl3) δ 
4.54 (s, 2H), 7.32 (s, 4H). 13C NMR (75MHz, CDCl3) δ 45.3, 128.9 (2C), 129.9 (2C), 
134.3, 135.9. 
 
2.4.19 Synthesis of 1-chloro-4-(2-chloroethyl)benzene  
1-Chloro-4-(2-chloroethyl)ethanol was reacted with SOCl2 as described in Section 
2.4.18. 1-Chloro-4-(2-chloroethyl)benzene was obtained as a yellow oil in quantitative 
yield. 1H NMR (300MHz, CDCl3) δ 2.99 (t, J=7.2, 2H), 3.65 (t, J=7.2, 2H), 7.11 (d, 
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J=8.4, 2H), 7.25 (d, J=8.1, 2H). 13C NMR (75MHz, CDCl3) δ 38.2, 44.6, 128.6 (2C), 
130.1 (2C), 132.6, 136.4. 
 
2.5. Summary 
The synthesis of 47 compounds was successfully achieved. All compounds were 
characterized by 1H NMR, 13C NMR and MS. The purity of compounds was determined 
by elemental analysis or reversed phase HPLC using two different mobile phases. The 
threshold requirement for purity was 95% and compounds that complied with this 
requirement were considered suitable for biological evaluation. Yields, NMR chemical 
shifts, MS data, yield and purity of synthesized compounds are given in Appendix 1.
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Chapter 3: Antiprion activity of acridine analogues 
 
3.1. Introduction 
This chapter describes the screening of selected synthesized compounds from 
Chapter 2 for antiprion activity. Evaluation was carried out in cells that were stably 
infected with scrapie protein PrPSc and capable of active replication of the protein 
(without associated cytotoxicity to the cells) leading to the accumulation of PrPSc in 
readily detected amounts.  In the presence of an active antiprion agent, PrPSc levels were 
reduced and served as a means of evaluating the potency of the test compound. The 
synthesized compounds were evaluated in two stages. In the first stage, 42 compounds 
(all Group 1 and 5 compounds, selected compounds in Groups 2, 3 and 4) were screened.  
From the results, two hits were identified and chemical modification of these compounds 
gave analogs that were evaluated in the second stage of screening.  
In an effort to understand the mode of action of the present series of compounds, 
two aspects were investigated, namely their interactions with cellular PrP by surface 
plasmon resonance and effect on cellular levels of PrPC. Surface plasmon resonance has 
been widely used by many investigators100,120,121 to investigate the binding of small 
ligands with prion protein. It is generally thought that binding to PrPC served to stabilize 
it and thus render the conformational change to PrPSc energetically less favourable. 
Binding may also affect the cellular localization of PrPC or cause a change in PrPC 
mediated signaling pathways that are critical to the disease progression. Hence, a 
correlation between binding affinities and antiprion activities is generally expected. 
However, there were instances where a compound with potent antiprion activity was 
 63
found to have low binding affinity for PrPC, or inactive compounds that had exceptionally 
good binding affinities. These may arise from non-specific binding (false positives) or 
instances where binding required additional modulation factors that were not present in 
the binding assay (false negatives). In spite of these exceptions, a compound that binds to 
PrPC is more likely to have antiprion activity than one that fails to exhibit any binding.  
As for the effect on cellular levels of PrPC, the assumption made was that a compound 
that reduced PrPC content would lead to a reduction in abnormal PrP formation and thus 
delay disease progression. 
An added requirement for an agent targeted for antiprion activity is its ability to 
transverse the blood brain barrier to reach its site of action in the brain. The blood brain 
barrier comprises endothelial cells and associated astrocytes found in the inner surfaces 
of blood capillaries that innervate the brain tissue. It is a “barrier” in the sense that it 
excludes most substances from the brain except those that are actively transported or 
have suitable physicochemical properties that permit passive diffusion to take place.  
These properties include molecular weight, hydrogen bonding capabilities and 
lipophilicity.105 Even if compounds comply with these properties, access to the brain may 
be minimal if they are substrates of the many ATP-binding cassette efflux transporters 
like P-glycoprotein (Pgp, ABCB2) and breast cancer resistant protein (BCRP, ABCG2) 
that are found in the blood brain barrier. Hence, an attempt was made to assess the 
potential of the active analogs identified in this chapter to transverse the blood brain 
barrier.  Selected actives were evaluated by the PAMPA-BBB assay122 which measures 
their permeability across polycarbonate filters impregnated with  porcine brain lipids and 
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one active analog (16) was tested on a cell line that over-expressed Pgp to determine if it 
was a substrate of this efflux protein. 
 
3.2. Experimental methods 
3.2.1. Evaluation of antiprion activity 
The cell models (ScN2a, N167, Ch2, F3) were provided by Dr Byron Caughey 
(Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National 
Institute of Allergy and Infectious diseases, National Institutes of Health, Hamilton, 
Montana) and the experiments were carried out in the laboratory of Dr Katsumi Doh-ura, 
Department of Prion Research, Tohoku University, Sendai, Japan. The assay was 
performed following reported methods.123-125 The cells were grown in minimal essential 
medium (Opti-MEM, Invitrogen) supplemented with 10% fetal calf serum, penicillin and 
streptomycin (0.1g/L each).  
Approximately 2x106 cells were seeded into each well of a six-well plate. Stock 
solutions of the test compounds were prepared in DMSO and aliquots were added to the 
wells to achieve the desired concentration. The final concentration of DMSO in each well 
was kept at less than 0.5% v/v. When the cells reached confluency after 3 days, they were 
examined microscopically (10x magnification) for signs of abnormal morphology. The 
medium was then removed from each well by aspiration, the cells were rinsed with cold 
PBS (2 ml) and treated with lysis buffer (500 µl) which comprised 0.5% Nonidet P-40 
and 0.5% sodium deoxycholate in PBS. The solution was transferred to safe-lock tubes 
for centrifugation at 6,000x g, 5 min, 4oC. The supernatant was treated with 5 µl of 
proteinase K (1 µg/µl, Merck) for 30 min (37oC), cooled on ice (2-3 min), followed by 
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addition of phenylmethanesulphonyl fluoride (PMSF, 5 µl of 0.1 M solution) to stop the 
reaction. The protein was precipated with 20 µl of glass fog solution 1% (Qbiogene Inc). 
The mixture was rolled over for 5 min and then centrifuged at 13,000x g  for 2 min.  
After removal of supernatant, the protein precipitate was dispersed in 20 µL of 
sample loading buffer and denatured for 5 min at 95oC. On cooling to room temperature, 
the protein samples were loaded on to polyacrylamide SDS-PAGE gel for 
electrophoresis. The prion proteins were detected using SAF83 (1:5,000; SPI-Bio, 
France), a primary  antibody against a human PrP fragment (amino acids 142-160) and an 
alkaline phosphatase-conjugated secondary antibody (anti-mouse IgG H&L, 1:20,000; 
Promega ®), followed by chemiluminescence. Immunoreactive signals were visualized 
with CDP-Star detection reagent (Amersham) and were analyzed by densitometry with 
the ImageJ program (National Institute of Health, Bethesda, USA). Three independent 
assays were performed for each concentration of test compound.  EC50 values and 95% 
confidence intervals were obtained by non-linear regression using the sigmoidal dose-
response equation from GraphPad Prism version 4.03 (GraphPad Software Inc., CA, 
USA). 
 
3.2.2. Determination of total and cell surface prion proteins  
The total level of normal cellular PrP was determined in non-infected N2a cells 
treated with test compound following the procedure described in Section 3.2.1. The 
difference was that samples were not treated with proteinase K and a smaller volume of 
supernatant (20 µl) was mixed with 5 µl of 5x concentrated sample loading buffer, boiled 
and then analyzed by immunoblotting as described. 
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 For the determination of cell surface prion protein, the method of Doh-ura et al.126 
was followed. Briefly, N2a cells were seeded and exposed to test compound for 3 days as 
described in Section 3.2.1. After this time, the medium was removed by aspiration, cells 
were rinsed with 2 ml cold PBS [without MgCl2 and CaCl2, referred to as PBS(-)] and the 
cells detached by adding the same PBS solution containing 0.1% collagenase (Wako Pure 
Chemical Industries Inc., Osaka, Japan) for 3 min at 37oC.  500µl of culture medium was 
then added to each well to inhibit the action of collagenase. The cell suspension from 
each well was dispensed into two tubes (approximately 0.5-2.5x106 cells/tube) which 
were then centrifuged (500x g, 4oC, 1 min). Cell pellets were resuspended in 500µl 
washing buffer which contained 0.5% inactivated fetal bovine serum in PBS (-) 
(FBS/PBS), centrifuged again and incubated with SAF83 (1:500) or isotype-matched 
control IgG1 for 20 min on ice.  They were then washed with FCS/PBS and incubated 
with goat F(ab’)2 fragment anti-mouse IgG(H+L)-PE (1:100) (Beckman Coulter Inc., 
CA) for 20 min on ice. After washing, fluorescent intensities were recorded using the 
EPICS XL-ADC flow cytometer (Beckman Coulter Inc., CA).  
 
3.2.3. Evaluation of binding affinity by surface plasmon resonance 
Recombinant human prion protein (amino acids 121-231; hPrP121-231, 
molecular weight 12,544.97 Da) was a gift from Dr. Katsumi Doh-ura, Department of 
Prion Research, Tohoku University Graduate School of Medicine, Sendai, Japan. The 
assay was performed on a BIAacore 3000 platform (BIAcor, Uppsala, Sweden). The 
sensor chip CM5 and amine coupling kit were purchased from GE Healthcare Bio-
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sciences AB (Uppsala, Sweden). The running buffer was prepared by filtering and 
degassing a phosphate buffer 1x, pH 7.4 containing 2.5% DMSO. 
The hPrP121-231 was dissolved in 10mM sodium acetate buffer, pH 4.5 
(10µg/ml) and immobilized on the CM5 chip to reach a density of ca. 3000 response 
units (RU) using amine coupling. A reference surface was prepared by treating a blank 
flow cell in the same way as the flow cell containing the immobilized peptide. Stock 
solutions of test compounds (2mM) were prepared in DMSO and diluted to 50 µM with 
phosphate buffer 1x, pH 7.4. Each analytical cycle consisted of running buffer for 60 
seconds (stabilization phase), a sample injection of 50 µM in running buffer for 120 
seconds (association phase) and running buffer for 150 seconds (dissociation phase).  
Flow rates were kept at 30 µl/min. Surface regeneration of the chip was carried out by 
injecting 10 mM NaOH (30 s, flow rate of 30µl/min). After regeneration, the surface was 
allowed to stabilize for ca 60 seconds before the next injection. The binding response 
curve was obtained by subtracting the background signal (from the reference flow cell) 
from that of the sample flow cell in order to correct for non-specific binding and bulk 
effects due to the analyte. The binding affinity was taken as the maximum response at the 
end of the association phase as seen from the binding response curve. Binding was 
expressed as % RUmax which is defined as the % theoretical maximum binding resonance 
units (RU) and determined by the following equation assuming a 1:1 stoichiometry: 
% max
RU of compound MW of proteinRU x x100%
RU of immobilized protein MW of compound
=  
 
3.2.4. Evaluation of permeability by the PAMPA-BBB assay 
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Porcine polar brain lipid (PBL) (catalog no. 141101) was purchased from Avanti 
Polar Lipids, Inc. (Alabaster, Alabama, USA). Dodecane was obtained from Sigma-
Aldrich. The acceptor plate was a 96-well filter plate (MultiscreenTM-IP, catalog no. 
MAIPN4510, PVDF membrane, pore size is 0.45µm) from Millipore (Bredford, USA) 
and the donor plate was a 96-well plate (catalog no. MATRNPS50, Millipore, Billerica, 
MA, USA). The 96-well UV plate (catalog no. 3535) was purchased from Corning Inc. 
(NY, USA). 
 Compounds were dissolved in DMSO at 10mM, and diluted in phosphate buffer 
solution 1x, pH 7.4 to 50 µM or 30 µM depending on their aqueous solubilities. An 
aliquot (300 µl) of the diluted solution was transferred to the donor well. The filter 
membrane was coated with 5 µl of 20 mg/mL PBL in dodecane and the acceptor well 
was filled with 150 µl of the same phosphate buffer solution. The donor plate was 
carefully aligned to the acceptor plate such that the underside of the membrane remained 
in contact with buffer solution in the donor wells. The sandwich assemble was incubated 
in an airtight humid box at room temperature for 10 hours. The concentrations of 
compound in the acceptor, donor and reference wells were determined by UV absorbance 
at 270nm using the Tecan Infinite 200 microplate reader. 
Permeability rate (Pe) and membrane retention (R) were calculated using the 
following equations: 




1 + r v
log 10     1-   1+ rv -1
1 -R
CA (t)
CD (0)  
R = 1 -
VA CA (t)  + VD CD (t)
VD CD (0)  
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where A is the active surface area of membrane (0.24cm2), t is the incubation time (s), VA 
and VD are the volumes (cm3) of the acceptor and donor chambers, rV=VD/VA, CA and CD 
are drug concentrations in the acceptor and donor chambers. 
 
3.2.5. Cell-based bidirectional transport assay 
Dulbeco’s Modified Eagle’s medium (DMEM) was purchased from Sigma (MO, 
USA). Fetal bovine serum was from Hyclone Lab Inc. (Logan, UT, USA). The MDCK-
WT (wild type) and MDCK-MDR1 (overexpressing Pgp) were gifts from Dr. Piet Borst 
(Netherlands Cancer Institute, University of Amsterdam, Netherlands). Western blotting 
was performed on these two cell lines to confirm the overexpression of Pgp by another 
laboratory member, the results of which had been published.127 Transwell® plates (Cat. 
no 3401, 12mm diameter, 0.4µm pore size) were obtained from Costar Corp. 
(Cambridge, MA, USA). The Millicell-ERS system was from Millipore Corp. (Bedford, 
MA, USA). Transport medium was Hank’s balance salt solution (HBSS) from Invitrogen 
(CA, USA) supplemented with 10mM HEPES at pH7.4 (HBSS-HEPES). 
10mM stock solutions of quinacrine and 16 were prepared in DMSO and further 
diluted to 10µM with the transport medium (HBSS-HEPES). The MDCK-MDR1 cell 
line was grown in DMEM supplemented with 10% fetal bovine serum, 100mg/L 
penicillin, and 100mg/L streptomycin at 37oC in an atmosphere containing 5% CO2. For 
transport assay, cells with passage number 3-8 were seeded at a density of 
300,000cells/well and grown for 4 days in 12-well Transwell® plates. Cell monolayers 
with transepithelial electrical resistance (TEER) values greater from 120-150Ωcm2 were 
used for the experiment.  On the day of assay, fresh medium was added to the cells. Two 
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hours later, they were washed twice and equilibrated with HBSS-HEPES medium for 30 
minutes. 500µl of 10µM test compounds was added to the apical chamber and 1500µl of 
HBSS-HEPES was dispensed to the basolateral chamber for determining apical to 
basolateral (AÆ B) transport. After 2h, cells were lysed with 600 µl of lysis solution 
(acetonitrile : water : formic acid = 70:30:0.1) for 10min and the cell debris removed by 
centrifugation (12,000x g, 5min, 4oC). Both chambers were thoroughly washed with 1ml 
of the same lysis solution and this wash solution was tested for presence of compounds 
adsorbing onto the plastic surface of the Transwell apparatus. Similarly, 500 µl of HBSS-
HEPES was introduced to the apical chamber and 1500 µl of the test solution to the 
basolateral chamber to determine the basolateral to apical (BÆA) transport.  Aliquots (10 
µl) were withdrawn from each chamber for quantification by LC/MS/MS. The 
experimental conditions were listed in Appendix 2.  
The integrity of the monolayer was determined by TEER value and by monitoring 
the transport of Lucifer yellow, a fluorescent marker for paracellular transport. TEER 
value was calculated using the following equation: 
TEER = (Rcell layer-Rblank) x A 
Where Rcell layer  = Resistance (Ω) of the cell molayer 
 Rblank = Resistance (Ω) of the blank (insert without cells) 
 A = Effective surface area of the insert (1cm2 for the 12-well insert) 
 
 Cell layers with TEER values in the range of 120-150Ωcm2 were deemed suitable 
for the bidirectional assay. 




V  x CJP = =
C A x t x C
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At A Bt B
0 D
C  x V  + C  x VMB (%) = x100%
C  x V
where J is the flux rate, C0 is the initial concentration in the donor compartment, Vr is the 
volume of the receiver compartment at the end of the assay, Cr is concentration of 
compound in the receiver compartment at the end of the assay, A is the effective surface 
area of the insert, t is duration of the assay (2h). 
 Mass balance was determined as:  
where CAt is the concentration of compound  in the apical compartment at the end of the 
assay, VA is volume of the apical compartment, CBt is the concentration of compound in 
the basal compartment at the end of the assay, C0 is the initial concentration in the donor 
compartment, VD is the volume of the donor compartment. 
3.2.6. Statistical analysis 
Pearson and Spearman correlation analyses were carried out using SPSS version 
13.0. (SPSS Inc., IL, USA). CLogP was determined by ChemDraw Ultra version 8.0 
(CambridgeSoft Corporation, MA, USA). SlogP was determined using MOE software 
version 2009.10 (Chemical Computing Group, Quebec, Canada). 
3.3. Results 
3.3.1. Antiprion activity of compounds on cell-based models  
Conventionally, prion assays detect amount of PrPSc by SDS-PAGE 
immunoblotting by standard techniques.92  Some groups have applied the dot-blot method 
to detect PrPSc from cells plated in 96-well format assay to increase high throughput 
screening.128,129 Blondel group has developed a cost-saving yeast-based assay to hasten 
the screening process.130 However, this assay is not very popular due to skepticism 
regarding significant differences between yeast and mammalian cells. For the purpose of 
screening our compounds for antiprion activity, we applied the well-established and 
 72
widely employed Western blot method developed by Dr Doh-ura41 eventhough it’s very 
labour intensive. Therefore, it is easier to compare IC50 values of our compounds to 
others screened in the same assay format which have been reported in literature. 
Cell lines used for screening antiprion activitites include mouse neuroblastoma 
N2a41, SMB.s15 or ScGT1129,131, mouse C1300 neuroblastoma-derived cell lines 
ScMNB132. Here we used an infected mouse neuroblastoma-derived cell-line, ScN2a 
(ATCC no: CCL131) was used to screen the antiprion activity of our compounds. This 
cell model comprises mouse neuroblastoma cells N2a that were stably infected with RML 
which was a mouse adapted scrapie strain.133 Screening was also carried out on N2a cells 
infected with another mouse adapted scrapie strain 22L. A subclone of N2a (N2a#58) 
which overexpressed PrPC by approximately 3-5 fold and stably infected with either 
RML or the human prion strain Fukuoka-1 was also used for screening.  A compound 
that demonstrated activity on both cell models was deemed to be more promising than 
one whose activity was restricted on only one model. Table 3.1 summarizes the various 
cell-based models used in the investigation. 
 
Table 3.1: Cultured cell models used for investigating antiprion activity of compounds 
Prion Strain Type of cell 
RMLa 22La Fukuoka-1b 
Mouse neuroblastoma cells N2a ScN2a N167 - 
Mouse neuroblastoma cells with PrP 
overexpression : N2a#58 
Ch2 - F3 
a: RML134 and 22L are mouse-adapted scrapie strains 
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b: Fukuoka-1 is a mouse adapted human prion strain135 
Briefly, antiprion activity was determined by incubating the test compound with 
the infected cells until confluency was attained. The cells were then lysed to give lysates 
that were treated with proteinase K and analyzed for PrP immunoreactivity. PrPC was 
readily digested by proteinase K and hence not detectable in the western blots. In 
contrast, PrPSc was resistant to enzymatic activity and would react sequentially with the 
prion antibody and secondary antibody to give a complex that was detectable by 
chemiluminescence.  The signal levels of the immunoblots were reduced in the presence 
of a compound with antiprion activity and monitoring the intensities of the bands served 
as a means of quantifying activity. Figure 3.1 shows the results of representative 
immunoblots obtained at different concentrations (0-3 µM) of a representative active 
(compound 16) and inactive (compound 47) test compound.   
 
Figure 3.1: Raw immunoblots of PrPSc formation in the presence of compounds 16 and 47 
in F3 cells. The top most line in each panel gives the test concentration (µM).  The first 
column on the right (‘0’) represents cells that were treated with DMSO only. 
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Activity was quantified in terms of the EC50 which was the effective 
concentration of test compound required to reduce PrPSc content to 50% of untreated 
ScN2a cells. It was determined by measuring the intensities of the immunoreactive 
signals over a range of concentrations. The results were plotted to give a sigmoidal curve 
from which EC50 was obtained. A representative plot is given in Figure 3.2.  
 
Figure 3.2: Plot of %PrPSc formation (equivalent to intensities of immunoreactive signals 
relative to untreated cells) in ScN2a cells treated with different concentrations of 
compound 16. EC50 was obtained from the descending portion of the sigmoidal curve 
using a commercial software GraphPad Prism version 4.03 (GraphPad Software Inc., CA, 
USA) 
Besides EC50, two other parameters were concurrently determined for each test 
compound. These were full antiprion activity (FAA) and maximal tolerant concentration 
(TC). FAA was the estimated lowest concentration required to clear more than 99% of 
PrPSc content, while TC was the approximate highest concentration that had no effect on 
the viability of infected N2a cells. Ideally, an active antiprion agent should combine low 






given by the ratio of TC to EC50.  In the first round of screening, 21 compounds from 
Groups 1-5 were evaluated on ScN2a cells.    
 
Table 3.2: Antiprion activities of Group 1 compounds on the ScN2a cell line. 
 
Compound Substituent (R) EC50 (µM)
a FAA (µM)b TC (µM)c Ratiod 
Quinacrine  0.23  (0.22, 0.25) 0.8 2.5 11 
1 n=2, R=C2H5 
0.021 
(0.019, 0.023) 0.1 4.0 190 
2 n=3, R=CH3 
0.11 
(0.09, 0.13) 0.3 1.0 9 
3 n=3, R=C2H5 
0.14 
(0.11, 0.17) 0.3 1.0 7 
4 n=4, R=C2H5 0.15 
(0.12,  0.19) 
0.4 1.0 7 
a: EC50 is the average of at least 3 independent determinations. 95% confidence intervals 
are given in the brackets. 
b: Full antiprion activity is the estimated lowest concentration of test compound required 
for complete reduction of PrPSc. 
c: Approximate maximal concentration that has no effect on the rate of cell growth to 
confluency. 
d: Ratio = TC/EC50. 
The positive control and reference compound, quinacrine was found to have an  
EC50  (0.23 µM) that was comparable to values reported by Doh-ura et al.41 (EC50 0.4 µM 
under similar experimental conditions) and Dollinger et al. 92 (EC50 0.3 µM, incubation 
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period of 7 days). The Group 1 compounds were structurally similar to quinacrine which 
would explain why their EC50 values were generally comparable to quinacrine except for 
1 (EC50 0.021 µM) which was 10 times more potent. In 1, the terminal N’,N’-
diethylamino functionality was separated from the 9-amino group on the acridine ring by 
two carbon atoms. Its outstanding activity may be influenced by the distance (2 carbon 
atoms) separating the two amino groups of the side chain since increasing the distance (as 
in 3 and 4) resulted in a loss in activity. The substitution of the terminal amino function 
did not seem to be critical for activity as seen from the similar EC50 values of the N’,N’-
dimethylamino (2, EC50 0.11 µM) and  N’, N’-diethylamino (3, EC50 0.14 µM) analogs. 
The activity of 4 was noteworthy because it was structurally most alike quinacrine except 
for the absence of a chiral carbon in its side chain.  That the EC50 value of 4 was very 
similar to quinacrine suggested that the loss of chirality did not adversely affect antiprion 
activity. 









Compound Substituent (R) EC50 (µM)a FAA (µM) b TC (µM) c Ratiod 
5 2’-N(CH3)2 
0.25 








e 2.0 4 
8 3’-N(C2H5)2 
1.01 
(0.85, 1.21) 2.5 3.0 3 
























(1.16, 1.42) 3.0 4.0 3 
15 N N CH33'
 
0.29 
(0.26, 0.33) 1.0 4.0 14 
16 N N CH34'
 
0.10 
(0.08, 0.12) 0.4 2.5 25 
a: EC50 is the average of at least 3 independent determinations. 95% confidence intervals 
are given in the brackets. 
b: As defined in Table 3.1. 
c: As defined in Table 3.2. 
d: Ratio = TC/EC50. 
e: “None” denotes the compound has no effect at non-toxic concentrations. 
 
The 12 compounds in Group 2 were characterized by the presence of a N9-
(substituted phenyl) side chain with tertiary N,N-dialkylamino groups (5-9) or nitrogen 
based heterocycles (10-16) as substituents. The antiprion activities of this group of 
compounds were generally weaker than quinacrine and Group 1, with only two 
compounds (11, 16) more potent than quinacrine and two others (5, 15) with comparable 
activity. The results showed that the following features were not critical in influencing 
activity, namely the type of substituent (basic heterocyclic ring or dialkylamino) attached 
to the ring and the position (ortho, meta, para) to which it was attached. Although the 
 78
most active compounds in Group 2 had basic heterocyclic substituents (piperidinyl in 11, 
N-methylpiperazinyl in 16), weak activities were also detected in members with similar 
groups (piperidinyl in 12, morpholinyl in 14). 
Table 3.4: Antiprion activities of other compounds (Groups 3,4,5) on the ScN2a cell line. 






































Nonee 0.4 2 
a: EC50 is average of at least 3 independent determinations. 95% confidence intervals are 
given in the brackets. 
b: As defined in Table 3.1. 
c: As defined in Table 3.2. 
d: Ratio = TC/EC50 
e: “None” denotes the compound has no effect at non-toxic concentrations. 
For the remaining compounds (Table 3.4), the most notable observation was the 
surprisingly good antiprion activity of 46 (EC50 0.13 µM) in spite of the absence of any 
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substitution on its 9-amino functionality. Interestingly, removing the 6-chloro and 2-
methoxy groups from the acridine ring of 46 gave 47 which was devoid of activity. While 
this may imply an important role for the acridine ring substituents, a comparison of the 
antiprion activities of the ring unsubsituted compound 48 (EC50 0.24 µM) and its ring 
substituted analog 7 (EC50 0.51 µM) showed otherwise. 
Selected compounds from the first round of screening were shortlisted for 
evaluation on other cell models, namely N167, Ch2 and F3.  They were 1, 16 and 46 
which had good activities on the ScN2a cell model, and compounds that were comparable 
or weaker than quinacrine on ScN2a (12, 15, 32). The positive control quinacrine was 
included. The results are given in Table 3.5.   
Table 3.5: Antiprion activities of quinacrine and selected compounds on different prion 
cell lines. 
Prion-infected cell lines 
























































































































0.4 Nonec Nonec Nonec Nonec NDd NDd 
a: Concentration (µM) required to reduce PrPSc content to 50% of untreated cells from 3 
independent determinations.  95% confidence limits are given in thebracket.   
b:  As defined in Table 3.1. 
c: No effect at non-toxic concentrations. 
 d: Not determined. 
 
As mentioned earlier, a promising antiprion hit compound would be active on 
more than one cell model. In this regard, compounds 1, 12, 46 were not promising hits 
and only 15, 16 and 32 warranted further attention. Quinacrine was also active against the 
4 cell models with potencies varying in the order of ScN2a (most potent) >  Ch2 > N167 
> F3 (least potent). No FAA value was obtained on N167 and F3 which meant that 
quinacrine was unable to completely eradicate PrPSc formation in these cells even when 
tested at the highest concentration that did not affect cell viability. Both N167 and F3 
were derived from the N2a subclone that over-expressed PrPC and this may account for 
their resistance to antiprion agents, as seen from the generally higher EC50 values on 
these models. Of the 3 hit compounds (15, 16, 32), 32 stood out in that it was equally 
active (EC50 0.41-0.49 µM) on ScN2a, Ch2 and N167 cell models although it lacked an 
FAA value on F3. In deciding which compound to focus on for structural modification, 
16 and 32 were selected because they were from different Groups and thus structurally 
dissimilar. 16 was preferred to 15 because it had a more desirable antiprion profile as 
seen from Table 3.5.     
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In the second phase of screening, 20 analogs related to 16 and 32 were evaluated 
on the ScN2a, N167 and F3 cell models. Ten analogs were prepared to interrogate the 
structure-activity relationship of 16. EC50 and FAA values of 6 analogs are presented in 
Table 3.6. 
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Table 3.6: Antiprion activities of structurally related analogs of 16 on the ScN2a, N167, and F3 cell lines. 
ScN2a cell line N167 cell line F3 cell line 

















































































































3.0 Noned - 8 
a: EC50 values were obtained from at least 3 independent determinations. 95% confidence intervals are given in the 
brackets. 
b: As defined in Table 3.2. 
c: Approximate maximal concentration that has no effect on the rate of ScN2a cell growth to confluency. 
d: “None” means that the compound has no effect at non-toxic concentrations. 
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The N-methyl group of the piperazine ring in 16 was replaced by ethyl in 17 and 
methyl carbonyl in 19. Both compounds were slightly more potent than 16 on ScN2a but 
failed to demonstrate activity on F3.  It was noted that the terminal nitrogen in piperazine 
was now part of an amide moiety in 19 and hence not basic. But this was unlikely to have 
affected the activity of 19, noting that 17 in which the terminal nitrogen of piperazine 
retained basic character had almost the same activity profile as 19.   
In 22, 23 and 24, a carbon spacer was inserted between the phenyl ring and the 
nitrogen heterocyle. In 22 and 24, the carbon spacer was a methylene group and both 
compounds were comparable to 16 in their activities on F3. In 23, a carbonyl group was 
inserted between the phenyl and 4-(1-piperazinyl) rings, thus introducing an amide bond 
between the 2 rings. Accordingly, the terminal basic ring (N-methylpiperazine or 
piperidine) of 22 and 24 would have greater conformational flexibility than the 
corresponding ring in 23.  It was tempting to attribute the significantly poorer activity of 
23 to a loss of rotational flexibility in its side chain. However other factors (lipophilicity, 
H bonding) may be involved as well. While a case may be made for retaining flexibility 
in the linker between the two rings, the more important finding to emerge from 22, 23 
and 24 was their consistent activity against all 3 cell models. Thus separating the 2 rings 
by a carbon spacer generally had a more positive effect on activity while changes made to 
the terminal nitrogen of piperazine (17, 19) were less favorable. 
Compound 42 was unlike the others listed in Table 3.6 in that it had no phenyl 
ring. In its place was a but-2-ynyl moiety which was used here as a phenyl isostere. The 
effect of this replacement was not encouraging. It was inactive on F3 although it was 
more potent than 16 on ScN2a. 
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Table 3.7: Antiprion activities of compounds 25, 45, 54, and 60 on the ScN2a, N167, and F3 cell lines. 
ScN2a cell line N167 cell line F3 cell line 


































































   
a: EC50 values were obtained from at least 3 independent determinations.  95% confidence intervals are given in the 
brackets. 
b: As defined in Table 3.2. 
c: Approximate maximal concentration that has no effect on the rate of ScN2a cell growth to confluency. 
d: “None” means that the compound has no effect at non-toxic concentrations. 
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Table 3.7 represents the remaining 4 compounds that were structural analogs of 
16. It was noted earlier that 46 which had only a 9-amino group demonstrated 
surprisingly good activity on ScN2a (EC50 0.13 µM). Here, it was shown that successive 
substitution of the 9-amino functionality with N-phenyl in 25 and N-methyl-N-phenyl in 
45 resulted in a progressive loss in activity (ScN2a). The observation that no F3 activity 
was observed for all 3 compounds (25, 45, 46) implied that having basic substituents on 
the phenyl was a necessary (but still not sufficient) requirement for F3 activity. The need 
to keep the NH on the 9-amino functionality may also be important but required 
confirmation. 
Compounds 54 and 60 were evaluated to provide insight on the contribution of 
the substituted acridine ring for antiprion activity. The 6-chloro-2-methoxyacridine ring 
was replaced by 6-chloro-1,2,3,4-tetrahydroacridine in 54 and 7-chloroquinoline in 60.  
These replacements resulted in a significant reduction in toxicity as seen from the higher 
concentrations (≥ 10 µM) required to adversely affect the viability of uninfected N2a 
cells. Of the two compounds, the quinolinyl analog 60 gave a better antiprion profile.    
Twelve analogs of 32 were evaluated to provide insight on the structure-activity 
relationship of 32 (Tables 3.8, 3.9, 3.10).  Compounds 33-36 were modified to include a 
para substituent (drawn from each of the four quadrants of the Craig Plot) on the benzyl 
sidechain of 32. As seen from Table 3.8, only the p-methyl analog 33 retained activity on 
the 3 cell models.  The methyl substituent in 33 was electron donating (-σ) and lipophilic 
(+π) and the combination of these properties may be reason why it had a better antiprion 
profile than the other p-substituted analogs 34-36.  
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ScN2a cell line N167 cell line F3 cell line 
Cmpd R 
EC50 (µM) a FAA (µM) b EC50 (µM) a FAA (µM) b EC50 (µM) a FAA (µM) b 
TC 
(µM) c 
32 H 0.42 (0.38, 0.46) 1.0 0.49 (0.49, 0.55) 1.5 0.80 (0.64, 1.00) None 2 
33 CH3 0.15 (0.12, 0.19) 3.0 0.62 (0.49, 0.80) 1.0 0.63 (0.53,  0.75) 3 5 
34 Cl 0.28 (0.24, 0.33) 1.0 0.34 (0.15, 0.78) 3.0 Noned - 12 
35 OCH3 0.082 (0.063, 0.11) 1.5 0.52 (0.47, 0.58) 2.0 Noned - 10 
36 CN 0.55 (0.49, 0.63) 1.0 0.14 (0.081, 0.25) 1.0 Noned - 5 
a: EC50 values were obtained from at least 3 independent determinations. 95% confidence intervals are given in the brackets. 
b: As defined in Table 3.2. 
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c: Approximate maximal concentration that has no effect on the rate of ScN2a cell growth to confluency. 
d: “None” means that the compound did not have the effect at non-toxic concentrations. 















































































   
a: EC50 values were obtained from at least 3 independent determinations. 95% confidence intervals are given in the brackets. 
b: As defined in Table 3.2. 
c: Approximate maximal concentration that has no effect on the rate of ScN2a cell growth to confluency  
d: “None” means that the compound did not have the effect at non-toxic concentrations.
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The effect of lengthening the carbon spacer between the piperidine and phenyl 
rings was investigated in 37 and 41. The results showed that both the 2-carbon (37) and 
3-carbon (41) homologs retained activity on the 3 cell models but with better activity 
found in the 2-carbon homolog 37. In fact, 37 was the most potent compound against F3 
(EC50 0.19 µM) identified in this investigation and it was able to clear PrPSc in F3 at a 
reasonably low concentration of 2 µM. Attaching a para-methyl group to the phenyl ring 
of 37 caused some loss in activity against F3. These results suggested that there was an 
optimal length for the carbon spacer separating the two rings possibly due to the need to 
maintain lipophilicity and/or flexibility of the side chain within certain desired limits.    
Replacing the piperidine ring of 32 with an 8-azabicyclo[3.2.1]octane ring gave 
43. This modification restricted the conformational flexibility of the piperidine ring. 
Antiprion activity of 43 showed a modest improvement compared to 32 across all 3 cell 
models.  On the other hand, 43 had the lowest FAA value (1.5 µM) among the test 
compounds.  Thus, restricting the conformational flexibility of the piperidine ring did not 
adversely affect activity.   
Table 3.10 gives the activities of the 6-chloro-1,2,3,4-tetrahydroacridine (51) and 
6-chloroquinoline (57) analogs of 32. The low toxicities of both compounds against non-
infected N2a cells were again observed but this time, both the tetrahydroacridine and 
quinoline analogs had comparable antiprion profiles.  
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Table 3.10: Antiprion activities of compounds 32, 51, 57 on the ScN2a, N167, and F3 cell lines. 
ScN2a cell line N167 cell line F3 cell line 
Cmpd Structure 














































a: EC50 values were obtained from at least 3 independent determinations. 95% confidence intervals are given in the brackets. 
b: As defined in Table 3.2. 
c: Approximate maximal concentration that has no effect on the rate of ScN2a cell growth to confluency 
d: “None” means that the compound did not have the effect at non-toxic concentration.
 93
3.3.2. Effect of lipophilicity on antiprion activity 
There are two basic functionalities in quinacrine, namely the acridine N (pKa 8.2) 
and the side chain diethylamino group (pKa 10.2).136 At physiological pH, it would exist 
predominantly in the di-protonated state (ca 86%) and with lesser amounts of the mono-
protonated species. The ClogP of quinacrine (6.72) provides an estimate of the 
lipophilicity of the non-protonated (free base) species while SlogP (3.97) gives the 
lipophilicity of the fully protonated quinacrine.137 
Most of the Group 1, 3 and 4 compounds have pKa values that fall within the 
range of quinacrine.  The Group 2 compounds have a different pKa profile because the 
side chain basic group was directly attached to the 9-(N-phenyl) ring and would thus be a 
weaker base. Like aromatic amines, the pKa of this nitrogen may be in the range of 5-6.  
Thus, assuming a pKa of 6 for the side chain amino function, di-protonated, mono-
protonated and free base species will be present at physiological pH, with the di-
protonated species likely to be present in smaller amounts than the other two species. 
Unlike di-protonated quinacrine, the mono-protonated species of Group 2 would be 
protonated at the ring nitrogen and not at the less basic side chain aniline-like nitrogen. 
Clog P and SlogP values have been estimated for the test compounds and are 
listed in Appendix 3. Neither parameter correctly reflected the lipophilicity of the 
compound at pH 7 but they provided a back-of-the-envelop means of ranking compounds 
in terms of their lipophilic character. Thus, for the same side chain present in 1 (N,N-
diethylaminoethyl), the tetrahydroacridinyl analog (50, Group 6) was less lipophilic, and 
the 7-chloroquinolyl analog (56, Group 7) even less so.  This was observed for other side 
chains as well (ClogP, SlogP  of 32 > 51 > 57; SlogP of 16 > 54 > 60).  
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An attempt was made to correlate EC50 values from ScN2a and F3 models with 
the lipophilicity of the compounds. A significant correlation was observed only with 
lipophilicity (expressed as either ClogP or SlogP) and EC50 of F3. The Spearman 
coefficients were - 0.660 (p < 0.05, 2-tailed, n =15) for Clog P and -0.704 (p < 0.05, 2-
tailed, n = 15) for SlogP. No correlation with lipophilicity could be established for EC50 
from ScN2a. The relationship between EC50 (F3) and ClogP (or SlogP) was inverse, 
implying that more potent compounds were more lipophilic. The interpretation of this 
relationship was difficult because the predominant state (ionized or non-ionized) of the 
compound was not represented by either ClogP (free base) or SlogP (fully protonated 
species). If the putative target was intracellular, only the non-protonated form (free base) 
was the one to transverse the membrane barrier to reach the site of action. Lipophilicity 
would then be better represented by ClogP and the correlation with EC50 reflected the 
accessibility of the compound to the target site. It must then be assumed that in spite of 
the small amounts of non-protonated species present, the equilibrium between the species 
was adjusted to give more of the non-protonated from as it was transferred across the 
barrier.  The correlation with SlogP was harder to explain and may have arisen because 
ClogP and SlogP were significantly correlated to each other when evaluated by either 
Pearson (coefficient : 0.708, p < 0.05, 2 tailed, n= 60) or Spearman (coefficient: 0.711, p 
< 0.05, n=60) bivariate correlation analysis. 
 
3.3.3. Evaluation of binding affinities of test compounds to human PrP121-231 by 
surface plasmon resonance 
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Surface plasmon resonance (SPR) was used to evaluate the direct binding affinity 
of the compounds for PrPC and to assess the correlation between antiprion activities and 
binding affinities. A truncated human prion protein comprising the carboxy-terminal 
polypeptide (residues 121-231) (hPrP121-231) was used for SPR measurements. It was 
preferred to the full length protein because of its greater solubility and stability under the 
experimental conditions. The protein was immobilized on a CM5 sensor chip 
(carboxymethylated dextran) to give a density of approximately 3000 response units 
(RU). Sensorgrams were obtained for the test compounds which were evaluated at a fixed 
concentration of 50 µM. The sensorgrams provided information on the rates at which the 
compound associated and dissociated from the immobilized peptide. Binding capacity 
was reflected by the maximum response unit (RU) obtained at the end of the association 
phase and quantified in terms of %RUmax, This value represented the percentage of the 
theoretical maximum response assuming a 1:1 stoichiometry for the interaction and was 
normalized to the molecular weights of both the peptide and test compound.  
Representative sensorgrams are given in Figure 3.3. 
Figure 3.3: Interactions of compounds with hPrP121-231 (A) Typical sensorgram of fast 
on/fast off compounds (B) Typical sensorgram of slow on/slow off compounds. Spikes 
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seen at the start and end of injections were due to a slight time delay in the reference cell 
and appeared when reference subtraction was carried out. 
The left panel (A) in the figure shows a sensorgram of a typical compound that 
associates rapidly with the immobilized peptide and dissociates equally fast on washing. 
The maximum RU attained for this compound (quinacrine) was 101 units, equivalent to 
%RUmax of 87.  The right panel B shows the sensogram of a compound that binds slowly 
and does not dissociate completely from the peptide as seen from the failure of the 
descending portion of the curve to reach the base line.  The %RUmax of this compound 
(54) was found to be 127.  Of the 38 (including quinacrine) evaluated, the majority (n = 
34) had profiles that were similar to A. A few compounds (n = 2) showed an intermediate 
profile in which the association and dissociation patterns were slower than A but faster 
than B (for example, 34, 42). 
 
Table 3.11: Binding response of test compounds (n =38) to hPrP121-231 using Surface 





EC50 on ScN2a 
cell line (µM) 
EC50 on F3 cell line 
(µM) 
23 248.06±21.69 231.6 1.23 4.10 
19 224.94±1.82 210.0 0.04 Noneb 
22 215.02±9.72 207.1 0.06 0.86 
17 184.44±24.10 194.2 0.08 Noneb 
4 174.15±7.28 177.6 0.15 NDc 
37 169.48±4.04 173.9 0.13 0.19 
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60 125.71±10.25 165.4 0.14 2.04 
2 132.16±3.75 163.6 0.11 NDc 
47 72.09±11.09 162.2 Noneb NDc 
3 140.18±1.73 162.1 0.14 Noneb 
35 91.8±18.78 159.8 0.08 Noneb 
42 165.21±13.24 158.7 0.03 Noneb 
1 115.54±18.11 153.4 0.02 NDc 
38 169.58±1.43 147.5 0.08 0.69 
24 162.7±7.12 144.4 0.10 0.64 
46 83.05±17.25 139.0 0.13 NDc 
51 92.1±7.18 138.2 0.54 1.19 
9 139.08±29.38 129.4 0.48 NDc 
54 113.75±14.38 127.2 0.08 Noneb 
15 145.25±22.05 122.4 0.29 1.49 
16 130.18±15.06 120.3 0.10 0.68 
41 109.6±1.64 114.8 0.09 1.04 
57 93.85±19.64 113.7 0.15 1.20 
36 129.97±7.89 109.2 0.55 Noneb 
6 94.13±11.20 107.2 0.32 NDc 
48 100.89±1.99 102.6 0.24 NDc 
7 99.77±4.10 100.6 0.51 Noneb 
13 68.08±1.08 99.2 0.90 NDc 
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34 94.54±0.33 98.3 0.28 Noneb 
8 97.69±11.88 97.7 4.24 NDc 
Quinacrine 101.48±14.31 87.3 0.23 1.88 
56 64.01±2.98 85.5 1.56 Noneb 
50 75.81±10.88 82.2 0.51 Noneb 
14 63.78±9.07 72.5 1.28 NDc 
33 85.19±6.63 69.8 0.15 0.63 
25 56.38±7.53 67.3 0.54 Noneb 
32 67.54±10.30 65.4 0.42 0.80 
45 35.00±9.48 43.2 2.51 Noneb 
a: Binding response was obtained from the maximum response at the end of the 
association phase from at least 3 experiments on two different chips.  
b: Inhibition of PrPSc formation was not observed up to the maximal tolerant 
concentration.  
c: Compound was not tested on the F3 cell line. 
 
Table 3.11 lists the binding response (RU), %RUmax and cell-based (ScN2a, F3) 
antiprion EC50 values of the test compounds. The %RUmax values are listed in order of 
decreasing magnitude. A few compounds (5, 10, 11, 12, 25, 43) were not evaluated 
because of inadequate solubility at the test concentration (50 µM). As seen from the 
Table 3.11, RU values ranged from 35 to 248. Nearly ¾ of the test compounds had 
%RUmax values that were greater than 100. Different threshold RU values had been cited 
to indicate binding to the immobilized protein. Heal et al.138 considered compounds to 
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bind to PrPC if they gave RU values of 3.5 and above  while Hosokawa-Muto et al.120 
considered an RU value greater than 30 units to be indicative of strong binding.  Both 
studies used the same Biacore CM5 sensor chip and either the full length protein (Heal et 
al.)138 or the truncated mouse PrPC (mPrPC 121-231) (Hosokawa et al.).120   
In this investigation, the %RUmax of quinacrine was 87. A lower value (37) was 
reported by Touil et al.121 for quinacrine, possibly because of differences in the nature of 
the protein (truncated human PrPC fragment of unknown length but likely to be a C-
terminal fragment) and other experimental conditions. Quinacrine was classified as a 
weak to moderate binder by Touil et al. 114 According to their criterion, compounds with 
very high %RUmax values (≥ 130) were multiple site binders while strong binders were 
compounds with values ranging from 50-129. Weak to moderate binders had values that 
were lower than 50.121 A 1:1 stoichiometry was assumed for compounds that were not 
multiple site binders.  
 Based on these criterion set by Touil et al.114 and using the values of quinacrine 
for comparison (87 in the present study versus 37 in the reported study, approximate 2-
fold difference), the following %RUmax values were proposed for multiple site, strong and 
weak to moderate binders:  Multiple site binders : %RUmax > 260; Strong binders : 
%RUmax between 100 – 259; Weak to moderate binders %RUmax < 100.  The distribution 
of compounds based on their binding affinities is given in Table 3.12. 
As seen from Table 3.12, none of the test compounds were identified as multiple 
site binders.  The majority (n = 30) were strong binders.  It was notable that all the Group 
1 compounds (dialkylaminoalkyl side chain attached to 9-amino function) were strong 
binders in contrast to quinacrine (weak to moderate binder), in spite of their close 
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structural similarities. The Group 7 compounds (4-amino-7-chloroquinolines) were also 
strongly represented among strong binders.  Among the moderate to weak binders (n=7), 
four of them had the same benzylpiperidinyl side chain (32, 33, 51, 57), including 32 
which was a potent hit compound. The other hit compound 16 (Group 2) had stronger 
binding affinities. These observations were in line with those reported by others 
regarding the effect of relatively minor changes in structure on SPR responses.100  
 
Table 3.12: Breakdown of test compounds based on Groups and %RUmax values  
Group Number 
Number of Strong binders 
(%RUmax between 100 - 259)a 
Number of Weak to Moderate 
binders    (%RUmax  < 100) a 
1 4 out of 4 0 out of 4 
2 10 out of 14 4 out of 14 
3 5 out of 8 3 out of 8 
4 2 out of 3 1 out of 3 
5 2 out of 2 0 out of 2 
6 2 out of 3 1 out of 3 
7 2 out of 3 1 out of 3 
a: Based on values given in Table 3.12.  
 
A cursory examination of compound potencies (EC50 values on ScN2a cells) and 
binding affinities expressed in terms of %RUmax suggested that more potent compounds 
were associated with greater binding affinities. For example, there were 9 compounds 
listed in Table 3.11 with EC50 values (ScN2a) less than 0.1 µM and all had %RUmax that 
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exceeded 100. To determine if this correlation is statistically significant, a bivariate 
Spearman correlation analysis was carried out on %RUmax values and EC50 values from 
ScN2a. Indeed, a significant correlation was observed (Spearman rho = -0.635, p <0.0001 
(2-tailed), n=37) and the same was observed when analysis was carried out with EC50 
(ScN2a) values and RU (Spearman rho = -0.573, p <0.0001, n=37). However, no 
correlation was noted for EC50 from F3 and RU or %RUmax, possibly because of the small 
number of compounds (n=15) involved. RU and %RUmax values were not correlated to 
ClogP values of test compounds. 
 
3.3.4. Evaluation of selected compounds for effects on the expression of total and 
cell-surface PrPC by uninfected mouse neuroblastoma cells (N2a) 
Having shown that almost all the compounds were strong binders of PrPC, 
investigations were carried out to determine if these compounds interfered with the 
production of PrPC. Interference with the synthesis of PrPC is one way by which antiprion 
activity may occur.  Thus, selected compounds were investigated for their effects on the 
expression of total PrPC and cell-surface PrPC. 
 Quinacrine and 16 were investigated for their effects on the expression of total 
PrPC by non-infected N2a. Briefly, N2a cells were incubated with different 
concentrations of test compound for 72 hours, after which the cells were lyzed and the 
supernatant was analyzed for the presence of PrPC by immunoblotting. The results are 
shown in Figure 3.4. It can be seen that both quinacrine and 16 did not reduce the 
intensity of bands that were characteristic of PrPC even at concentrations exceeding their 
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EC50 values. The effect of quinacrine was anticipated as it is known not to interfere with 
the synthesis of PrPC. 
Compound 16 (µM) Quinacrine (µM) 
    
Figure 3.4: Effects of 16 and quinacrine on the total prion protein PrPC expression. Bars 
on the left indicate molecular sizes of 45.7kDa, 32.5kDa, and 18kDa. The 
values at the top indicate the concentrations (µM) of test compounds. 
 
PrPC is a glycoslyated protein which is held on the cell surface by a 
glycophosphatidyl inositol anchor.139 Its presence is detected by reaction with fluorescent 
antibodies and quantifying the intensity of fluorescence by flow cytometry.140 This was 
investigated for N2a cells that were exposed to test compound as well as control cells that 
were left untreated. The distribution of treated and untreated (control) cells would show a 
close overlap if the test compound did not interfere with PrPC expression. If the 
compound reduced PrPC expression, less fluorescent antibodies would be attached to the 
cell surface resulting in lower fluorescence and a left shift (indicating lower fluorescence 
intensity) in the distribution of treated cells. As seen in Figure 3.5, overlapping curves 
were observed for treated and non-treated cells tagged with the fluorescent antibodies 





of cell surface PrPC by normal N2a cells. It was noted that curves 1 and 2 which 
represented treated and non-treated cells tagged with isotype matched immunoglobulins 
(non-fluorescent) respectively did not show a strong overlap. This was attributed to the 
intrinsic fluorescence of the test compounds. They may be adsorbed on to PrPC or the 
membrane surface and were not washed out during the sample preparation process. The 
greater displacement of curve 2 for 32 was probably due to the stronger intrinsic 
fluorescent property of 32.  
         (a) Quinacrine at 0.4µM       (b) Compound 16 at 2µM    (c) Compound 32 at 2µM 
 
Fluorescence intensity in log scale 
Figure 3.5: Retention of mAb-PrPC complexes on the cell surface of N2a cells in the 
presence of (A) quinacrine (0.4 µM) and (B) compound 16 (2 µM) (C) compound 32 
(2µM). Line 1 : N2a cells not exposed to test compound, immunostained with isotype- 
matched control immunoglobulin instead of anti-PrP antibody. Line 2: N2a cells exposed 
to test compound, immunostained with isotype-matched control immunoglobulin instead 
of anti-PrP antibody. Line 3: N2a cells not exposed to test compound, immunostained 















3.3.5. Evaluation of the potential of test compounds to transverse the blood brain 
barrier 
The parallel artificial membrane permeation assay (PAMPA) was introduced by 
Kansy141 to predict the oral absorption of early discovery drug candidates and has since 
been developed into a high throughput technique by the pharmaceutical industry. An 
equivalent assay (PAMPA-BBB) has been developed to evaluate blood brain barrier 
permeabilities of target compounds.122  Both assays operate on the same principle except 
that in the PAMPA-BBB assay, the barrier is made up of porcine brain lipids in dodecane 
instead of phospholipids for the PAMPA assay. Briefly the method involved measuring 
the rate at which the test compound diffused across the lipid layer separating the donor 
compartment (comprising of test compound at 30 or 50 µM in phosphate buffer, pH 7.4) 
from the acceptor compartment filled with the same buffer solution. After 10 hours, the 
amount of test compound in the two compartments were determined by ultra-violet 
spectroscopy and calculated to give the effective permeability (Pe). Validation of the 
method was made by determining Pe values of reference compounds (quinidine, caffeine, 
verapramil) and confirming that they fell within the reported values.122  It should be noted 
that the assay does not provide any mechanistic insight as to how the compound moves 
across the barrier.  It was assumed that compounds transversed the membrane by passive 
diffusion. Table 3.13 provides the Pe values of selected antiprion compounds. Also 
included are the Pe values of other compounds (18, 20, 21, 39, 40) that were synthesized 




Table 3.13: Permeability values and LogP values 
Compound Pea ( x10-6 cm/s) R (membrane retention)a LogPb 
Quinidine 11.48±1.19 0.06±0.03 2.48 
Caffeine 2.46±0.33c 0.01±0.01 -0.80 
Verapamil 18.45±2.26c 0.26±0.10 5.69 
Quinacrine 19.30±2.52 0.24±0.06 5.02 
1 20.98±1.01 0.45±0.01 4.14 
2 13.34±2.20 0.12±0.06 3.57 
3 21.98±4.56 0.30±0.11 4.25 
4 16.37±2.89 0.23±0.03 4.70 
5 10.27±5.11 0.41±0.16 5.72 
6 2.51±0.09 0.48±0.09 5.72 
7 1.68±0.81 0.77±0.08 5.72 
8 5.60±1.83 0.41±0.04 6.40 
9 4.26±0.49 0.55±0.07 6.40 
10 3.98±1.54 0.40±0.05 6.04 
15 4.56±0.35 0.67±0.05 5.48 
16 8.13±2.75 0.54±0.09 5.48 
17 6.13±2.03 0.49±0.21 5.81 
18 6.51±0.23 0.47±0.07 5.06 
19 8.79±0.37 0.34±0.16 4.75 
20 10.29±0.06 0.36±0.06 6.72 
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21 6.07±1.78 0.45±0.05 6.64 
24 5.28±0.34 0.75±0.05 6.11 
34 15.53±0.85 0.45±0.18 5.70 
35 7.54±2.47 0.68±0.10 5.02 
36 9.15±1.11 0.71±0.05 5.18 
37 7.68±2.69 0.63±0.14 5.43 
38 7.39±1.70 0.65±0.13 5.91 
39 7.98±0.85 0.63±0.15 5.98 
40 11.90±2.62 0.66±0.10 5.30 
42 11.52±1.24 0.38±0.04 3.49 
43 8.31±1.28 0.45±0.10 5.42 
46 14.81±4.63 0.44±0.21 3.17 
48 12.47±2.19 0.54±0.30 5.96 
a: Values are presented as mean ± standard deviation 
b: LogP values were determined by ChemDraw Ultra 7.0 
c: Pe values for caffeine and verapramil were reported to be as 1.3 x 10-6 cm/s and 16 x 
10-6 cm/s  respectively.122     
 
The Pe values of the compounds ranged from 22 x 10-6 cm/s to 1.7 x 10-6 cm/s.  
The average Pe values of the major groups represented in Table 3.13 were computed to 
give an idea of permeability changes across these groups, not withstanding the fact that 
not all compounds in each group were evaluated for their Pe values.  It is seen that the 
Group 1 compounds (1-4) had higher mean Pe values (18.2 x 10-6 cm/s) than Group 2 (5-
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24, 6.0 x 10-6 cm/s) or Group 3 (34-40, 9.6 x 10-6 cm/s) compounds. Greater permeability 
was thus found among functionalized acridines that had 9-dialkyaminoalkylamino side 
chains (Group 1) compared to those with functionalized 9-phenylamino (Group 2) or 9-
(N-benzylpiperidin-4-yl)amino (Group 3) side chains.  
Di et al.122 proposed a means of classifying compounds as “CNS +” (high brain 
penetration) or “CNS –“ (low brain penetration) based on PAMPA-BBB results. CNS + 
compounds had Pe values > 4.0 x 10-6 cm/s, CNS – compounds had Pe values < 2.0 x 10-6 
cm/s while CNS+/- compounds (uncertain BBB permeation) had values between 2.0 x 
10-6 cm/s and 4.0 x 10-6 cm/s. Since the present method was based on the reported 
protocol122  and the Pe values of standard compounds (caffeine, verapamil) determined 
here corresponded closely to those indicated in the report, it was reasonable to use the 
reported threshold values to deduce the likely brain permeation properties of the listed 
compounds. Thus, except for some Group 2 compounds (6, 7, 10) which had Pe values < 
4.0 x 10-6 cm/s, the remaining compounds had Pe values that were within the “CNS+” 
range.   
The retention of the test compound by the barrier that separated the donor and 
acceptor cells was also monitored. Compounds with high permeabilities were found to 
have low membrane retention and vice versa. Thus, the Group 1 compounds which had 
the highest Pe values in Table 3.13, had low mean retention values (0.28 ± 0.14) while 
Group 2 and 3 compounds with lower Pe values were retained to a greater degree in the 
membrane. While the high level of membrane retention would hamper diffusion across 
the barrier, it may also function as a “depot” from which compound is released into the 
interior of the cell over time. 
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Having shown that the test compounds had permeabilities that were indicative of 
good penetration across the CNS, a representative compound (16) was evaluated to 
determine if it was a substrate of the efflux transporter Pgp. The Pgp transporter was 
involved in the efflux of quinacrine across the BBB142 and contributed to its low levels of 
accumulation in the brain.95,99  Ghaemmaghami et al.99 showed that when administered to 
mice in which the multidrug resistant (mdr) genes responsible for expression of Pgp were 
removed, levels of quinacrine in the brain were nearly two orders of magnitude higher 
than those in normal mice.  In this part of the investigation, 16 which showed promising 
antiprion activity in cell models, was investigated to determine if it was a Pgp substrate. 
As shown in Table 3.13, 16 had a Pe value of 8.13 x 10-6 cm/s which was indicative of 
good permeability into the brain. Briefly, two cell lines were used for this purpose, 
namely Madin-Darby Canine Kidney (MDCK) cells that were stably transfected with 
human MDR1 cDNA so that they had higher levels of Pgp (MDCK-MDR1) and wild-
type/parental MDCK cells (MDCK-WT) that had normal levels of Pgp. Figure 3.6 shows 
the immunoblots from the cell lines showing the over-expression of Pgp in the same 
MDCK-WT and MDCK-MDR1 cells used for this bidirectional assay. 
                
 
                                                            
                                                                                                                     
Figure 3.6: Over-expression of Pgp in MDCKII-MDR1 cells compared to its wild type 
MDCKII-WT. Blot was done by the labmate Sim Hong May.127 
      MDCKII/MDR1     MDCKII/WT 
   Pgp (170kDa)         
   β-actin                       
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The cells are seeded on the insert (porous filter support) of a Transwell cell 
culture chamber. When confluent, the cells covered the surface of the support to form an 
intact layer with minimal “gaps” in between cells that permitted the test compound to 
move unimpeded across the filter. To ensure the tightness of the cell layer, the 
transepithelial electrical resistance (TEER) of the cell layer was monitored during the 
period of its growth. In these experiments, the cell layer was considered suitable for 
experimentation when TEER values were in the range of 120-150Ωcm2. There were two 
chambers in the Transwell , namely the apical (A) chamber which was the compartment 
in contact with the apical (“top”) surface of the cell layer and the basolateral (B) chamber 
which was in contact with the basolateral (“bottom”) surface of the cell layer (Figure 
3.7). The test compound in buffer was placed in the A chamber and the rate at which it 
transversed the cell layer into the B chamber (containing only buffer) was monitored and 
expressed as the apparent permeability in the A to B direction (P AÆB).  The movement of 
the compound in the opposite direction (PBÆA) was also monitored. If the compound was 
a Pgp substrate, the 2 permeability values would differ, with PBÆA > PAÆB.   Compounds 
with PBÆA  / P AÆB  (“efflux ratio”)  that exceeded 2 were deemed to be substrates of 
efflux proteins.105 
 
Figure 3.7: Transwell apparatus comprises of 2 compartments designated as apical and 
basolateral chambers separated by a layer of confluent cells. 
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Table 3.14 gives the PBÆA  and  PAÆB values of quinacrine and 16 from MDCK WT and 
MDCK-MDR1 cells. The efflux ratio of quinacrine in the MDCK-MDR cells was almost 
4 times greater than the ratio from parental MDCK cells in keeping with the Pgp-
substrate property of quinacrine. In the case of 16, the efflux ratios in MDCK-MDR1 and 
MDCK-WT cells were 2.4 and 1.2 respectively. The 2 fold difference in efflux ratios of 
16 suggested that it was a weaker Pgp substrate compared to quinacrine. 
 
Mass balance measurements showed that most of quinacrine and 16 (ca > 50%) could be 
accounted in experiments involving BÆA diffusion but not in the AÆ B direction. The 
poor mass balance in the AÆB direction was attributed in part to the significant amount 
of compounds retained by the membrane and to a lesser degree by adsorption to the walls 
of the cell chamber. Pgp is asymmetrically expressed in cells, with higher levels found in 
the apical surface than the basolaterial surface. Thus the high level of membrane retention 
observed in the AÆB direction (60-80%, except quinacrine in MDCK-MDR1 cells) may 
implicate binding of the compound to Pgp or other proteins.  
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Table 3.14: Permeability, efflux ratio, mass balance, cell retention and % adsorption onto the Transwell apparatus of Quinacrine and 
16 across MDCK-WT and MDCK-MDR1 cell monolayers. 
Papp (x10-6cm/s)a Mass balance (%)a Cell retention (%)a 
Adsorption on 




















0.14±0.02 0.34±0.10 2.4 12.6±10.9 73.0±13.9 67.0±14.4 44.2±12.8 6.1±3.7 3.1±2.5 
a: Values were presented as Mean ± Standard deviation from three independent experiments. 
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3.4. Discussion 
The ScN2a cell model is widely used for the in vitro screening of potential 
antiprion agents and many promising antiprion agents like quinoline and acridine 
derivatives123 have been identified using this cell model. Here, it was noted that 
while many compounds demonstrated good antiprion activity on ScN2a, they 
were generally less active or inactive against cell models derived from other 
species of scrapie proteins.  For example, 1 which had the lowest EC50 on the 
ScN2a model failed to demonstrate the same level of activity on Ch2, N167 and 
F3 models. In this investigation, promising antiprion leads were compounds that 
retained activity against ScN2a as well as other cell models, in particular, the F3 
model. By these criteria, only 15 compounds had EC50 values against F3. These 
EC50 values were also higher than those obtained for other cell models infected 
with the mouse prion proteins. Structural requirements for activity against F3 did 
not always coincide with those for activity against ScN2a. Notably, lipophilicity 
in terms of ClogP (and SlogP) was significantly correlated to F3 EC50 values but 
not ScN2a EC50 values. 
The first round of screening identified 2 promising hits (16 and 32) which 
had submicromolar EC50 values on 3 cell models (ScN2a, N167, F3). Both 
compounds were closely matched in terms of antiprion activity and equivalent to 
quinacrine in terms of EC50 values (< 2 µM). Structural modifications of 16 and 
32 were carried out in an effort to improve antiprion activity and to provide 
insight into the structure-activity relationship.  In this regard, modifications on 32 
gave better outcomes. Two analogs of 32 (37 and 43) were identified which had 
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lower EC50 values on F3. Moreover, unlike 32 which had no FAA value on F3, 
these were available for both 37 and 43 which meant that they could eliminate 
PrPSc in F3 at non-toxic concentrations. In the case of 16, modification of its 
structure was less promising and no analog with an improved antiprion activity 
was identified. Compounds 22 and 24 are possibly the most promising members 
to emerge but they did not offer any significant advantage in terms of antiprion 
profile over 16.  
An analysis of structure-activity trends showed the presence of a well 
defined SAR which has the following key features.  
(i) Of the 7 groups, Groups 2 and 3 gave the most promising compounds, 
as exemplified by 16 (from Group 2) and 32 (from Group 3). Both groups were 
characterized by the presence of a substituted phenyl or piperidinyl ring at the 9-
amino functionality of the acridine ring. There was a clear preference for these 
motifs over that of a dialkylaminoalkyl side chain (present in Group 1 and 
quinacrine) at the same position.   
(ii) A basic substituent on the 9-(N-phenyl) substituent was necessary if a 
broad spectrum of antiprion activity was desired. Thus, 25 which did not have a 
basic substituent attached to the phenyl ring was moderately active on ScN2a but 
inactive on N167 and F3. A single basic functionality was probably adequate for 
activity. This was deduced from 24 which had a piperidinyl side chain but was 
nonetheless as potent as its piperazine analog 22. More examples were seen in the 
moderately good antiprion activities (ScN2a) of 10-14, all of which have 
monobasic heterocyclic rings. 
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(iii) In both hit compounds (16, 32), two rings (phenyl and N-containing 
heterocyle) were either linked directly (16) or via a carbon atom (32). There was a 
trend towards improved activity when an additional carbon atom was inserted 
between these rings so that they were joined by a longer and more flexible linker. 
This was seen from 22 and 24 where the two rings are separated by a methylene 
moiety and in 37 where the rings were linked via a 2 carbon atom linker. The 
improvement in antiprion activity may be due to the increase in the number of 
rotatable bonds leading to greater conformational flexibility. The concurrent 
increase in lipophilicity may have also contributed to the improved activity 
profile.   
(iv) Lower toxicities and slightly poorer antiprion profiles were found for 
the tetrahydroacridine analogs in Group 6 and quinoline analogs in Group 7. The 
loss in antiprion activity was dependent on the substituent attached to the 9-
amino/4-amino group. From the limited examples, the loss in activity (F3) was 
less in compounds with the 1-benzylpiperidin-4-yl side chain of 32 (51, 57) than 
those with the (4-methylpiperazin-1-yl) phenyl side chain of 16 (51, 57).    
Surface Plasmon Resonance measurements showed that almost all the 
compounds had strong binding affinities to a truncated C-terminal human PrPC 
fragment. There was also a statistically significant correlation between binding 
affinities to PrPC and EC50 values from ScN2a, but not F3 probably because of the 
smaller number of compounds with EC50 values on this cell model. Many of the 
compounds exhibited greater binding affinities than quinacrine on this platform 
but may have a different mode of interaction with the prion protein. Among these 
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compounds were those in Groups 1 and 7. Of the 2 potent analogs 16 and 32, only 
16 was classified as a strong binder. Interestingly, 32 and other analogs with the 
same side chain as 32 (benzylpiperidinyl) were weak binders. The correlation 
between EC50 (ScN2a) and binding affinities was reassuring but should not 
discount the involvement of other targets for these compounds.  Besides showing 
that the target compounds investigated here have good binding affinities to PrPC, 
it was seen that active analogs like 16 and 32 did not alter total cellular and 
surface PrPC levels .Such a reduction is desirable as it leads to lower PrPSc levels.  
The PAMPA-BBB assay was used to assess the potential of the present 
series of compounds to transverse the blood brain barrier by passive diffusion. 
The magnitude and narrow 20-fold range of the apparent permeability values (Pe) 
point to moderate permeabilities within this series. Many of the more potent leads 
identified in this study (16, 37, 38) were less permeable than quinacrine in this 
assay but the difference was no more than 3 fold and for 16, may be compensated 
by its poorer Pgp substrate properties compared to quinacrine. Based on these 
preliminary investigations, the present series of target compounds had good 
potential to transverse the BBB.  The contrasting effects of lipophilicity on 
antiprion activity (ScN2a) and membrane permeability (Pe) point to the need to 
strike a balance with regards to the lipophilicity of the compound. A compound 
that was highly lipophilic may have good antiprion acitivity but this may be 





Forty 9-aminoacridine analogs that were structurally related to quinacrine 
were evaluated for antiprion activity on a battery of cell-based models for prion 
infection.  Almost all the compounds demonstrated activity on the ScN2a model, 
with EC50 values ranging from 0.03 µM to 4 µM (150 fold variation). A smaller 
number of compounds (15) were active on the F3 model and their EC50 values 
(0.2 µM to 4 µM) spanned a narrower 20 fold range. The most promising 
compounds were found in Groups 2 (22, 23) and 3 (37, 43).  They have 
submicromolar EC50 values on 3 cell models (ScN2a, N167, F3) and were able to 
completely eradicate PrPSc in the more resistant F3 model at low concentrations 
(FAA ≤ 3 µM). Analysis of SAR revealed well defined trends for activity which 
suggested a common mode of interaction. This may involve the ability of the 
compounds to bind to PrPC as revealed by SPR measurements. The potential of 
the 9-aminoacridine analogs to transverse the blood brain barrier was comparable 
to that of quinacrine based on their apparent permeability constants (Pe) from the 
PAMPA-BBB assay and one active analog (16) showed a lower tendency to 
function as a Pgp substrate.  In conclusion, the 9-aminoacridine template was a 
promising template from which potential antiprion agents with good in vitro 
potencies and drug-like properties for BBB permeability may be derived.  
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Chapter 4:  Protection of mouse hippocampal HT22 cells against 
glutamate induced cell death 
 
4.1. Introduction 
The glutamate-induced programmed cell death of mouse hippocampal 
HT22 cells, also known as oxytosis, is one of the most robust models available to 
characterize the oxidative mechanisms involved in neuronal degeneration.143 
HT22 cells are immortalized neuronal cells with no ionotropic glutamate 
receptors that could mediate excitotoxicity which involves the activation of 
glutamate receptors, entry of calcium ions into cells and death due in part to the 
generation of mitochondria-derived reactive oxygen species (ROS).144-147 In 
oxytosis, the death of HT22 cells in the presence of high glutamate concentrations 
(ca. 100 µM) was triggered by diminished cystine uptake into the cell via the 
cystine/glutamate antiporter which carries cystine into the cells at the expense of 
the outflow of glutamate. The decreased cystine uptake led to the depletion of 
intracellular glutathione (GSH), a cysteine-containing tripeptide vital for cell 
survival because of its ability to act as an enzyme cofactor and antioxidant. As the 
intracellular GSH level diminished, there was a biphasic increase in ROS levels 
which was initially linear and coupled to the fall in GSH levels. This was 
followed by an exponential rise in ROS not linked to diminishing GSH levels. It 
was proposed that this second phase of ROS production was related to the 
activation of 12-lipooxygenase which induced an exponential burst of ROS from 
the mitochondria by an unknown mechanism.148 A sharp rise in intracellular 
 118
calcium levels caused by the activation of soluble guanylate cyclase then 
followed,149 triggering the massive cell death that characterizes oxytosis which 
morphologically resembles necrosis (mitochondrial swelling, cytoplasmic 
vacuolation) but is more alike apoptosis in terms of biochemical changes 
(requirement for RNA and protein synthesis).143 Most discussions on glutamate-
induced cell death focus on the excitotoxicity pathway but oxytosis is also 
relevant because many neurons do not have ionotropic glutamate receptors but are 
still killed by excess glutatmate in trauma and ischemia.150 
Many compounds are reported to protect cells from oxytosis by 
interrupting with one or more of the three distinct events involved in the cell death 
cascade, namely preventing the depletion of GSH, interfering with ROS 
production and inhibiting calcium influx.143 Flavonoids and tyrphostins were 
interesting examples of such compounds in that fairly small modifications in the 
parent scaffold resulted in analogs that have defined effects on oxytosis. For 
example, a series of flavonoids were categorized as those acting like quercetin, 
galangin or flavonol.151 Quercetin-related compounds upregulated the activity of 
the enzyme (γ-glutamylcysteine synthetase), galangin-related compounds were 
antioxidants and reduced accumulated intracellular ROS while flavonol-related 
compounds were proposed to interfere with the influx of calcium into the cell. In 
the same way, changes in the substitution of the phenyl ring of tyrphostins which 
were derivatives of benzylidene malononitrile, resulted in compounds that 
interrupted specific steps in the oxytosis pathway.152 Some tyrphostins increased 
the basal level of GSH, others acted as antioxidants and eliminated ROS that 
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accumulated as a result of glutamate treatment and yet others which were not 
antioxidants or did not reduce GSH levels, were mitochondrial uncouplers, 
collapsing the mitochondrial membrane potential and thus reducing the generation 
of ROS from the mitochondria.   
This chapter describes the ability of the synthesized compounds to protect 
HT22 cells from glutamate-induced cell death. The investigations were prompted 
by reports that melatonin153 and N,N-diphenyl-p-phenylenediamine (DPPD)154 
protected HT22 cells from glutamate challenge. Herrera and co-workers153 
proposed that melatonin targeted mitochondria to prevent ROS while the 
protective effect of DPPD was attributed to the modulation of gene expression 
leading to the production of proteins with presumably protective properties. 
Structurally, melatonin and DPPD have in common an NH group with limited or 
no basic properties. In melatonin, the NH is part of the indole ring while in DPPD, 
the NH is flanked by two aromatic rings and thus, weakly basic (Figure 4.1). A 
structure-activity investigation showed that 4-aminodiphenylamine retained 
neuroprotective activity but not phenylene diamine or aniline, thus emphasizing 
the need to retain the NH between two aromatic rings for activity. Herrera et al. 
reported that tryptamine and 5-methoxytryptamine, like melatonin, protected 
HT22 cells against glutamate challenge. However, the observation that N-
acetyltryptamine failed to demonstrate activity diminished somewhat the 
importance of the indole NH, although it was the only shared feature among the 
active indole analogs. 
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Of the synthesized compounds, those in Group 2 (and selected members of 
groups 5, 6 and 7) were structurally related to DPPD in having an NH linked to 
two aromatic rings. This motif was absent from the other groups. Hence, it was 
conceivable that the Group 2 compounds would protect HT22 cells from 
glutamate induced cell death due to the presence of the aromatic ring-NH-
aromatic ring motif while compounds in other groups that lack this structural 
motif would have weaker activity or none at all. To test this hypothesis, selected 
compounds from Groups 1-7 that had structurally diverse side chains were 
evaluated for their ability to protect HT22 cells from 5mM glutamate challenge. 
In the case of compounds identified to have protective activity, further 
investigations were carried out to determine if protection was due to GSH 
depletion, preventing ROS accumulation or interfering with calcium influx.  
Figure 4.1: Structures of melatonin, tryptamine and its derivatives, DPPD and 
related compounds.  
 
4.2. Experimental methods 
4.2.1. Materials:  
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The following chemicals were purchased from Sigma-Aldrich Chemical 
Company (MO, USA):  2’,7’-Dichlorofluorescein diacetate (H2DCF) , propidium 
iodide (PI), sulfosalicyclic acid, reduced glutathione (GSH), bovine serum 
albumin (BSA),  baker’s yeast glutathione reductase (E.C. no: 1.6.4.2), potassium 
persulfate 99.99%, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 97% 
(trolox), 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), (2,4-
dinitrophenyl) thiocyanate (DNTB), nicotinamide adenine dinucleotide phosphate 
(NADPH), glutamic acid, penicillin, and streptomycin. Fluo-3 AM and 
dihydrorhodamine 123 (D123) were obtained from Molecular Probes (Eugene, 
Oregon, US). Lysis buffer containing 20mM HEPES, 150mM NaCl, 1.5mM 
MgCl2, 1mM EDTA, 1%v/v TritonX-100 and protease inhibitor, Bradford protein 
dye were purchased from Bio-Rad Laboratories (CA, USA). Dulbecco’s Modified 
Eagle’s medium (DMEM) was prepared by the Media Preparation Unit of 
National University Medical Institutes, Singapore). Fetal bovine serum (cat. no 
10270-106) and trypsin 0.5% 10x with EDTA 4Na (cat. no 15400-054) were 
obtained from Gibco (Auckland, New Zealand). Dimethyl sulfoxide was 
purchased from Merck (NJ, US). Phosphate buffered saline (PBS, pH 7.4, cat. no 
BUF-2040-10x1L) from 1st Base (Singapore) was diluted to 1x using deionized 
water.  PBS 1x contained 10 mM phosphate buffer, 137 mM NaCl and 2.7 mM 
KCl.  
 
4.2.2. Cell Culture 
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HT22 cells were kindly provided by Dr David Schubert (The Salk Institute 
for Biological Studies, La Jolla, CA, USA). The cells (passages 3-15, taking 
passage number 1 for cells received from Dr Schubert) were grown on tissue 
culture flasks (Nunclon ™ ∆ Surface, Thermo Fisher Scientific, Roskilde, 
Denmark) in DMEM supplemented with 10% FBS, penicillin 100mg/L, 
stryptomycin 100mg/L and glucose 4.5g/L. When the cells reached approximately 
50% confluency, they were trypsinized and seeded into appropriate receptacles at 
specified cell densities and grown for 24 hours in a humidified incubator (5% 
CO2, 37oC) for the various experiments.  Bradford protein assay kit (cat. no #500-
203) was obtained from BioRad Laboratories (CA, US). 
 
4.2.3. Cytotoxicity Assay 
HT22 cells were seeded into 96 well plates at a density of 5000 cells/well 
in the above mentioned DMEM (100 µl/well) and incubated for 24 h, 37oC and 
5% CO2. Stock solutions of test compounds were prepared in DMSO and serially 
diluted with media. A stock solution (10 mM) of glutamic acid was prepared in 
DMEM and diluted two fold to give a final concentration of 5 mM in each well. A 
control well contained only glutamate (5 mM) while test wells contained 
glutamate (5 mM) and test compound (at a specified concentration). For the latter, 
the two fold dilution of the glutamate stock solution was made with media 
containing test compound. Another set of wells contained only test compound at 
various concentrations. In all cases, the final concentration of DMSO was kept at 
no more than 0.1% v/v per well. After 24 h at 37oC (5% CO2), the medium in 
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each well was removed by decanting, PBS was carefully added to wash the cells 
and 100 µl of MTT solution (0.5 mg/ml prepared in PBS 1x) was added to each 
well for 3 h at 37oC, 5% CO2. Thereafter, the supernatant from each well was 
removed and DMSO (150µl) was added to dissolve the purple formazan crystals. 
The plates were incubated for an additional 30 minutes before UV absorbance 
readings were taken at 590 nm on a microtitre plate reader (InfiniteTM 200 series, 
Tecan Instruments Inc., NC, USA).  
 
Cell viability at a stated concentration of test compound was expressed as follows: 
% Cell viability =  [A Test Compound -  A No cells]  / [ A Cells Only +  A No Cells]  x 100 
where A is the average absorbance readings of sample wells. 
 
EC50 values were determined from logarithmic plots of % cell viability 
versus concentration using Prism GraphPad Version 4.03 (San Diego, CA, USA) 
with constraints set at 0-100%. At least 3-7 determinations were made for each 
compound at different times to give mean values. EC50 values were obtained for 
each compound in the presence of 5 mM glutamate to assess neuroprotective 
potential and in the absence of glutamate to determine its intrinsic cytotoxicity to 
HT22 cells.   
 
4.2.4. Determination of glutathione content 
5 x 105 HT22 cells were seeded in 100mm culture dishes and incubated for 
12 h (37oC, 5% CO2). They were then treated with 5mM glutamate with/without 
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test compound (final concentration of 1 µM) or were left treated (control) for 
another 12h. Each treatment arm was tested in duplicate on separate plates, with 
one plate used for GSH determination and another for protein determination so 
that total GSH levels could be normalized for total protein content. 
For GSH determination, the cells were washed twice with ice-cold PBS, 
trypsinized and centrifuged (2,000x g, 5 min, 4oC). The supernatant was discarded 
and cell pellets were lysed with 1 ml of 3%w/v sulfosalicyclic acid in PBS, 
vortexed and centrifuged (12,000x g, 5min, 4oC) to remove precipitated proteins. 
GSH content of the supernatant was determined by the method described by 
Tietze155 with some modifications. The assay was carried out on a 96-well plate. 
In each well was added 140 µl of 0.3 M NADPH, 40µl of sample supernatant 
(diluted with sulfosalicyclic 3% in PBS if necessary) and 5 µl of 50units/ml 
glutathione reductase. The plate was warmed to 30oC and 20 µl 6 mM DNTB was 
added and quickly placed on the plate reader (InfiniteTM 200 series, Tecan 
Instruments Inc., NC, USA) to monitor the change in UV absorbance reading at 
412nm for 10 minutes at 1 minute intervals. In this assay, GSH oxidized DTNB to 
give the yellow colored 5-mercapto-2-nitrobenzoate anion. The oxidized GSSG 
(originally present in sample as well as derived from GSH oxidation) was reduced 
by glutathione reductase to give GSH which reacted with DTNB. The recycling 
process greatly improves assay sensitivity and the GSH content was proportionate 
to the rate at which the yellow benzoate anion was generated. For samples with 
low GSH content, the rate of anion formation was slow and monitored over 10 
min while in cases where GSH content was high, the sample was diluted to obtain 
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absorbance readings within the linear range. To determine the GSH content, a 
standard curve (rate of anion formation versus concentration) was constructed 
using known amounts of GSH (1-100 µg/ml) under similar assay conditions. Each 
test compound was evaluated in 3 separate determinations. 
For protein determination, the cells were washed twice with ice-cold PBS, 
trypsinized and centrifuged (2000x g, 5 min, 4oC). The supernatant was removed 
and cell pellet was treated with 400 µl lysis buffer, mixed and incubated at 4oC 
for 30min. The tubes were centrifuged at 12,000x g for 5 min to remove insoluble 
proteins and debris. Protein content of the supernatant was determined with the 
BioRad Bradford protein kit.156 Briefly, 160 µl of the supernatant was thoroughly 
mixed with 40µl Bradford dye for at least 5min but not more than 30 min. 
Absorbance readings were taken at 595 nm. The protein content was determined 
from the standard curve prepared with bovine serum albumin. The total 
glutathione content in each sample was expressed as concentration of glutathione 
in nmoles per mg protein. 
 
4.2.5. Determination of Trolox Equivalent Antioxidant Capacity (TEAC) 
values 
TEAC measures the ability of a compound to quench free radicals 
(antioxidant capacity) compared to that of a standard antioxidant, trolox which is 
a water soluble vitamin E analog. TEAC values were measured using the ABTS 
decolorisation assay as described by Re et al.157 The method was modified to 
accommodate the use of 96 well plates rather than cuvettes. Briefly, the 
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quenching of the stable radical cation of ABTS (ABTS•+) was accompanied by 
the loss of its deep purple colour (monitored at 734 nm) over time. The rate at 
which this loss occurred was compared to that observed under similar conditions 
with trolox and given as a ratio (TEAC). A stock solution of ABTS radical cation 
(ABTS•+) was obtained by reacting 7mM ABTS and 2.45mM potassium 
persulfate in PBS and allowed to stand in the dark at room temperature for 12-16 
hours. This solution was diluted with PBS before each experiment to give an 
absorbance of 0.700±0.020 at 734nm. Test compounds were prepared in stock 
solutions of 2mM in DMSO. Aliquots of test compound stock solution (diluted 
with PBS where necessary) were dispensed into the 96-well plates and topped up 
with the diluted ABTS solution to 200 µl to give the desired concentration of test 
compound. For example, a concentration of 10 µM was obtained by adding 1 µl 
of test compound stock solution (2 mM) and 199 µl of the diluted ABTS solution. 
Absorbance was measured on a plate reader (Benchmark Plus, BioRad, PA, US) 
at 734 nm over 10 minutes at 1 minute interval at 30oC. The plate was shaken 
vigorously (but carefully) before each reading. The assay was performed in the 
dark or dim light. Sample containers were wrapped in aluminum foil to protect 
from light. 
 
 The degree of quenching was determined from the equation: 
+
+
Absorbance of ABTS  in the presence of test compoundDegree of quenching = 1 - 
Absorbance of ABTS  in the absence of test compound
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The degree of quenching was plotted against different concentrations (at 
least 5 concentrations, ranging from 1µM to 20 µM) of a test compound and the 
gradient of the straight line was determined. At least 3 independent 
determinations were made for each compound. The experiment was repeated with 
trolox. The ratio of the gradients of the test compound and trolox gives the TEAC. 
A compound with a TEAC value of 2 has twice the radical quenching ability of 
trolox under similar experimental conditions. 
Gradient of the plot of test compoundTEAC = 
Gradient of the plot of Trolox
 
 
4.2.6. Determination of intracellular ROS levels 
Intracellular accumulation of ROS was determined with H2DCF158 which 
is a cell permeant, non-fluorescent compound that accumulates in cells upon 
deacetylation by membrane-bound esterases. In the presence of ROS, H2DCF is 
oxidized to give fluorescent 2’, 7’-dichlorofluorescein (DCF).159 HT22 cells were 
seeded at a density of 2x105 cells in a 60-mm tissue culture dish (Corning, NY, 
US). After incubating for 12h at 37oC in 5% CO2 atmosphere, the cells were either 
treated with 5 mM glutamic acid only or 5 mM glutamic acid in the presence of 
test compound and further incubated for another 12h. H2DCF at a final 
concentration of 5 µM was added during the last 30 min of the incubation 
period.160 Medium containing detached cells was collected and the attached cells 
were trypsinized. Floating and detached cells were pooled together and 
centrifuged at 2,000x g for 5 min at 4oC. The pellets were washed once with ice 
cold phenol red-free DMEM containing 2% FBS and resuspended again in 1 ml 
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of the same medium containing propidium iodide (PI, 1 µg/ml). Fluorescence 
intensities were collected on 10,000 cells using Dako Cytomation Cyan LX (CA, 
US) with excitation wavelength of 488 nm and emission wavelength of 520 nm 
for DCF, and excitation wavelength of 488 nm and emission wavelength of 610 
nm for PI. Data was analysed with the Summit software version 4.3 (Dako, 
Glostrup, Denmark). At least 3 independent determinations were made for each 
test compound.  The ROS produced in the presence of test compound was 
expressed as a percentage of the total ROS generated in the presence of 5 mM 
glutamate. 
 
4.2.7 Determination of mitochondrial ROS levels 
Mitochondrial ROS production was investigated using dihydrorhodamine 
123 (D123), an uncharged, non-fluorescent agent that was converted by oxidation 
to the fluorescent dye rhodamine 123 (R123). D123 is commonly used either as a 
marker of mitochondrial function or as a specific indicator of mitochondrial ROS 
production.161 Cells with viable mitochondria or with high levels of mitochondrial 
ROS convert D123 to R123 at a faster rate than cells with dysfunctional 
mitochondria or with low levels of ROS. D123 (5 µM) in DMEM was loaded into 
HT22 cells following the protocol described in Section 4.2.6. Fluorescence 
intensity was collected on 10,000 cells using Dako Cytomation Cyan LX (CA, 
US) with excitation wavelength of 488 nm and emission wavelength of 520 nm. 
Data was analyzed with the Summit software version 4.3 (Dako, Glostrup, 
Denmark). At least 3 independent determinations were made for each test 
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compound. The ROS levels measured in the presence of test compound was 
expressed as a percentage of the ROS levels measured in cells treated with 5 mM 
glutamate. 
 
4.2.8 Determination of cytosolic calcium levels 
The intracellular level of calcium was determined using Fluo-3 
acetyoxymethylester (AM) as described elsewhere.162 The membrane permeable 
Fluo-3 AM is converted to Fluo-3 on hydrolysis by esterases in cells and Fluo-3 
increases its green fluorescence when it binds to calcium ions. HT22 cells were 
grown and exposed to glutamate or glutamate and test compound as described in 
Section 4.2.6. Cells were then loaded with Fluo-3 AM (1 µg/ml) in the final 30 
minutes of incubation. Cells were gently trypsinised, centrifuged (2,000x g, 5 
min, 4oC), washed once with ice-cold PBS (1x, pH 7.4) and re-suspended in 1ml 
of phenol red-free DMEM. Fluorescence intensity was collected on 10,000 cells 
using Dako Cytomation Cyan LX (CA, US) with excitation wavelength of 488 
nm and emission wavelength of 520 nm. Data was analysed with the Summit 
software version 4.3 (Dako, Glostrup, Denmark). At least 3 independent 
determinations were made for each test compound. The intracellular calcium 
levels measured in the presence of test compound was expressed as a percentage 
of the total calcium measured in cells treated with 5 mM glutamate. 
 
4.2.9. Statistical Analysis 
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Data was analyzed for statistical significance using the nonparametric 
Wilcoxon signed rank test (SPSS version 13.0, IL, USA) 
 
4.3. Results 
4.3.1. Effects of test compounds on glutamate induced cell death of HT22 
cells 
To determine if the synthesized compounds were effective against 
glutamate-induced toxicity, HT22 cells were exposed to glutamate (5 mM) and 
test compound (at various concentrations) for 24 hours and cell viability was 
determined by the MTT assay. Most cells exposed to 5 mM glutamate alone were 
non-viable (ca 0-10 % viability) after 24 hours. If a compound protected against 
glutamate induced cell death, this profile will be reversed and greater levels of 
cell viability would be evident even in the presence of glutamate. Protective 
ability of the compound was quantified in terms of its half maximal effective 
concentration (EC50) which was the concentration at which 50% of cells remained 
viable in the presence of 5 mM glutamate. EC50 value was determined from dose 
response curves, as shown in Figure 4.2 for 16. Figure 4.2 also shows the dose 
response curves of 16 exposed to HT22 cells in the absence of glutamate. These 
determinations served to evaluate the cytotoxicity of the compound. Ideally, a 
compound should protect against glutamate toxicity at low EC50 while having no 
intrinsic toxicity on the HT22 cells (high EC50). 
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Figure 4.2: % Cell viability of HT22 cells exposed to various concentrations of 
compound 16 in the presence and absence of 5mM glutamate. 
 
Table 4.1 gives the EC50 values of compounds in Groups 1-7 for 
protection from glutamate induced cell death and intrinsic cytotoxicities on HT22 
cells.  Quercetin was included as a positive control as its protective effects had 
been reported.151 Determinations were also made for quinacrine which is the lead 
compound for the current series.    
 
Table 4.1: Protective and cytotoxic ½ maximal effective concentrations (EC50) 
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 (0.19, 0.79) (5.74, 9.84) 






















































































































































































































































































































a: EC50 values are the mean of 3-7 replicates. 95% confidence intervals are given 
in brackets.. 
b: Ratio of EC50 values give an indication of the potential of the compound as a 
protective agent against glutamate induced oxytosis in HT22 cells 
c: “Nil”: Compound has no protective activity.   
 
As seen from Table 4.1, compounds with protective activities were found 
in Group 2 and in lesser numbers, Groups 5, 6 and 7, with EC50 values spanning a 
relatively narrow 20–fold range (0.18 µM to 3.65 µM). The positive control 
quercetin had an EC50 of 3.13 µM which was comparable to its reported value (3 
 141
µM) obtained under similar conditions.151  Quinacrine and its analogs in Group 1 
were devoid of protective activity.  
 
The following structure-activity relationships were deduced from the results. 
(i) The N-phenyl ring present in the Group 2 compounds was an essential 
feature for activity. Removing the N-phenyl group to give the unsubstituted 
primary amino function (as in 46) abolished protective activity. The N-phenyl 
ring was also present in the other active compounds of Groups 5, 6 and 7 and in 
only one instance (tetrahydroacridinyl analogs of Group 6), its omission to give 
the primary 9-amino function resulted in a loss of activity. The exceptional 
activity of 49 (EC50 2.22 µM) stood in contrast to that of other compounds with 
the primary amino function (46, 47 and 55) which were inactive.  The loss of 
activity when the 9-(N-phenyl) substituent was replaced with 9-phenoxy (44) 
further attested to the importance of retaining this feature.  
(ii) The inactivity of 45 in which the 9-NH2 group was di-substituted with 
methyl and phenyl groups was a significant finding as it highlighted the 
importance of maintaining a secondary amino function with an intact NH group. 
Thus, the essential motif for activity was an aromatic ring-NH-aromatic ring 
feature which was present in all the active compounds (barring 49). Replacing one 
of the aromatic rings with an alkyl /alkynyl side chain (as in Group 1 and 42) or a 
heterocyclic ring (for example Group 3 and 43) abolished activity altogether. 
(iii) Substitution of the 9-(N-phenyl)amino moiety in Group 2 was not 
critical for activity but served to moderate activity, possibility by influencing the 
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physicochemical properties of the final compound. That substitution was not 
essential was seen from 25 which in spite of its un-substituted state had strong 
protective properties (EC50 0.54 µM). The likelihood of substituents influencing 
activity by moderating the physicochemical profiles of the compound was 
suggested by the markedly weaker protective activities of compounds with 
hydrophilic substituents such as cyano (26) and hydroxyl (30, 31) as compared to 
those with lipophilic groups like methoxy (29) and fluoro (27, 28). Indeed, a 
significant and inverse relationship was noted when EC50 values and ClogP values 
of the Group 2 compounds were analyzed by Spearman bivariate correlation 
(Spearman rho = -0.542, n= 27,  p = 0.01, 2 tailed). When extended to all 
compounds (n = 34, including those in Groups 5-7), the relationship was still 
maintained (Spearman rho = -0.594,  p = 0.01 level,  2 tailed). Thus, protective 
activity was directly correlated to lipophilicity, which within each group was 
influenced by the type of substitution on the 9-amino /4-amino.  
(iv) The most active compound identified from this investigation was 21 
(EC50 0.18 µM) which belonged to Group 2 and had a benzoylpiperazine side 
chain attached to the para position of the 9-(N-phenyl) ring. Replacing this side 
chain with structurally similar side chains like acetylpiperazine (19, EC50 0.50 
µM) and cyclohexylcarbonylpiperazine (20, EC50 1.34 µM) reduced activity by 
only a narrow 7-fold margin. In fact, the variation in activity within Group 2 was 
limited to no more than 17 fold, an indication of the preferential status of the 
Group 2 motif for protective activity. 
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(v) Active compounds were also identified in Groups 5, 6 and 7 and the 
activities of these compounds showed that the acridine ring need not be 
substituted (Group 5), or could be replaced with other ring systems like 6-chloro-
1,2,3,4-tetrahydroacridine (Group 6) and 6-chloroquinoline (Group 7). However, 
for the same side chain at the 9-amino (or 4-amino) functionality, the most potent 
compounds were those that had the 6-chloro-2-methoxyacridine ring. Compounds 
with the 4-diethylaminophenyl (9, 48, 53, 59) side chain and 4-(4-
methylpiperazin-1-yl) phenyl (16, 54, 60) side chain were illustrative of this point. 
(vi) The cytotoxicities of the active compounds were also determined and 
the relative difference between cytotoxicity and protective activity for each 
compound was given by the ratio of the two EC50 values.  As seen from Table 4.1, 
ratios ranged from 3.5 (31) to 110.5 (21), as compared to a ratio of 3.7 for 
quercetin. Thus, the active compounds had desirable profiles of good activities 
coupled with low toxicities. In terms of cytotoxicities, the Group 6 and 7 
compounds had extremely low toxicities with EC50 values that could not be 
determined (> 25 µM) in many instances. 
 
4.3.2. Effect of incubation time on protective effects against glutamate-
induced cell death 
In the preceding section, protective effects were evaluated by exposing 
HT22 cells to both test compound and glutamate, added at the same time, for 24 
hours. To determine if protective effects were affected by the sequence at which 
test compound/glutamate was added, a time course experiment was carried out for 
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selected compounds (5, 6, 11, 15, 16, 25) in Group 2. These compounds were 
chosen because they had different amino substituents (diethylamino, piperidinyl, 
4-methylpiperazinyl) except for 25 which had an unsubstituted 9-(N-phenyl) ring. 
They also have fairly close EC50 values (0.30 µM to 0.62 µM). From the 
experiments to determine EC50 values, it was known that at 1 µM compound, cells 
were significantly rescued from the glutamate-induced cell death. At 2 µM 
compound, cells were completely saved from the toxic effect of 5mM glutamate. 
Moreover, some compounds have toxicities around 5µM. Hence, in this 
experiment, the compounds were investigated at only two concentrations of 1 µM 
and 2 µM. In view of the narrow concentration window, meaningful dose 
dependent effects over a broad concentration range could not be carried out. 
Nonetheless, the results in figure 4.3 showed that there was evidence of dose-
dependent cytoprotective effects at selected incubation times as discussed in the 
subsequent paragraphs. 
HT22 cells were incubated with glutamate for periods varying from 8 
hours to 14 hours, followed by removal of the media and addition of fresh media 
containing test compound (at 1 µM) and glutamate (5 mM) for a period of time 
equivalent to 24 hours less period of exposure to glutamate. Thus, cells exposed 
to glutamate for 8 hours will be incubated with compound and glutamate for the 
remaining 16 hours while cells exposed to glutamate for 14 hours, will be 
incubated with compound and glutamate for only 10 hours. Cell viability was then 
determined after the incubation period (24 hours). 
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Figure 4.3: Effect of compounds added after exposure to glutamate (5 mM). Each 
point is a mean of 3 independent determinations. * indicates significant difference 
in cell viabilities when treated with 1µM and 2µM compound (p<0.05, 
independent T-test). 
 
Figure 4.3 shows the effects of 5, 6, 11, 15, 16, 25 at 1 µM and 2µM on 
viability of HT22 cells exposed to varying periods of glutamate. It was seen that 
cell viability remained at almost 100% after 8 hours glutamate exposure and was 
*
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maintained at approximately 80% viability after 12 hours glutamate exposure. 
With longer periods of glutamate exposure, the protective effects of these 
compounds were no longer evident, although at a higher concentration of 2 µM, 
two compounds (6, 16) were able to significantly increase cell viability after 14 
hours glutamate exposure as compared to 1 µM (p<0.05, independent T-test). 
 
4.3.3. Effects of compounds 16, 25, 45 and 46 on glutathione levels in HT22 
cells challenged with glutamate 
The initiating event in oxidative glutamate toxicity is the loss of GSH 
from the cells which is caused by the inhibition of cystine uptake by glutamate. 
Cellular GSH is rapidly depleted within 8 hours of glutamate exposure.143 The 
measurement of intracellular GSH is based on a cyclical process involving the 
oxidation of GSH by DTNB to generate the colored 5-mercapto-2-nitrobenzoate 
anion and oxidized GSSG. The latter is reduced back to GSH by the enzyme 
glutathione reductase (Figure 4.4). The recycling process greatly improves the 
sensitivity of the assay and GSH content is determined from the rate at which the 


















Figure 4.4: Principle of the total glutathione assay. 
 
Compounds 16, 25, 45 and 46 were incubated with glutamate (5 mM) for 
12 hours and GSH content was determined thereafter. The compounds were tested 
at 1 µM which was approximately 1.5-2 times the EC50 of 16 and 25. Compounds 
45 and 46 had no protective EC50 values (Table 4.1). As seen from Figure 4.5, 
none of the compounds prevented the loss of GSH caused by glutamate. Thus 16 
and 25 protected HT22 cells from glutamate toxicity by a mechanism(s) that did 
not involve altering GSH metabolism.  
Total glutathione level after 12h treatment
100.00




















Figure 4.5: Effects of test compounds (1 µM) on the intracellular GSH levels of 
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HT22 cells exposed to glutamate (5 mM) and test compound for 12 hours. Control 
consists of cells treated with 0.1%v/v DMSO.  
 
4.3.4. Quenching of the nitrogen based ABTS•+ cation radical by test 
compounds 
The exposure of HT22 cells to glutamate leads to a biphasic increase in 
ROS levels. The first phase is closely linked to GSH depletion and involves a 
linear increase in ROS levels to about 10% of its maximum value.143  The second 
phase involves an exponential rise in ROS levels to almost twice that of basal 
levels in untreated cells and is attributed to an increase in mitochondrial activity. 
The preceding section showed that selected compounds did not prevent the fall in 
GSH levels that accompanied exposure of HT22 cells to glutamate. As the 
intracellular ROS levels would be expected to increase under these conditions, it 
was of interest to determine if the test compounds were antioxidants with radical 
quenching properties. To this end, the Trolox Equivalent Antioxidant Capacity 
(TEAC) of selected test compounds were determined. The scavenging of the 
stable nitrogen radical cation (ABTS•+) which is generated from the oxidation of 
ABTS by potassium persulfate (Figure 4.6) is a well established procedure for 
obtaining TEAC values.157 This method requires comparing the quenching ability 
of the test compound to that of a standard antioxidant trolox. A compound with a 
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Figure 4.6: Generation of ABTS•+ from the oxidation of ABTS. 
 
Table 4.2:  TEAC and protective EC50 values of test compounds. 



































Compound Side chain (R) TEAC values a
Neuroprotective 
EC50 (µM) b 
1 n=2, R=C2H5 Nilc Nilc 
2 n=3, R=CH3 Nilc Nilc 
3 n=3, R=C2H5 Nilc Nilc 












Compound Side chain (R) TEAC values a
Neuroprotective 
EC50 (µM)b 
5 2’-N(CH3)2 2.25±0.06 0.43 (0.19, 0.93) 
6 3’-N(CH3)2 0.77±0.02 0.41 (0.19, 0.85) 
7 4’-N(CH3)2 0.91±0.13 0.45 (0.23, 0.87) 
8 3’-N(C2H5)2 0.64±0.05 0.44 (0.21, 0.92) 
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Compound Side chain (R) TEAC valuesa 
Neuroprotective EC50
(µM) b 




































Compound Side chain (R) TEAC valuesa 
Neuroprotective EC50
(µM)b 







0.90±0.01 0.74 (0.50, 1.07) 
a: TEAC values are mean ± standard deviation for at least 3 determinations. 
b: Values are mean of 3-7 replicates with 95% confidence intervals given in  
brackets. 
c: No neuroprotective activity.  
 
The TEAC values of selected test compounds are given in Table 4.2. The 
most striking observation was that compounds that were protective against 
glutamate-induced cytotoxicity had TEAC values while those with no protective 
properties, had none. There was however no significant correlation between 
TEAC and EC50 values of the active compounds, which was apparent from a 
casual examination of the data. For example, the isomeric 9-N-
(diethylaminophenyl) analogs 5, 6 and 7 had comparable EC50 values (0.41 to 
0.45 µM) but 5 had a TEAC value (2.25) that was twice that of 6 and 7 (TEAC 
values are 0.77 and 0.91 respectively). As a whole, the TEAC values in Table 4.2 
were low (< 1 in most instances). 
Figure 4.7 shows a plot of % quenching (after 10 minutes of incubation 
with ABTS•+) versus concentration of test compound.  It can be seen that for 
some compounds (trolox and 16), quenching ability increased with concentration, 
while for others (quinacrine, quercetin, 5), quenching tapered off after a certain 
concentration and did not show concentration-dependence thereafter. In the case 
of quinacrine, quenching of ABTS•+ reached a plateau at 5 µM and at that point, 
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absorbance was reduced to only 20% of the control. There was however a linear 
rise up to 5 µM but calculating its TEAC based on that portion of the curve 
actually gave quinacrine a TEAC equivalent to that of trolox. This would over-
estimate its quenching properties and it was decided that no value would be 
assigned to quinacrine. In the case of quercetin, there was also limited 
concentration dependence (up to 5 µM) but the % quenching reached the 
maximum level before leveling off. The absence of concentration dependence for 
some compounds was a puzzle. One explanation may be that for these 
compounds, the radical species that was formed after donating a radical (likely 
H•) to quench ABTS•+, now in turn competed with ABTS•+ for radicals. This 
competition may be more significant at higher concentrations of the test 
compound.  
Figure 4.7: Effect of drug concentrations on the degree of scavenging ABTS·+ 
radicals at the10th minute. 
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4.3.5. Effects of compounds 16, 25, 45 and 46 on intracellular ROS 
production 
In the preceding section, it was found that only compounds with protective 
EC50 values against glutamate induced toxicity of HT22 cells were able to quench 
the ABTS radical cation. While this may imply a radical scavenging role for the 
test compound, the caveat is that the ABTS radical quenching assay is a non-cell 
based assay and free radicals (stable nitrogen based radicals) are generated in an 
aqueous environment. In contrast, free radical generation (predominantly ROS) in 
glutamate induced toxicity occurs in the cytoplasm and mitochondria. The 
antioxidant potential of a compound would thus depend not only on its intrinsic 
scavenging activity but also its ability to penetrate lipid bilayers to reach the sites 
of ROS generation, a property that is not adequately addressed by the quenching 
assay involving ABTS radical cations. Hence, in this section, the effect of 
selected test compounds (16, 25, 45 and 46) on intracellular accumulation of ROS 
was determined with H2DCF158 which is a cell permeant,  non-fluorescent 
compound that accumulates in cells upon deacetylation by membrane-bound 
esterases.  
In the presence of ROS, H2DCF is oxidized to give fluorescent 2’,7’-
dichlorofluorescein (DCF).159 The test compound (1 µM) was incubated with 
glutamate (5 mM) for 12 hours before the determination of ROS levels by DCF 
fluorescence using flow cytometry.  It was found that  16 and 25 protected HT22 
cells against glutamate toxicity while 45 and 46 had no protective property. 
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Figure 4.8 shows representative 2-dimensional data obtained from the 
analyses of 16 and 45 in the presence of DCF (for measurement of ROS) and 
propidium iodide (PI, for measurement of cell death).  Panel A shows the profile 
of untreated HT22 cells, with most cells in the R5 section indicating live cells 
with basal levels of ROS. When exposed to glutamate (Panel B), more cells were 
found in R2 which depicted non-viable cells. Panel C shows cells challenged with 
glutamate in the presence of 16. The profile differed from glutamate challenged 
cells (Panel B) in that there were more viable cells (R5) and fewer dead cells 
(R2). This was taken as an indication that 16 restored cell viability to a state 
resembling that of untreated cells. In contrast, 45 failed to rescue cells from 
glutamate challenge (Panel D) and the profile of cells treated with 45 and 
glutamate resembled that of cells treated with glutamate alone (Panel B).     
 
(A) DMSO (B) Glu 5mM 
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(C) Glu 5mM + compound 16 1µM (D) Glu 5mM + compound 45 1µM 
Figure 4.8: Effect of 16 and 45 on ROS levels and viability of HT22 cells treated 
with glutamate after 12 h of incubation.  The horizontal axis displayed DCF 
fluorescence. The vertical axis displayed PI fluorescence. Data from 10,000 live 
cells were collected for each panel. 
Figure 4.9 depicts the ROS levels monitored by DCF fluorescence (based 
on sector R5) in the presence of test compounds and glutamate.  Quantification of 
DCF fluorescence showed that 16 and 25 significantly reduced ROS levels 
(p=0.08 and 0.012 respectively) compared to that observed in the presence of 
glutamate alone but the ROS levels were still higher than the basal levels found in 
untreated cells (p=0.028 and 0.018 respectively). Compounds 45 and 46 were 
unable to prevent the increase in ROS on glutamate exposure. The inactivity of 45 
compared to the radical scavenging activity of 25 was striking and emphasized the 




















Figure 4.9: ROS levels monitored by DCF fluorescence (based on sector R5). 
HT22 cells were treated with glutamate acid 5mM with/without test compound at 
1µM for 12h. Untreated cells exposed to media and DMSO were included as 
control. * indicates significant difference (p <0.05) from cells treated with 
glutamate alone. # indicates significant difference (p <0.05) from control 
untreated cells. Both analyses were carried out with the Wilcoxon signed rank test 
(SPSS v13.0).  
To determine if the test compounds affected mitochondrial ROS 
production, cells incubated with glutamate and test compound were probed with 
the fluorescent ROS sensitive agent dihydrorhodamine 123 (D123) which is an 
uncharged, non-fluorescent agent that is converted by oxidation to the fluorescent 
dye rhodamine 123 (R123). D123 is commonly used either as a marker of 
mitochondrial function or as a specific indicator of mitochondrial ROS 
production.153 Cells with viable mitochondria or with high levels of mitochondrial 
ROS convert D123 to R123 at a faster rate than cells with dysfunctional 
mitochondria or with low levels of ROS. 
* *# #
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   Figure 4.10 shows that cells treated with glutamate and 16 (or 25) 
accumulated significantly lower levels of mitochondrial ROS than cells treated 
with glutamate alone. In fact, the ROS content of these cells were comparable to 
that found in untreated cells. In contrast, there was no decrease in mitochondrial 
ROS levels in cells co-treated with glutamate and 45 (or 46). These results 
reinforced the notion that the radical quenching properties of 16 and 25 

























Figure 4.10: Mitochondrial ROS level monitored by D123 fluorescence. HT 22 
cells were treated with glutamate 5mM with/without test compound (1µM) for 
12h. Untreated cells exposed to media and DMSO was included as a control 
(change DMSO to control) * indicates significant difference (p < 0.05) from cells 
treated with glutamate alone. Analyses were carried out with the Wilcoxon test 
(SPSS v13.0).  
4.3.6. Effects of compounds 16, 25, 45 and 46 on intracellular calcium levels 
The increase in mitochondrial ROS levels observed in glutamate induced 
oxidative toxicity is closely linked to an influx of intracellular calcium which is a 
* *
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necessary step that precedes cell death.143 Thus it was of interest to determine if 
16 and 25 prevented the rise in intracellular calcium levels that was linked to the 
demise of HT22 cells exposed to glutamate. For this purpose, calcium levels were 
monitored with Fluo-3 AM, a membrane permeable calcium ion specific 
fluorescence indicator. Fluo-3 AM is converted to Fluo-3 on hydrolysis by 
esterases in the cell and Fluo-3 increases its yellow-green fluorescence when it 
binds to calcium ions. 
As shown in Figure 4.11, cells treated with glutamate showed a sharp rise 
in Fluo-3 fluorescence, indicating an increase in intracellular calcium levels. A 
sharp decline to almost basal levels was observed when cells were co-incubated 
with glutamate and 16 (or 25).  In the case of 45 and 46, levels of intracellular 




















Figure 4.11: Intracellular Ca2+ levels monitored by Fluo-3 AM fluorescence. 
HT22 cells were treated with glutamic acid 5mM with/without test compound (1 
µM) for 12hours. Untreated cells exposed to media and DMSO was included as a 
control (change DMSO to control) * indicates significant difference (p < 0.05) 
* *
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from cells treated with glutamate alone. Analyses were carried out with the 
Wilcoxon test (SPSS v13.0).  
4.4 Discussion 
The present investigation was undertaken to provide support for the 
hypothesis that compounds with an aromatic ring –NH– aromatic ring motif were 
able to protect neuronal HT22 cells from glutamate-induced oxidative cell death. 
From the results obtained, it is evident that there was indeed a link between this 
structural feature and protective activity. Prior to this finding, only N.N-diphenyl-
p-phenylenediamine (DPPD) and related analogs (Figure 4.1) provided evidence 
of this association.154 Here it is shown that the two aromatic rings need not be 
phenyl but that one of them may be a N-containing heteroaromatic ring. Of the 
compounds that complied with this structural requirement, 80% were from Group 
2 in which the heterocycle was 6-chloro-2-methoxyacridine, and the rest were 
from groups 5, 6 and 7 where an unsubstituted acridine, 6-chloro-
tetrahydroacridine and quinoline were the heterocyclic groups.  
Using the Group 2 compounds, 16 and 25, as representative members, it 
was found that these compounds protected HT22 cells from glutamate challenge 
by influencing similar pathways. Both compounds could not prevent the fall in 
GSH levels that followed glutamate exposure. This may imply that there was no 
effect on the transcription or activity of enzymes like γ-glutamylcysteine 
synthetase, glutathione reductase, glutathione peroxidase involved in GSH 
metabolism. On the other hand, both compounds quenched and prevented the 
accumulation of ROS arising from glutamate exposure. Radical quenching 
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activity was assessed from the TEAC values and it was notable that besides 16 
and 25, only compounds with protective EC50 values had TEAC values, implying 
a radical scavenging role for the active compounds, not withstanding the 
limitations of the method used to generate TEAC. The monitoring of intracellular 
ROS levels with DCF provided more convincing evidence of the ability of 16 and 
25 to cross membrane barriers and quench free radicals.  
In contrast to 16 and 25, compounds 45 and 46 which had no protective 
EC50 values did not show radical quenching properties in similar experiments. 
The inactivity of these compounds provided a strong case for proposing the 
specific involvement of the NH group when flanked by aromatic rings in the 
quenching of radicals. One possibility was that under certain conditions, the 9-NH 
lost one proton by radical abstraction by hydroxyl or similar radical to generate an 
amine cation radical (Figure 4.6) which would quench highly oxidizing radicals 
like OH•.  
 
Figure 4.12: Formation of radical anion from the dissociation of the NH bond in 
compound 25. 
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As seen in Figure 4.12 in which 25 was used as an example, electron 
delocalization and stabilization of the radical specie arising from the loss of H• 
served to promote its formation and enhanced the radical quenching properties of 
25. Reference to the possible radical quenching potential of the NH bond had 
been alluded to in two other instances. DPPD was reported to possess antioxidant 
properties as it decreased intracellular ROS levels in PC12 cells.163,164 Quinacrine 
was cited as an antioxidant based on electron spin resonance measurements that 
demonstrated its ability to scavenge hydroxyl radicals.104 Structurally, both 
compounds do not have phenolic OH or tertiary CH groups that are normally 
linked to antioxidant activity and it was thus assumed that their radical quenching 
properties were due to the NH group. It was noted however that in the present 
investigation, quinacrine did not protect HT22 cells from glutamate toxicity and it 
did not have a measurable TEAC value. The discrepancy may be attributed to the 
non-cell based nature of the electron spin resonance experiments that were used to 
demonstrate the antioxidant properties of quinacrine and the high concentrations 
(≥ 10 µM) of quinacrine that were required for this activity. In the determination 
of TEAC by the ABTS•+ quenching experiments, the scavenging properties of 
quinacrine were observed up to 5 µM only beyond which concentration 
dependence was not evident.   
An important feature of the protective effects of all the test compounds 
was their ability to rescue HT22 cells when added at the same time as glutamate. 
Priming of cells by initially exposing them to the test compound followed by 
glutamate did not appear to be necessary (although it was not investigated here).  
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Interestingly, this was required for DPPD and the implication was that its 
protective effects could involve the activation of a particular transcription 
pathway leading to the production of certain protective proteins. Besides rescuing 
HT22 cells concurrently exposed to glutamate, several Group 2 compounds (5, 6, 
11, 15, 16, 25) demonstrated latent protective effects in that they could rescue 
HT22 cells when added 10-12 hours after glutamate exposure.  Latent protective 
effects were also reported for flavonoids and Nec-1 but at much higher 
concentrations of the test compound  (10 µM for flavonoids, and 25 µM for Nec-
1).151,165  In comparison, the Group 2 compounds were effective at much lower 
concentrations (1 µM).  
The latency of the protective effects of the Group 2 compounds suggested 
that these compounds interfered with the later stages of oxidative cell death, 
namely the ROS surge from the mitochondria and the influx of calcium into the 
cells. The finding that 16 and 25 did indeed reduce mitochondrial ROS as 
measured by D123, a specific indicator of mitochondrial ROS production, and 
also prevented the increase in intracellular calcium levels that was associated with 
the mitochondrial ROS surge, strongly indicated that these compounds targeted 
the mitochondria to bring about their protective effects.  A detailed investigation 
as to how these two closely linked events were disrupted by 16 and 25 is beyond 
the scope of this thesis. Some possibilities are that the compounds function as 
mitochondrial uncouplers and prevent the hyperpolarization of mitochondria 
which results in ROS generation, or interact with channels that are responsible for 
calcium influx, or interfere with signaling mechanisms linking high ROS levels 
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and the opening of calcium channels. That 45 and 46 failed to affect either the 
mitochondrial ROS surge or calcium influx further emphasized the importance of 
the aromatic ring – NH – aromatic ring motif for activity.   
 
4.5. Conclusion 
The main findings of this chapter are summarized in the following points: 
(i) Only the 9-(N-phenyl)amino-6-chloro-2-methoxyacridines of Group 2 
protected HT22 cells from glutamate-induced oxidative cytotoxicity. The acridine 
ring may be unsubstituted or replaced with 6-chloro-1,2,3,4-tetrahydroacridine or 
7-chloroquinoline with no loss of protective activity, in so far as the phenyl-NH-
heterocyclic ring motif is maintained. The substituted acridine ring was associated 
with the most potent activity while analogs with the tetrahydroacridine and 
quinoline rings were less cytotoxic. For many compounds, the difference in 
protective and cytotoxic EC50 values was more than 10 folds which made them 
attractive lead candidates for future investigation. 
(ii) A variety of substituents may be introduced at the 9-(N-phenyl) ring 
with relatively small variations (no more than 17 fold) in protective activity. The 
lipophilicity of the compound which was influenced mainly by the type of group 
present on the 9-(N-phenyl) ring played a significant role, with greater protective 
activity observed with more lipophilic compounds.  
(iii) Time-related experiments showed that Group 2 compounds protected 
against glutamate induced cell death when present at the same time as glutamate, 
as well as when introduced after the addition of glutamate. Representative Group 
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2 compounds (5, 6, 11, 15, 16, 25) were able to “rescue” cells exposed to 
glutamate for as long as 8-10 hours.    
(iv) The protective effects of the Group 2 compounds were not related to 
their effects on GSH levels which remain greatly diminished in cells exposed to 
both test compound and glutamate. Thus, up-regulation of rate limiting enzymes 
involved in GSH biosynthesis may be discounted as a mode of action of these 
compounds.  
(v) The ability to quench free radicals and/or prevent their accumulation 
was strongly associated with the ability of the compounds to protect cells against 
glutamate induced cell death. This was seen from their TEAC values which 
indicated antioxidant activity in a cell-free system as well as their ability to 
prevent the increase in intracellular ROS levels induced by glutamate. The 
presence of an intact NH group at the 9-position of the acridine was an important 
requirement for activity, suggesting that this group is linked to the antioxidant 
potential of the compounds.  
(vi) The latent protective effects of the active compounds were attributed 
to their effects on mitochondrial ROS levels and influx of calcium, both of which 
were late-stage events linked to glutamate-induced cell death.  As in (v), an intact 
NH at the 9 position of the acridine ring was an important requirement for 
activity.
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Chapter 5: Anti-cholinesterase activity of synthesized compounds 
 
5.1 Introduction 
One of the objectives of this thesis was to investigate the multi-targeting 
potential of the acridine scaffold in neurodegenerative disorders. Thus far, the 
functionalized acridines synthesized in this report had demonstrated in vitro 
antiprion activity and were able to protect mouse hippocampal cells from 
glutamate induced oxytosis. In this chapter, the anti-cholinesterase activities of 
the synthesized compounds were explored, prompted in part by the structural 
resemblance of several synthesized compounds, particularly those in Group 6, to 
the prominent anti-cholinesterase agent tacrine. 
Tacrine (9-amino-1,2,3,4-tetrahydroacridine, Figure 5.1), a reversible 
inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), was 
the first drug to be approved by the United States Food and Drug Administration 
for palliative treatment of mild and moderate Alzheimer’s disease (AD).166 
However, it was subsequently withdrawn because of its association to 
hepatotoxicity, slow pharmacokinetics and high incidence of side effects.167 
Nonetheless, interest in the tetrahydroacridine scaffold was not dampened and 
several derivatives were synthesized and evaluated for AChE inhibitory 








Tacrine                 Donepezil 
Figure 5.1: AChE inhibitors approved for the treatment of Alzheimer’s Disease. 
The binding interaction of tacrine with AChE had been investigated in 
detail. A crystalline complex of tacrine with Torpedo AChE showed that the 
tetrahydroacridine ring of tacrine was stacked against the indole ring of a 
tryptophan residue (Trp 84) which was a key component of the anionic site of 
AChE.171 The ring nitrogen (protonated) of tacrine formed a hydrogen (H) bond 
to the main-chain carbonyl oxygen of His 440, one of the 3 amino acids of the 
catalytic triad (the others are Ser 200 and Glu 327) responsible for the hydrolysis 
of the substrate acetylcholine by a charge relay mechanism. H bonding between 
the 9-amino group of tacrine and water molecules were also observed. 
   An alternative binding mode was proposed by Pang and Kozikowski172 
based on computer aided docking. They showed that tacrine had two binding loci 
on the Torpedo AChE, one at the anionic site (π-π interactions with Trp 84 as 
described in the preceding paragraph) and another at the peripheral anionic site 
(PAS) which was located at the opening of the enzymatic binding pocket 
(“gorge”) of AChE. The PAS which was rich in aromatic residues (such as Trp 
279, Tyr 70, Phe 290) was proposed to be a “low affinity” binding site for tacrine, 
which would explain the inability of  crystallography to reveal the binding of 
tacrine to this peripheral site. The apparent role of the PAS was to increase the 
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concentration of acetylcholine at the opening of the active site pocket, ensuring 
that sufficient amounts were made available to the catalytic site which lies at the 
base of the narrow binding pocket.173 Thus, low affinity binding rather than tight 
binding of the substrate to this site was more appropriate. In the case of BChE, the 
sister enzyme of AChE, the number of aromatic residues at the PAS was greatly 
diminished because the active site of this enzyme was wide enough to permit 
diffusion of the putative substrate (the endogenous substrate of BChE has yet to 
be identified) or ligand to the catalytic site of the enzyme.174 
Other functionalized acridines have also been reported to inhibit AChE. 9-
Aminoacridine was as potent as tacrine as an inhibitor of AChE inhibitor175 but 
unlike tacrine, it was proposed to bind to the aromatic residues of the PAS.176 
Alkylene-linked tacrine dimers in which the tetrahydroacridine rings were 
separated by 5-7 carbon atoms were exceptionally strong inhibitors of 
AChE.169,170 They were proposed to bind to both the PAS and the anionic site. In 
view of the absence of PAS in BChE, the bis-tacrines inhibited AChE to a 
significantly greater extent than BChE.169 An interesting observation was that the 
bis-tacrine analog in which the two rings were separated by five carbon atoms, 
disrupted the catalytic triad of AChE and induced unique reorientations at the 
active-site gorge.170 In spite of these drastic rearrangements caused by the 
binding, the inhibitor was still more potent than tacrine in inhibiting AChE, 
suggesting that the energetics of the π-π stacking interactions could overcome the 
energy barrier involved in the re-orientation process.   
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In view of the available literature on the AChE inhibitory properties of 
functionalized acridines and tetrahydroacridines, it was of interest to determine if 
the N-substituted 9-aminoacridines (Groups 1-5), 9-amino-1,2,3,4-
tetrahydroacridines (Group 6) and 9-aminoquinolines (Groups 7) synthesized here 
would inhibit AChE. Thus, a key objective of this chapter was to evaluate their 
AChE inhibitory activities and establish relevant structure-activity relationships. 
The inhibitory potencies of compounds 32, 51 and 57 (Figure 5.2) were of 
particular interest because they bear a N-benzyl-4-piperidinyl side chain which 
was present in donepezil, a long acting anti-AChE agent that is used clinically for 
the symptomatic treatment of AD (Figure 5.1). Compound 51 may be considered 
as a hybrid molecule incorporating the tetrahydroacridine ring of tacrine (but with 
an additional 6-chloro atom) and the side chain of donepezil while 32 and 57 were 
variants of 51, with acridine and quinoline rings in place of tetrahydroacridine. 
Tacrine-donepezil hybrids had been synthesized and reported as AChE inhibitors 
(Figure 5.2)177 and it would be of interest to determine how the hybrid molecules 
in this chapter compare in terms of AChE inhibitory activity.   
 
Figure 5.2: Tacrine-donepezil hybrid molecules reported by Shao et al.177  
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In view of the structural differences between the active sites of AChE and 
BChE, most inhibitors selectively inhibit one enzyme over the other. Tacrine 
itself was a stronger inhibitor of BChE (IC50 92 nM) than AChE (IC50 223 nM).169 
Selective inhibition of BChE had been proposed as a desirable feature for anti-AD 
drugs because BChE activity was found to be significantly increased in the human 
AD brain while AChE activity was decreased.178,179 If so, BChE activity would 
then contribute significantly to the hydrolysis of acetylcholine180 and would be a 
promising target for AD. Thus it was of interest to determine the AChE / BChE 
selectivity profiles of the synthesized compounds.  
 
5.2. Experimental methods 
5.2.1. Determination of inhibitory effects on AChE and BChE 
Human acetycholinesterase (EC3.1.1.7, AChE), equine 
butyrylcholinesterase (EC3.1.1.8, BChE), dithiobisnitrobenzoic acid (DTNB), and 
substrates acetylthiocholine iodide and butyrylthiocholine iodide were purchased 
from Sigma Aldrich Chemical Co, Singapore. Test compounds were screened for 
their anti-cholinesterase activities at a final concentration of 3µM following  the 
Ellman method.181 The assay was carried out on a 96-well plate, with each well 
containing 300 µl of 0.1 M phosphate buffer (pH 8.0), 10 µl of 0.01 M DTNB, 1 
µl of 2 units/ml of AChE or BChE solution, 10 µl of stock solution of test 
compound (prepared in DMSO) and 2 µl of 0.075 M substrate. The substrate was 
added last to start the reaction. Control wells containing the same composition but 
without test compound (10 µl DMSO) were included to give the basal 
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(uninhibited) AChE or BChE activity. Absorbance at 412 nm was recorded every 
minute for 10 minutes at 37oC on a Bio-Rad Benchmark Plus microplate reader. 
The rate of reaction was taken as the slope of the absorbance curve over time. To 
account for non-enzymatic hydrolysis of the substrate, wells containing the same 
composition as the above but without enzyme were concurrently monitored. Non-
enzymatic hydrolysis was however not observed. The percent inhibition was 
calculated as the percentage of the reaction rate of test compound over that of 
vehicle control. Compounds with percent inhibition greater than 75% were further 
tested at 5 concentrations to determine IC50 values using GraphPad Prism v4.03 
(GraphPad Software Inc., CA, US). 
For the determination of enzyme kinetics of selected potent compounds, a 
fixed amount of the enzyme (1 µl of 2 units/ml of AChE or BChE solution) was 
used for these determinations with substrate concentrations ranging from 0 to 450 
mM for both AChE and BChE assays. Determinations were made in the absence 
and presence of test compound. At least 3 different concentrations of test 
compound were used in each instance and the experiment was repeated on 3 
different occasions. Inhibition types and inhibition constants (Ki) were determined 
by SigmaPlot v11.0 and Enzyme Kinetic v1.3 add-on (Systat Software, Inc, CA, 
US). 
The dependence of reaction rate on substrate concentration was assumed 
to follow the Michaelis-Menten kinetics as given in Equation (1) where v = rate of 
hydrolysis, [S] = substrate concentration, Km = dissociation constant for the ES 
complex, equivalent to the concentration of substrate required to produce a rate of 
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Vmax /2 and Vmax = maximal rate of reaction which is attained at infinite substrate 
concentration. 
v = Vmax [S]  /  Km + [S]             (1) 
Taking the reciprocal of Equation 1 gives Equation 2: 
         1/v = 1/ Vmax  + Km / Vmax [S]     (2) 
A plot of 1/v versus 1/S gives a straight line which is the Lineweaver-Burk plot.  
The interception of the x-axis is -1/Km and the interception of the y-axis is 1/Vmax. 
Ki is the intersection point in the Dixon plot (plot of 1/v vs. [I]).182 
 
5.2.2. Molecular modeling 
The x-ray crystallographic complexes of Torpedo californica AChE and 
tacrine (PDB code 1ACJ) and donepezil (PDB code 1EVE) were used for 
docking. The tested compounds were built and minimized by the forcefield 
MMFF94x in Molecular Operating Environment (MOE) 2008.10 (Chemical 
Computing Group, Montreal, Canada). Tacrine was removed and the protein was 
protonated in GOLD software (The Cambridge Crystallographic Data Center, 
Cambridge, UK). The binding site was defined as 15Å from the oxygen of Tyr 
124 side chain as this atom was at the center of the active site.183 100 runs were 
performed for each compound using automatic genetic algorithm parameters. The 
default values of these parameters were: population size: 100, selection pressure: 
1.1, number of operations: 105, number of islands: 5, niche size: 2, migrate: 10, 
mutate: 95, and crossover: 95. Finally, docked poses were visualized and 
examined on MOE.   
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 Similarly, the x-ray crystallographic structure of human BChE (PDB code 
1P0M) was used for docking. Since Tyr 124 was not found in the BChE binding 
site, the latter was defined by the following amino acid residues: Trp 82, Glu 197, 
Ser 198, Glu 325, His 438, Asp 70, Asn 68, Gln 119, Ala 277 which make up the 
anionic catalytic site, catalytic triad and peripheral anionic site.184 Docking 
parameters were similar to those used for the docking onto TcAChE.  
 
5.3. Results  
5.3.1. AChE and BChE inhibitory activities 
AChE and BChE activities were determined by the Ellman’s method181 
which was adapted to a 96-well plate format in this study. Briefly, the assay was 
based on the release of thiocholine when the substrate acetylthiocholine or 
butyrylcholine was hydrolyzed by their respective enzymes (Figure 5.3). 
Thiocholine reacted with 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) by a redox 
reaction to give colored 5-mercapto-2-nitrobenzoate anion which was detected 
spectrophotometrically. When the enzyme was inhibited, less of the yellow 
colored anion would be generated and this was used as a means of assessing the 



























Figure 5.3:  Reactions involved in the determination of AChE activity by the 
Ellman’s method. 
 
5.3.1.1. Inhibition of AChE and BChE at a fixed concentration (3 µM) of test 
compound 
Table 5.1 gives the % inhibition of AChE and BChE by Group 1-7 
compounds tested at a fixed concentration of 3 µM. From the results, the more 
potent compounds were short-listed for the determination of IC50 values. Noting 
that tacrine at 3 µM inhibited AChE and BChE by 91% and 98% respectively, a 
threshold value of 75% inhibition was set for identifying compounds that might 




Table 5.1: Percent inhibition of AChE and BChE by compounds in Groups 1-7 








Compound Side chain (R) % Inhibition AChEa % Inhibition BChEa
1 n=2, R=C2H5 30.4±6.0 83.9±1.5 
2 n=3, R=CH3 32.6±3.4 63.5±4.6 
3 n=3, R=C2H5 47.4±3.9 66.3±0.4 











Compound Side chain (R) % Inhibition AChE a % Inhibition BChE a 
5 2’-N(CH3)2 34.9±1.4 48.0±9.9 
6 3’-N(CH3)2 18.4±7.6 86.3±1.2 
7 4’-N(CH3)2 50.6±2.8 57.1±4.6 
8 3’-N(C2H5)2 31.7±1.8 51.6±5.4 





































17 N N CH2CH34'
 
52.0±4.9 68.3±2.7 
18 N N CH2CH2CH2OH4'
 
NDb NDb 
19 N N COCH34'
 
43.7±2.7 10.2±7.9 
20 N N COC6H114'
 
23.7±5.7 14.7±0.7 
21 N N COC6H54'
 
30.4±3.9 6.5±4.9 
22 N N CH3CH24' 49.6±1.9 25.1±5.6 









25 H 40.9±5.0 30.5±4.5 
26 4’-CN 19.2±2.2 -1.7±3.4 
27 4’-F 45.8±6.4 0.7±0.9 
28 3’,4’-diF 47.2±7.6 -4.6±5.6 
29 4’-OCH3 46.4±9.8 31.3±4.4 
30 3’-OH 5.3±4.7 -3.6±1.6 









Compound Side chain (R) % Inhibition AChE a % Inhibition BChE a
32 n=1, R=H 69.1±3.1 41.9±3.3 
33 n=1, R=CH3 38.3±1.9 12.8±3.8 
34 n=1, R=Cl 64.9±4.9 32.8±3.1 
35 n=1, R=OCH3 34.3±2.1 8.6±5.0 
36 n=1, R=CN 34.0±3.8 35.5±0.9 
37 n=2, R=H 67.8±1.0 38.7±0.6 
38 n=2, R=CH3 71.1±5.3 36.7±2.5 
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39 n=2, R=Cl 78.5±0.2 30.5±5.1 
40 n=2, R=OCH3 82.0±1.6 20.9±1.5 
































Compound Side chain (R) % Inhibition AChE a % Inhibition BChE a













Compound Side chain (R) % Inhibition AChE a % Inhibition BChE a




































Compound Side chain (R) % Inhibition AChE a % Inhibition BChE a
































a : % Inhibition is presented as mean ± SEM from 3 independent determinations. 
b:  Not determined 
 
Notwithstanding the limitations of deducing structure activity relationships 
based on % inhibition, some important observations could be made at this stage of 
the investigation. 
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(i) Outstanding anti-AChE activity was observed in Group 6, with all 6 
compounds inhibiting AChE by more than 75%. The ring scaffold in Group 6 (6-
chloro-1,2,3,4-tetrahydroacridine) was structurally related to that of tacrine except 
for the presence of an addition 6-chloro atom on the ring. It was apparent that the 
6-chloro atom did not adversely affect anti-AChE activity as seen from the 
comparable activities of tacrine and 49. On the other hand, inhibitory activity was 
affected by the type of substitution on the 9-amino functionality. In this regard, a 
phenyl or substituted phenyl ring at the 9-amino group (as in 52, 53, 54) was less 
favored as compared to a diethylaminoethyl (50) or 1-benzyl-piperidin-4-yl (51) 
side chain. 
(ii) Three compounds in Group 3 inhibited AChE by more than 75%. The 
ring scaffold in this Group was 2-methoxy-6-chloroacridine, which was also 
present in Groups 1, 2 and 4 . But no active compounds were observed in these 
groups. Thus, it was clear that the anti-AChE activity of Group 3 compounds was 
due more to the side chain attached to the 9-amino functionality of the ring than to 
the ring itself. In Group 3, the side chain was 1-benzyl-4-piperidinyl (32) or its 
structural variants. Interestingly, the 1-benzyl-4-piperidinyl side chain was present 
in the clinically used anti-AD drug, donepezil. However, the compound in Group 
3 with this side chain (32) was not an exceptional inhibitor of AChE (69%), 
suggesting that the change in scaffold (tetrahydroacridine to acridine) contributed 
to the diminished activity. However,  this was compensated to an extent  by 
lengthening the alkyl chain separating the terminal phenyl from the piperidine 
ring of the side chain to two carbon atoms (in which case substitution of the 
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phenyl ring was required, as seen in 39 and 40) and three carbon atoms (as seen in 
41). The 3-carbon homolog 41 (96% inhibition) was as potent as tacrine (91% 
inhibition) in inhibiting AChE. On the other hand, the 2-carbon homolog 37 was a 
weak inhibitor (67%, and comparable to 32) and required substitution on the 
phenyl ring to bring about greater inhibition. 
(iii) Groups 1, 2, 4 and 7 did not yield compounds that inhibited AChE by 
more than 75%. Their poor activities reflected interplay of the ring scaffold and 
the substituent attached to the 9-amino functionality in influencing inhibitory 
activity. The 6-chloro-2-methoxy acridine ring was not a favored ring scaffold 
and when coupled with a phenyl/substituted phenyl at the 9-amino group, resulted 
in poor anti-AChE activity. Thus none of the 26 compounds in Group 2 inhibited 
AChE by more than 75%. An alkyl or alkynyl side chain attached to the same ring 
scaffold was also detrimental as seen from the poor activities of Group 1 and 43 
of Group 4. 7-Quinoline was even less favored as a ring scaffold as seen from the 
exceptionally poor activities of the Group 7 compounds. In fact, for the same side 
chain at the 9-amino/4-amino function, compounds with the quinoline ring had 
the lowest anti-AChE activity. 
(iv) 9-Aminoacridine (47) of Group 4 was a potent AChE inhibitor which 
was in keeping with literature reports.175 The sharp decline in activity when a 
substituted phenyl was attached to the 9-amino functionality (as in 48) provided 
further confirmation of the detrimental effect of this structural modification. 
(v) Turning to anti-BChE activities of Groups 1-7, it was noted that 
Groups 3 and 6 which yielded the most active anti-AChE compounds were not 
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particularly outstanding as anti-BChE agents. This was most apparent in Group 3 
and to lesser degree in Group 7 where 3 compounds (49, 50, 51) were still able to 
inhibit BChE by more than 75%. Interestingly, good BChE inhibitory activity was 
observed among many compounds in Groups 1 and 2 which had poor anti-AChE 
activities. Clearly, the dialkylaminoalkyl and substituted phenyl substitutents on 
the 9-amino functionality did not adversely affect BChE activity. There was an 
indication that an unsubstituted acridine ring may be a desirable scaffold for 
BChE activity but this is based on only one compound (48) which inhibited BChE 
by 86% as compared to 56% for its Group 2 analog (9). The N-substituted 4-
amino-7-chloroquinolines of Group 7 were found to be extremely weak inhibitors 
of BChE.   
 
5.3.1.2. AChE and BChE inhibitory activities of selected compounds based 
on IC50 determination 
In the next stage of the investigation, IC50 values for AChE and BChE 
inhibition were determined for compounds that inhibited either enzyme by more 
than 75%. These were 39-41 (Group 3), 47 (Group 5), 49-54 (Group 7) which 
inhibited AChE by more than 75%, and  1, 4 (Group 1), 6, 10, 24 (Group 2), 47, 
48 (Group 5), 49 -51 (Group 7) which inhibited BChE by more than 75%. The 
results are given in Table 5.2. Representative plots of % inhibition versus 
concentration are given in Figure 5.3. 
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> 3000 0.46 
a IC50 was determined by GraphPad Prism v4.03 from at least three independent 
experiments. 95% Confidence intervals are given in brackets. 
b  Ratios > 1 indicate selective inhibition of BChE. Ratios < 1 indicate selective 
inhibition of AChE. In cases where IC50 ≥ 3000 nM, a value of 3000 was taken to 
compute the ratio. 
c  Reported IC50 for human AChE : 147 nM ±11 50,  424 nM ±21 185 
d Reported IC50 for human BChE : 36 nM ± 4 50;  45.8 nM ± 3.0 185 




Figure 5.4: Anti-AChE activities vs. concentrations of tacrine, compounds 47, 49, 
and 51. 
With IC50 values, a more definitive structure-activity relationship could be 
obtained, the main points of which are highlighted in the following paragraphs. 
Introducing a 6-chloro atom on to tacrine gave 49, which was a stronger 
(20 folds) and more selective inhibitor of AChE. Its selectivity ratio 
(IC50AChE/IC50BChE) was 0.58 implying selective inhibition of AChE, as compared 
to 28 for tacrine which indicated selective inhibition of BChE. The preference for 
selective inhibition of AChE was observed for all the compounds in Group 6 
which share the same ring structure as 49, implying an important role for the 6-
chloro atom in changing the inhibitory preference. 
When the tetrahydroacridine ring of tacrine was replaced by acridine, the 
resulting compound 47 (9-aminoacridine) maintained the same inhibitory profile 
as tacrine, both in terms of IC50 values and preferred inhibition of BChE. 
Interestingly, substitution of the 9-amino of 47 with a 4-(diethylaminophenyl) 
group (48) sharply decreased both AChE and BChE inhibitory activities, besides 
reducing the preference for BChE inhibition. The Group 2 compounds (6, 10, 17, 
24) were very similar to 48 in this regard: they were also poor AChE inhibitors 
(IC50 > 3000 nM) and had the same selectivity ratios as 48 (2.3 compared to 2.2-
4.5). Thus, the poor AChE inhibitory activities of the Group 2 compounds owed 
more to the presence of the  9-(N-substituted phenyl)amino side chain (comparing 
47 and 48) and less to the inclusion of chloro and methoxy groups to the acridine 
ring. Indeed, when the substituted phenyl ring was removed and replaced by the 
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donepezil-like side chains of Group 3, there was a marked improvement of AChE 
inhibitory activity as well as a return to selective inhibition of AChE, comparable 
to that observed with the tetrahydroacridine analogs of Group 6. In contrast, 
replacing the substituted phenyl ring of Group 2 with a diethylaminoalkyl side 
chain (1, 4 in Group 1) retained the same inhibitory profile. Both Group 1 and 2 
compounds were weak AChE inhibitors, with an apparent selectivity for BChE 
inhibition. 
The most potent AChE inhibitor identified in this investigation was the 
compound 51 from group 6 (IC50 5.7 nM). It was more potent than tacrine and 
also highly selective for AChE inhibition (selectivity ratio of 0.02). No compound 
was identified to be a more potent BChE inhibitor than tacrine although 47 (9-
aminoacridine) and 49 (9-amino-6-chloro-1,2,3,4-tetrahydroacridine) had almost 
comparable IC50 BChE values as tacrine. They were however less interesting 
compounds because of their under-functionalized structures. The Group 6 
compound 50 was the next most potent BChE inhibitor identified here. It was also 
a stronger AChE inhibitor than tacrine and had a selectivity ratio of 0.5, indicating 
preferred inhibition of AChE. 
 
5.3.1.3. Kinetics of the inhibition of AChE/BChE by tacrine and compounds 
47, 49-51 
Next, the modes of inhibition of tacrine and selected AChE and BChE 
inhibitors (47, 49, 50, 51) identified in this study were investigated. The rates of 
AChE or BChE-catalyzed substrate hydrolysis were determined over a range of 
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substrate concentrations and transformed to the reciprocal Lineweaver-Burk plot 
for more accurate determination of Km and Vmax of the enzyme. When repeated in 
the presence of different concentrations of inhibitor, Ki of the inhibitor 
(dissociation constant of the enzyme-inhibitor or EI complex) was obtained and 
the type of inhibition (competitive, non-competitive, uncompetitive, mixed 
inhibition) deduced from the Lineweaver-Burk plot. Non-competitive and 
uncompetitive-type inhibitions are uncommon for single substrate reactions, thus 
the types of inhibition observed here were likely to be of the competitive or mixed 
inhibition types. The Km of AChE was estimated to be 0.15 mM which was 
comparable to a reported value (0.17 mM) in the literature using the same method 
and enzyme source.183 The Km of BChE was found to be 0.54 mM but no value 
from the literature could be found for comparison. Representative Michaelis-
Menten and Lineweaver Burk plots for the steady state hydrolysis of substrate by 
AChE and BChE, and in the presence of inhibitors tacrine, 49 and 51 are 



















































































































































































Figure 5.5: Steady-state inhibition of AChE hydrolysis acetylthicholine and 
Lineweaver-Burk plots of initial velocity versus substrate concentrations in (A) 
absence of an inhibitor, presence of inhibitors (B) tacrine, (C) 49 and (D) 51 are 





































































































































































































Figure 5.6: Steady-state inhibition of BChE hydrolysis acetylthicholine and 
Lineweaver-Burk plots of initial velocity vs. substrate concentrations in (A) 
absence of an inhibitor, presence of inhibitors (B) tacrine, (C) 49 and (D) 51 are 
presented. Lines were derived from a weighted least-squares analysis of the data 
points. 
Inspection of the Lineweaver-Burk plots obtained for the hydrolysis of 
acetylthiocholine by AChE in the presence of inhibitors tacrine, 47, 49-51 showed 
increasing slopes (lower Vmax) and smaller x-intercepts (higher KM) with 
increasing concentration of inhibitor. This profile was typical of mixed inhibition.  
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In mixed inhibition, the inhibitor (I) binds to both the ES (enzyme 
substrate) and ESI (enzyme-substrate-inhibitor) complexes. The substrate S 
dissociates from the ES complex at a faster rate from the ESI complex. Thus the 
ESI complex is nonproductive. As long as the inhibitor is present, some of the 
enzyme will always be in the non-productive ESI state, even at very high 
substrate concentrations. In effect, this lowers the concentration of the free 
enzyme. Therefore, Vmax will be less than that of the free enzyme (steeper 
gradients in the presence of inhibitor). Moreover, a portion of the enzyme 
available for substrate binding will be in the low affinity EI form. Thus, the Km 
will be greater than that for the free enzyme. 
  On the other hand, the Lineweaver-Burk plots obtained for the hydrolysis 
of substrate by BChE in the presence of inhibitors, tacrine, 47, 49-51 is typical of 
competitive inhibition. In competitive inhibition, the inhibitor competes with the 
substrate for binding at the active site. The affinity of the substrate for the enzyme 
is thus reduced (larger Km) but at sufficiently high substrate concentrations, the 
inhibitor is displaced by the substrate, thus maintaining the same Vmax. In the 
Lineweaver Burk plot, the substrate-only response is displaced in the presence of 
inhibitor to yield steeper responses that intersect at the same point on the y-axis 
but not at the x axis. 
Table 5.3 summarizes the inhibition type, Ki and selectivity ratios of 
tacrine, 47 and 49-51 for the inhibition of AChE and BChE. With one exception 
(AChE inhibition by 47), the sequence of inhibitory potencies expressed in terms 
of Ki closely parallel their IC50 values for both enzymes. In the case of 47, its IC50 
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value for AChE inhibition (224 nM) was comparable to that of tacrine (182 nM) 
but in terms of Ki, 47 was a stronger inhibitor than tacrine, The selectivity ratios 
obtained using Ki or IC50 values showed similar trends. 
 
Table 5.3: Inhibition type, Ki and selectivity ratios of Tacrine, 47 and 49-51 for 












(Ki AChE  /Ki  BChE)
Tacrine Mixed 120.2 Competitive 2.2 54.6 
47 Mixed 87.6 Competitive 2.8 31.3 
49 Mixed 5.7 Competitive 6.8 0.83 
50 Mixed 7.4 Competitive 18.3 0.40 
51 Mixed 1.8 Competitive 36.3 0.05 
 
5.3.2. Docking of tacrine, compounds 49 and 51 onto the AChE and BChE 
binding pockets 
In this section, the binding modes of tacrine and two potent inhibitors 49 
and 51 at the AChE and BChE binding pockets were investigated by docking 
simulations using available crystallographic structures of the two enzymes. For 
AChE, two co-crystallized structures of ligands and Torpedo AChE (TcAChE) 
were explored as docking templates. They were PDB 1ACJ where the ligand is 
tacrine, and 1EVE where the ligand is donepezil. 
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The primary amino acid sequences of Torpedo AChE and human AChE 
(hAChE) had a relatively low similarity score of 53 but the sequences of their 
active sites were highly conserved.186 This was also demonstrated by aligning the 
active sites of TcAChE (1ACJ) and hAChE (1B41) using the ClustalW2 program 
(Appendix 4) and viewing the superimposed active sites of the two enzymes by 
MOE (Appendix 5). The strong overlap of their active sites supported the use of 
TcAChE as a docking platform for this investigation. 
  
5.3.2.1. Docking of tacrine, 49 and 51 to Torpedo AChE (1ACJ) 
Before 49 and 51 were docked in the binding pocket of TcAChE derived 
from 1ACJ, cognate docking of tacrine was carried out. Tacrine was removed 
from its co-crystallized complex with the enzyme and subsequently re-docked. 
The pose of the re-docked tacrine was found to be similar to the original pose of 
tacrine in 1ACJ, thus confirming the validity of the docking protocol. The re-
docked tacrine was orientated with its tricyclic ring sandwiched between the 
indole ring of Trp 84 and the phenyl ring of Phe 330, both of which were 
important residues of the catalytic anionic site. Stabilization was provided by π-π 
stacking of the aromatic rings. Another interaction was H bonding of the 9-amino 
function with two water molecules. The original pose of tacrine in 1ACJ showed 
H bonding between the ring N and the carbonyl oxygen of the His 440 backbone 
but this was not observed in the re-docked pose. The original pose of tacrine in 
1ACJ and its re-docked pose in the same enzyme are shown in Figures 5.7 and 
5.8.   
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Figure 5.7: Tacrine (in pink) in the binding pocket of TcAChE (PDB code 1ACJ). 
 
Figure 5.8: Original (pink) and re-docked (cyan) poses of tacrine in the binding 
pocket of TcAChE (PDB code 1ACJ).  
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Compound 49 (6-chlorotacrine) was a stronger AChE inhibitor than 
tacrine (Ki of 5.7 nM compared to 120.2 nM for tacrine, Table 5.3). Its pose in the 
binding pocket of the enzyme showed that like tacrine, its tetrahydroacridine ring 
was sandwiched between Trp 84 and Phe 330 (Figure 5.9). The ring was also 
aligned in such a way that there was more space at its aromatic end than the non-
aromatic end. This permitted the 6-chloro atom to project into a hydrophobic 
pocket lined by the side chains of Trp 432 and lle 439. The extra van der 
Waals/hydrophobic interactions afforded by this alignment stabilized 49 in the 




Figure 5.9: Poses of 49 (cyan) and tacrine (pink) at the AChE binding pocket 






Figure 5.10: The 3D structures of three proposed docked pose of 51 in cyan. 
 
The docking of 51 to the AChE binding pocket yielded three poses with 
equivalent GOLD scores (pose 1: -11.88, pose 2: -12.73, pose 3: -14.09). The 
magnitude of these scores did not denote strong binding affinity to the binding 
pocket, possibly because the pocket was “moulded” to accommodate tacrine and 
the cross-docking with 51 involved a structurally larger and different molecule.  
The three poses shared many common binding features. First, the 
tetrahydroacridine ring of 51 was aligned in the vicinity of Gly 119, Gly 118, Ser 
122 which were key residues of the oxyanion hole. The oxyanion hole stabilizes 
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the transient tetrahydral enzyme substrate complex by accommodating the 
negatively charged carbonyl oxygen through H bonding with the backbone NH 
residues of these amino acids. They are found midway down the gorge and close 
to the catalytic triad residues. The tetrahydroacridine ring was held in this position 
by H bonding between the protonated N of the tetrahydroacridine ring and the 
catalytic triad residue Ser 200 and van der Waals/hydrophobic interaction 
between the saturated ring of the tetrahydroacridine and Phe 290, Phe 288, Phe 
331 which are residues found near the opening of the gorge (Trp 279 which is a 
PAS residue is nearby). Interestingly, in the third pose, the tetrahydroacridine ring 
was “flipped” so that its 6-chloro atom projected into this hydrophobic pocket. 
The second common feature observed among the 3 poses was the 
alignment of the terminal benzyl ring at the bottom of the gorge, with one face of 
the ring stacked against the indole ring of Trp 432. Trp 432 and lle 429 were 
mentioned earlier as the amino acids that form the hydrophobic pocket into which 
the 6-chloro atom of 49 was inserted (Figure 5.10). Trp 432 and Trp 84 are also 
adjacent to each other and Trp 84 was earlier identified as one of the aromatic 
residues (the other is Phe 330) that formed π-π interactions with the 
tetrahydroacridine ring of tacrine and 49. 
Lastly, all three poses showed the protonated piperidine ring of the side 
chain inserted between Trp 84 and Phe 330. The distances between the rings were 
measured and found to exceed the optimal distance required for π-π stacking 
interactions. Thus, van der Waals or hydrophobic forces may be involved in 
interactions between the rings.  
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5.3.2.2. Docking of donepezil, tacrine, 49 and 51 to Torpedo AChE (1EVE) 
The docking pose of donepezil in the binding pocket of TcAChE (PDB 
1EVE) had the following features (Figure 5.11): (i) The aromatic ring (indanone) 
was aligned at the mouth of the active site gorge and formed π-π stacking 
interactions with the indole ring of Trp 279 which was situated at the peripheral 
anionic site at the mouth of the gorge; (ii) The protonated piperidine ring 
established cation-π interactions with Phe 330 in the middle of the gorge; (iii)  
The benzyl ring displayed classical  parallel π-π stacking with Trp 84 at the base 
of the gorge. 
 
Figure 5.11: Donepezil (pink) in the binding pocket of AChE (PDB 1EVE). 
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Cognate docking of donepezil into the same binding pocket was successful 
and there was a good overlap between the poses of the original and re-docked 
donepezil molecules in the binding pocket (provide figure).  The re-docked 
donepezil showed the same interactions (i) - (iii) as those observed in the original 
crystal structure. 
 
Figure 5.12: Donepezil (pink) was redocked in the binding pocket of AChE and 
showed the same interactions as observed in the crystal structure. 
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  Next, tacrine was docked into the AChE binding pocket. The pose showed 
that the tacrine was inserted into the gorge, with π-π stacking between its middle 
ring and Phe 330 (distance of 3.63 Å between the mid-points of the two rings) as 
well as its end-aromatic ring and Tyr 334 (distance of 4.06 Å) (Figure 5.13). No H 
bonding was observed.  The side of the tetrahydroacridine ring not facing Phe 330 
and Tyr 334 was oriented towards Gly 118 and Gly 117 which are residues in the 
oxyanion hole.   
 
Figure 5.13: Pose of tacrine in the Torpedo AChE binding pocket (1EVE). Gold 
score of this pose was 45.97. 
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Compared to the pose of tacrine in the binding pocket derived from 1ACJ, 
obvious differences were evident. In that pose, tacrine was sandwiched between 
Phe 330 and Trp 84 and the ring was inserted deeper into the gorge. This was not 
observed in the pose derived from the binding pocket from 1EVE (Figure 5.14). 
Notably, the two poses were orthogonal to each other. Another observation was 
the change in the position of Phe 330 in the two crystal structures, which 
illustrated the propensity of Phe 330 to behave as a “swinging gate” that was 
capable of a range of conformations.187 
 
Figure 5.14: Comparison of docking poses of tacrine in binding pocket derived 
from 1ACJ (Yellow tacrine, amino acid residues in green) and 1EVE (pink 
tacrine, amino acid residues in grey). 
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Moving on to 49, the docking pose of this molecule closely resembled that 
of tacrine in terms of the type of interactions involved (π-π stacking) and location 
(mid-way along the gorge). The difference however was that in 49, the 
interactions now involved the middle ring of the tricyclic ring and Tyr 334 
(distance of 4.53 Å) which meant that the molecule was now located near the 
upper reaches of the gorge. Moreover, the 6-chloro atom of 49 protruded into a 
hydrophobic pocket lined by Phe 330 and Trp 84 (distances 4.00 Å and 3.67 Å 
respectively) and there was H bonding between the ring N and Tyr 121 (2.33 Å). 
Hence, the position of 49 along the mid-gorge region was displaced towards the 
mouth of the gorge as seen in Figures 5.15b. 
 
Figure 5.15: (a) Pose of compound 49 in Torpedo AChE (1EVE). (b) Pose of 





Next, the docking pose of 51 in the AChE binding pocket of 1EVE was 
examined (Figure 5.16).   
 
Figure 5.16: Pose of compound 51 in the AChE binding pocket (1EVE). Gold 
score was 54.93. 
 
The following features were observed: 
(i) The tetrahydroacridine ring of 51 was aligned near the mouth of the 
binding pocket, in the vicinity of Trp 279 (distance of 3.66 Å or 3.89 Å from 
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middle or end non-aromatic ring). In donepezil, Trp 279 formed π-π stacking 
interactions with the indanone ring. 
(ii) The 6-chloro atom of the tetrahydroacridine ring projected into a 
pocket lined by some hydrophobic residues like Leu 282, Leu 287 and polar 
residues like Ser 286 and Arg 289. 
A close-up of these interactions is shown in Figure 5.17. 
 
Figure 5.17: Pose of compound 51 (red) in the AChE pocket (1EVE) showing 
interactions involving the tetrahydroacridine ring. Trp 279 is highlighted in white. 
(iii) The protonated piperidinyl ring occupied a large pocket lined by 
aromatic residues Tyr 121, Phe 331, Leu 333 and Tyr 334. These residues are 
found in the vicinity of the anionic catalytic site. However, the distances between 
the piperidine ring and these aromatic residues fell within the range of 4-5 Ǻ and 
were unlikely to contribute towards cation – π interactions. 
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Figure 5.18: Pose of compound 51 (red) in the AChE pocket (1EVE) showing 
interactions involving the protonated piperidine ring.  Tyr 121, Phe 331, Phe 290, 
Tyr 334 are highlighted in white. 
(iv) The terminal benzyl ring formed π-π stacking interactions with Phe 
330 (distance of 3.03 Å).  
 
Figure 5.19: Pose of compound 51 (red) in the AChE pocket (1EVE) showing 
interactions involving the terminal benzyl ring and Phe 330 (white). Trp 84 which 
is at the bottom of the gorge is shown in gold.  
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When the poses of donepezil and 51 were superimposed (Figure 5.20), it 
was observed that both molecules made broadly similar interactions with the 
active site, except that different amino acid residues were involved as 51 was 
aligned somewhat higher up the binding pocket than donepezil. Thus, the 
aromatic rings of both molecules established π-π stacking interactions with Trp 
279. Stacking interactions (π-π) with aromatic residues (Trp 84 for donepezil, Phe 
330 for 51) were also involved in holding down the terminal benzyl ring. The 
middle piperidine ring of donepezil was involved with cation π interactions with 
Phe 330 but these were not observed for 51, which might explain the lower 
docking score assigned to 51 (54.93) compared to donepezil (63.53). 
 
 
Figure 5.20: Pose of compound 51 (pink) and donepezil (orange) in the AChE 
pocket (1EVE).  
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When the poses of 51 in the two binding pockets (1EVE, 1ACJ) were 
compared, significant differences in orientation were observed (Figure 5.21). In 
1ACJ, 51 was oriented “across” the binding pocket and the tricyclic ring was 
aligned at the oxyanion hold by H bonding to Ser 200 and hydrophobic 
interactions involving the 6- chloro atom. The middle piperidine ring was located 
between Phe 330 and Trp 84 and the terminal benzyl ring formed π-π stacking 
interactions with Trp 432 at the catalytic anionic site. In 1EVE, 51 was oriented 
“lengthwise” with the aromatic ring at the PAS and the benzyl ring at the catalytic 
anionic site (Phe 330). The piperidine ring was found in a hydrophobic pocket 
lined by aromatic residues found midway along the gorge.  
 
   
Figure 5.21: (a) Poses of compound 51 in Torpedo AChE derived from 1EVE 
(pink) and 1ACJ (yellow). Gold score of the pose in 1EVE is greater than that in 




5.3.2.3. Docking of tacrine, 49 and 51 to BChE 
The BChE inhibitory properties of tacrine, 49 and 51 were investigated on 
equine BChE. Unfortunately, the crystal structure of equine BChE is not available 
for docking simulations.  However, the primary sequences of equine and human 
BChE were known to share a high degree of similarity (89%).188 Hence, human 
BChE extracted from a co-crystallized complex of human BChE in complex with 
a choline molecule (PDB code 1P0M) was used for the docking experiments.  
There were several differences between the binding pockets of AChE and 
BChE. The active site of BChE is much larger (500 Å3) than its AChE counterpart 
(300 Å3). Of the 14 aromatic residues that line the active site gorge of AChE and 
determine its narrow aspect, six are substituted in BChE with smaller aliphatic 
and even polar residues. For instance, Phe 330 which is an important aromatic 
residue of the catalytic anionic site of AChE is replaced by Ala 528 in BChE. The 
absence of Phe results in diminished cation-π interactions between charged 
ligands and the BChE anionic site. However, the other catalytic anionic site 
residue Trp 82 (Trp 84 in AChE) is present in BChE. 
  The highest scored pose of tacrine in BChE showed the tetrahydroacridine 
ring stacked onto the Trp 82 residue by π-π interactions. The 9-amino function of 
tacrine established two H bonds with a histidine residue His 438 (one of 3 
residues of the catalytic triad) and glutamic acid residue (Glu 197) (Figure 5.22).  
Compound 49 showed a similar binding pose as tacrine at the BChE binding 
pocket (Figure 5.23).  The limited contribution of the 6-chloro atom of 49 to the 
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binding interaction was notable and could have accounted for the similar 
inhibitory activities of tacrine and 49 at BChE. 
 
Figure 5.22: Representation of the binding mode of tacrine (shown in cyan stick) 
in the CAS of BChE. 
 
Figure 5.23: Representation of the binding mode of 49 (shown in cyan stick) in 
the CAS of BChE. 
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  The highest scored binding pose of 51 at the BChE binding pocket is 
shown in Figure 5.24. It was observed that the tetrahydroacridine ring remained 
stacked onto the Trp 82 residue by π-π interactions. In addition, the protonated N 
of the ring formed cation-π interactions with the imidazole ring of His 438. 
Notably, the 4-benzylpiperidine side chain did not establish productive 
interactions with the binding pocket of BChE which would account for the 
significantly reduced BChE inhibitory activity of 51. 
 
Figure 5.24: Representation of the binding mode of 51 (shown in cyan stick) in 
the CAS of BChE. 
 
5.4. Discussion 
The most potent AChE inhibitor identified in this investigation is 51 from 
Group 6.  This compound was described as a tacrine-donepezil hybrid molecule in 
the introduction to this chapter and it was anticipated to be a potent AChE 
inhibitor in keeping with previously reported tacrine-donepezil hybrids.177  
Compound 51 was indeed a more potent AChE inhibitor than tacrine and of 
comparable activity to the other hybrid molecules reported by Shao et al.177 
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An analysis of the structure-activity trends showed that the 6-chloro atom 
on the tetrahydroacridine ring of 51 played a key role in bringing about selective 
affinity for AChE. Because of its lipophilic nature, the 6-chloro atom was able to 
establish van der Waals /hydrophobic interactions with the numerous aromatic 
(and non-polar) residues found in the AChE binding site. The docked poses of 49 
and 51 showed that even when the tetrahydroacridine ring was oriented at 
different sites of the AChE binding pocket, the 6-chloro atom fitted into 
hydrophobic pockets that enhanced the affinity of the ring to the binding site. 
Thus, cross docking of 49 in 1ACJ showed the 6-chloro slotted into a 
hydrophobic pocket formed by Trp 432 and lle 439 at the vicinity of the catalytic 
anionic site near the base of the active site gorge whereas in 1EVE, the 6-chloro 
projected into the hydrophobic pocket formed by Phe 330 and Trp 84.  In the case 
of 51 which showed significantly different poses when cross docked with 1ACJ 
and 1EVE, the 6-chloro atom still contributed to binding interactions. In 1ACJ, it 
fitted into a hydrophobic pocket formed by Phe 290 and Phe 288 at the peripheral 
anionic site while in 1EVE, it was found in a pocket was lined by hydrophobic 
and polar residues. Not surprisingly, the presence of the 6-chloro atom did not 
confer any advantage to the binding of 51 to BChE which lacked hydrophobic 
aromatic residues. The most highly scored pose of 51 at the BChE binding site did 
not show binding interactions involving the 6-chloro atom. 
From the SAR, it was deduced that while compounds with the 6-chloro 
atom were selective inhibitors of AChE, inhibition potency was largely 
determined by the substituent at the 9-amino position of the acridine 
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/tetrahydroacridine ring. Of the various substituents investigated, the 1-benzyl- 4-
piperidinyl side chain present in 51, emerged as the most favored. An examination 
of the binding poses of 51 consistently showed the stacking of benzyl ring against 
aromatic residues like the indole ring of Trp 432 (in 1ACJ) or Phe 330 (in 1EVE). 
Compound 51 had two distinct docking poses depending on whether it was cross 
docked on 1ACJ or 1EVE. The differences between the two poses were 
enumerated in Section 5.3.2.2. In terms of scoring, the pose derived from 1EVE 
was significantly higher and thus considered more reliable, in the absence of 
evidence from more rigorous methods like molecular dynamics simulation.  Not 
unexpectedly, this pose had several similarities to that observed for donepezil, 
namely the orientation of 51 along the length of the binding gorge, with the 
tricyclic ring at the PAS and the terminal benzyl ring sited within the catalytic 
anionic site.  
               It is of interest to note that the most potent tacrine-donepezil hybrid 
reported by Shao et al. (Figure 5.1) had an IC50 of 6 nM for the inhibition of rat 
brain AChE. This value was comparable to that of 51 in spite of the different 
sources of AChE. The binding mode of the tacrine-donepezil hybrid is depicted in 
Figure 5.25. The orientation of this molecule in the Torpedo AChE binding 
pocket was very similar to that of donepezil, except for an additional H bond 
between the amide NH of the molecule and OH of Tyr 121. Very likely the 
extended nature of this molecule allowed it to span the entire length of the binding 
pocket and occupy both the peripheral and catalytic anionic sites.  Compound 51 
was not as long as this compound and its terminal benzyl ring interacted with Phe 
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330 found midway along the gorge, and not Trp 84 found at the base of the gorge. 
Nonetheless, in spite of its shorter length, 51 was as potent as the tacrine-
donepezil hybrid.  
 
Figure 5.25: Interaction of a tacrine-donepezil hybrid molecule (IC50 AChE from 
rat cortex homogenate 6 nM)  reported by Shao et al.177 with the Torpedo AChE 
binding pocket (PDB 1EVE). 
 
When the benzylpiperidine ring was attached to other scaffolds like the 6-
chloro-2-methoxyacridine ring (Group 3) and the 7-chloroquinoline ring (Group 
7), AChE inhibitory activity was diminished and the selectivity for this enzyme 
was lost. Even then, among the different side chains attached to the 7-
chloroquinoline ring, the compound with the benzylpiperidine ring remained as 
the most potent AChE inhibitor. Group 3 yielded 3 compounds that were potent 
AChE inhibitors (more than 75% inhibition at 3 µM) but the analog with the 
benzylpiperidinyl side chain (32) was not included among these potent inhibitors. 
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Rather, for this ring scaffold, the 2-carbon and 3-carbon homologs of (39-41) 
were identified as potent inhibitors. Docking of representative Group 3 and Group 
7 compounds onto the AChE/BChE binding pockets were not done but would 
have provided useful insight as to how the ring scaffold and side chain of these 
compounds influenced affinity to the respective proteins. 
 
5.5. Conclusion 
This chapter has provided a better understanding of the structural 
requirements for AChE and BChE inhibitory activities of the Group 1-7 
compounds. In summary, the optimal ring scaffold for AChE inhibition was the 6-
chlorotetrahydroacridine ring. Attaching different side chains to the 9-amino 
group of this scaffold did not cause a significant loss in AChE activity as 
compared to the same modifications on the 6-chloro-2-methoxyacridine and 7-
chloroquinoline scaffolds. Among the different side chains attached to the 9-
amino /4-amino functionality, the most favoured was the 1-benzyl-4-piperidinyl 
side chain or its variants as seen in the Group 3 analogs. The most detrimental 
groups were phenyl or substituted phenyl side chains, in particularly when 
attached to the 6-chloro-2-methoxyacridine scaffold. In the case of BChE 
inhibitory activity, the most potent inhibitors were still those with a 6-
chlorotetrahydroacridine ring but there was a greater tolerance for the 6-chloro-2-
methoxyacridine scaffold and the 9-N-substituted phenyl side chain. Thus many 
Group 2 compounds were submicromolar inhibitors of BChE. In terms of 
selectivity for either enzyme, compounds with the 6-chlorotetrahydroacridine 
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template (Group 6) and those that had donepezil-like side chains attached to the 6-
chloro-2-methoxyacridine ring (Group 3) were selective inhibitors of AChE. On 
the other hand, compounds from the other groups showed a marginal preference 
for BChE inhibition. 
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Chapter 6: Conclusions and future work 
In this thesis, we tested the hypothesis that acridine is a fruitful template in 
neurodegenerative diseases. Sixty compounds were designed, synthesized, and 
tested for three biological activities: antiprion, neuroprotective, and 
anticholinesterase activities. Acridine analogues have different structure-activity 
relationships for each biological activity. 
Forty seven compounds organized across seven groups were synthesized 
and evaluated on in vitro cell models of scrapie infected murine neuroblastoma 
cells. The investigation identified compounds from Groups 2 and 3 that were 
more potent than quinacrine against F3 cells which comprised murine 
neuroblastoma cells stably transfected with a human scrapie strain Fukuoka-3. 
The most promising compounds were 16 and 32 which were subsequently 
modified to give analogs with improved (in the case of 32) or comparable (in the 
case of 16) activities. Well defined structure-activity relationships were observed 
and key points are summarized in Figures 6.1 and 6.2. Thus, analogs of 
quinacrine with improved (submicromolar) potencies against cell based prion 
infections were successfully obtained by applying established lead optimization 
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Figure 6.1: Structural modification of compound 16 and effects on antiprion 
activity determined on F3 cell model. Red fonts indicate changes that reduce 
activity while blue fonts indicate changes that enhance activity. 















Figure 6.2: Structural modification of compound 32 and effects on antiprion 
activity determined on F3 cell model. Red fonts indicate changes that reduce 
activity while blue fonts indicate changes that enhance activity. 
 
To determine if these compounds retained sufficient drug-like features that 
would permit passage across the blood brain barrier, permeability across porcine 
brain lipids were determined on the in vitro PAMPA BBB assay. Except for a 
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small number of compounds from Group 2, the other compounds tested had 
permeability values (Pe ) that exceeded the threshold limit (4.0 x10-6 cm/s) 
proposed by Di et al.122 for blood brain barrier permeability. Thus, there was a 
strong likelihood that these compounds including those with promising antiprion 
activity like 16, 24 and 37 are able to cross the blood brain barrier.  In the case of 
16, it was also assessed to be a poor substrate (less so than quinacrine) of the 
efflux protein Pgp, high levels of which are found in the cells of the blood brain 
barrier.  Thus, although 16 had a smaller Pe value than quinacrine (8.13 x10-6 cm/s 
versus 19.30 x10-6 cm/s), its weaker affinity for the efflux protein was a point in 
its favor. Whether this would finally translate into higher levels in the brain would 
require confirmation in animal models. Thus, future areas of work would include 
the determination of (i) pharmacokinetic profiles of the more promising antiprion 
agents on oral or intravenous dosing to determine if sufficient levels accumulated 
in brain tissues; (ii) efficacies in animal models of prion infection for those 
compounds identified to have acceptable pharmacokinetic profiles; (iii) Pgp 
affinities of a larger selection of members from the various Groups to determine if 
the Pgp-substrate profile of 16 (from Group 2) was also observed among other 
members. 
 Another objective of this thesis was to determine if the functionalized 
aminoacridines of Groups 1-7 possessed neuroprotective properties in addition to 
their antiprion activity. If such properties are demonstrated, it would enhance the 
standing of the 9-aminoacridine ring as a privilege scaffold for agents designed to 
act on neurodegenerative disorders. Two targets associated with 
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neurodegeneration / neurodegenerative disorders were selected, namely 
glutamate-induced cell death (oxytosis) which is a novel form of programmed cell 
death and acetylcholinesterase, an acknowledged target for drugs acting on 
Alzheimer’s disease (AD). 
Investigations on the ability of the synthesized compounds to protect 
murine hippocampal HT22 cells from glutamate-induced cell death were 
prompted by reports that compounds with a non-basic NH group flanked by 
aromatic rings were protective against cell death induced by this pathway. The 
hypothesis was that Group 2 compounds that had this motif would have protective 
properties while other groups that lacked this feature would have weaker activity, 
if any. This was indeed found to be true. Only the Group 2 compounds 
demonstrated protective properties and similar to antiprion activity, a well-defined 
structure-activity relationship was observed. Figure 6.3 summarizes key structural 
modifications of 16 (a Group 2 compound) that influenced its ability to protect 
HT22 cells against glutamate induced cell death. Compound 16 was found to have 
a neuroprotective EC50 of 0.62 µM and a 14 fold “safety window” as assessed 
from the ratio of its EC50 for cell cytotoxicity versus EC50 for neuroprotection. 
Modification of 16 led to 21, the most active compound identified in this study, 
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Figure 6.3: Structural modification of compound 16 and effects on EC50 for 
protection against glutamate induced toxicity of HT22 cells. Red fonts indicate 
changes that reduce activity while blue fonts indicate changes that enhance 
activity. 
Mechanistically, the protective effects of 16 (and possibly other members 
of Group 2) were linked to its ability to quench free radicals, in particular those 
released by the mitochondria at the later stages of oxidative cell death. Future 
work in this area would be to determine how 16 and related analogs targeted the 
mitochondria. Some possibilities are its role as a mitochondrial uncoupler or 
ability to interact with channels that are responsible for calcium influx or 
interference with signaling mechanisms that mediate the opening of calcium 
channels. 
Investigations of the anti-AChE activities of the Group 1-7 compounds 
were prompted in part by the structural resemblance of these compounds to 
tacrine, a known anti-AChE agent once used for the palliative treatment of 
Alzheimer’s disease.  In particular, the Group 6 compounds share the same ring 
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scaffold as tacrine. Furthermore, several compounds possess a side chain (4-
benzyl-piperidin-4-yl) that is present in another known anti-AChE agent 
donepezil presently used for the symptomatic treatment of AD. Thus several 
members in Groups 3 and 6 were identified as “tacrine-donepezil” hybrids and 
they were anticipated to be more potent AChE inhibitors. This was duly observed. 
The Group 6 compounds yielded members with nanomolar to low submicromolar 
IC50 for AChE inhibition and the member with the donepezil like side chain (51) 
emerged as the most promising AChE inhibitor. Compound 51 was a mixed 
inhibitor of AChE with Ki of 1.8 nM (compared to 120.2 nM for tacrine). It was 
20 times for selective for AChE inhibition compared to BChE inhibition. The 











with 6-Cl-2-CH3Oacridine  
Figure 6.4: Structural modification of compound 51 and effects on IC50 for 
inihibtion of AChE. Red fonts indicate changes that reduce activity. 
 
It is interesting to note that besides its outstanding anti-AChE profile, 51 
exhibited reasonably good activity against prion infected cell lines. While it was 
not the most potent member, 51 had low micromolar EC50 values and was able to 
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fully clear the prion infection of all three cell lines tested. Moreover, it had limited 
cytotoxicity when evaluated on murine hippocampal HT22 cells (EC50 20 µM) 
and murine neuroblastoma cells N2a (EC50 5 µM). AChE was reported to play a 
key role in accelerating Aβ-peptide deposition and promoting of formation of Aβ-
plaques in AD, and inhibition of AChE had led to the slowing down of these 
processes.189,190 In view of the ability of 51 to inhibit AChE and to arrest the 
accumulation of scrapie prion protein (PrPSc) in cell-based assays, it would be of 
interest to further determine its effects on protein misfolding. 51 has 
submicromolar IC50 values in antiprion assay and low nanomolar IC50 value 
against AChE. Levels of prion proteins and AChE apparently differ from those in 
vitro assays. Therefore, it remains to be tested if combination effects of 51 is 
beneficial or adverse in vivo. Of interest would be its effects on Aβ plaque 
formation in the thioflavin T assay and the accumulation of protein aggregates in 
prion protein misfolding cyclic amplification.   
In conclusion, this thesis had shown that functionalized aminoacridines 
were attractive starting points for the design of compounds for antiprion activity, 
inhibition of oxytosis and inhibition of AChE.  While structural requirements for 
these activities were different, they were found in compounds that shared a 
common template. Eventhough multiple drug targets may manifest side effects, in 
certain cases, combined therapeutic effects may lead to fruitful clinical outcome 
especially in complicated diseases which involve interconnected biological 
conditions such as neurodegenerative disorders. Future work should focus on 
improving the drug-like features of promising target compounds to enhance 
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 Appendix 1: Spectroscopic data, yield, and retention time of 
synthesized compounds 
 
1H-NMR and 13C-NMR spectra were recorded on a Bruker DPX 300MHz 
spectrometer and chemical shifts were reported in δ (ppm) relative to the internal 
standard TMS. Mass spectra (MS, nominal) were collected on a LCQ Finnigan 
MAT mass spectrometer. Atmospheric pressure ionization (APCI) or electron 
spray (ionization (ESI) were used as probes. Reactions were routinely monitored 
by thin layer chromatography using silica gel 60 F 254 plates from Merck, with 
UV light as a visualizing agent. Column chromatography was performed using 
silica gel G (0.04-0.063mm) from Merck. Solvents were of analytical grade or 
distilled from technical grade. Purity analysis was verified by high pressure liquid 
chromatography (HPLC) or by combustion analysis. Combustion analyses (C, H, 
N) were determined by Perkin-Elmer PE 2400 CHN/CHNS elemental analyzer by 
the Department of Chemistry, National University of Singapore. All chemicals 
were purchased from Sigma Aldrich Chemical Company (MO, USA), Tokyo 
Chemical Industry (Tokyo, Japan), and Alfa Aesar (MA, USA). 
 
The purity of the compounds were determined by reverse phase HPLC with two 
different solvent systems (methanol/water and acetonitrile/water). Compounds 
were considered sufficiently pure for biological evaluation if they gave a single 
peal on the HPLC chromatogram, with peak area not less than 95%. The test 
compound was dissolved in methanol and injected through a 50 µl loop at a flow 
rate of 1ml/min, with UV detection at 254 nm.  Each compound was tested with 
two mobile phases: methanol-water and acetonitrile-water. Retention time (tR in 
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min) and peak area of test sample (P) were recorded in each case from at least two 
determinations.   
 
Mobile phases and columns used are listed in the table below 
Condition Column Mobile phase 
A1 ODS1, 4.6x250mm, 
10µm, 80Ǻ (Waters 
Spherisorb®)  
water 10% + methanol 90% + formic 
acid 0.01% 
A2 ODS1, 4.6x250mm, 
10µm, 80Ǻ (Waters 
Spherisorb®)  
water 10% + acetonitrile 90% + formic 
acid 0.01% 
B1 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 10% + methanol 90% + formic 
acid 0.01% 
B2 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 30% + methanol 70% + formic 
acid 0.03% 
B3 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 50% + methanol 50% + formic 
acid 0.05% 
B4 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 10% + acetonitrile 90% + formic 
acid 0.01% 
B5 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 30% + acetonitrile 70% + formic 
acid 0.03% 
B6 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 
water 50% + acetonitrile 50% + formic 
acid 0.05% 
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B7 Zorbax Eclipse XDB-C18 
(Agilent Technologies®) 





dihydrochloride (1): Yellow solid. Yield 74%. 1H NMR (300MHz, CDCl3) δ 
1.41 (t, J=7.2, 6H) 3.39 (q, J=7.2, 4H), 3.80 (t, J=6.4, 2H) 4.06 (s, 3H) 4.63 (t, 
J=6.4, 2H) 7.55 (dd, J1=2.7, J2=9.3, 1H) 7.67 (t, J=8.3, 1H) 7.80 (dd, J1=4.2, 
J2=9.2, 1H) 7.86 (d, J= 2.7, 1H) 8.01 (d, J=2.9, 1H) 8.49 (dd, J1=1.5, J2=9.4, 
1H). MS (ESI) m/z [M+] 358.1. Elemental analysis: C20H24N3OCl.2HCl.H2O 
found 53.33 % C (calcd 53.51%), found 6.03% H (calcd 6.24%). 
 
6-Chloro-N-(3-(dimethylamino)propyl)-2-methoxyacridin-9-amine 
dihydrochloride (2): Yellow solid. Yield 70%. 1H NMR (300MHz, CD3OD) δ 
2.48 (q, 2H) 2.94 (s, 6H) 3.36 (t, J=7.2, 2H) 4.04 (s, 3H) 4.29 (t, J=7.2, 2H) 7.52 
(dd, J1=2.1, J2=9.3, 1H) 7.64 (dd, J1=2.5, J2=9.3, 1H) 7.77 (d, J=9.3, 1H) 7.82 
(d, J=2.0, 1H) 7.91 (d, J=2.3, 1H) 8.51 (d, J=9.4, 1H). MS (ESI) m/z [M+] 344.1. 
Elemental analysis: C19H22N3OCl.2HCl.2¼H2O found 50.02% C (expected 
49.89%), found 5.99% H (expected 6.24%). 
 
6-Chloro-N-(3-(diethylamino)propyl)-2-methoxyacridin-9-amine 
dihydrochloride (3): Yellow solid. Yield 55%. 1H NMR (300MHz, CD3OD) δ 
1.35 (t, J=7.3, 6H) 2.48 (m, 2H) 3.45-3.30 (obs, m, 6H, in acetic acid-d) 4.04 (s, 
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3H) 4.30 (t, J=7.2, 2H) 7.50 (dd, J1=2.0, J2=9.3, 1H) 7.63 (dd, J1=2.4, J2=9.3, 
1H) 7.76 (d, J=2.5, 1H) 7.81 (d, J=1.9, 1H) 7.92 (d, J=2.3, 1H) 8.51 (d, J=9.4, 
1H). MS (ESI) m/z [M+] 371.9. C21H26N3OCl.2HCl.2½H20 found 51.58% C 
(calcd 51.48%), found 6.80% H (calcd 6.74%).  
 
6-Chloro-N-(4-(diethylamino)butyl)-2-methoxyacridin-9-amine 
dihydrochloride  (4): Yellow solid. Yield 56%. 1H NMR (300MHz, CDCl3) δ 
1.33 (t, J=7.3, 6H) 1.93 (m, 2H) 2.11 (m, 2H) 3.25 (m, 6H) 4.03 (s, 3H) 4.24 (t, 
J=6.8, 2H) 7.50 (d, J=8.9, 1H) 7.63 (d, J=9.0, 1H) 7.74 (d, J=9.2, 1H) 7.80 (d, 
J=2.2, 1H) 7.88 (d, J=2.1, 1H) 8.50 (d, J=9.3, 1H). MS (ESI) m/z [M+] 386.1. 
Elemental analysis: C22H28N3OCl.2HCl.1¾H2O found 53.82% C (calcd 53.88%) 




hydrochloride (5): Yellow solid. Yield 70%. 1H NMR (300MHz, CDCl3) δ 3.31 
(s, 6H) 3.77 (s, 3H), 7.45 (m, 2H) 7.53 (d, J=2.1, 1H) 7.61-7.66 (m, 2H) 7.71 (dd, 
J1=11, J2=2.4, 1H) 7.73.-7.88 (m, 2H) 7.98 (d, J=1.8, 1H) 8.03 (d, J=9.6, 1H). 
MS (ESI) m/z [M+] 378.1. HPLC: condition A1 tR=3.518min P=100%, condition 
A2 tR=3.471min P=100%. 
 
N1-(6-Chloro-2-methoxyacridin-9-yl)-N3,N3-dimethylbenzene-1,3-diamine 
(6): Orange solid. Yield 70%. 1H NMR (300MHz, CDCl3) δ 2.98 (s, 6H), 3.76 (s, 
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3H), 6.63 (q, J1=8.7, J2=16.0, 2H),  6.99 (m, 2H), 7.05 (dd, J1=2.2, J2=9.3, 1H), 
7.20 (m, 2H) 7.30 (d, J=2.0, 1H), 7.84 (d, J=9.4, 1H), 7.98 (d, J=9.2, 1H), 8.13 (d, 
J=1.4, 1H), 10.81 (s, 1H).  13C NMR (75MHz, CDCl3) δ 40.5, 55.7, 103.0, 106.7, 
110.4, 110.6, 112.8, 116.1, 118.3, 120.8, 124.8, 127.4, 128.2, 130.2, 135.1, 138.7, 
140.3, 141.9, 151.5, 151.8, 155.9. MS (ESI) m/z [M+] 378.0. HPLC: condition A1 
tR=4.313min P=100%, condition A2 tR=3.518min P=98.5%. 
 
N1-(6-Chloro-2-methoxyacridin-9-yl)-N4,N4-dimethylbenzene-1,4-diamine 
(7): Purple red crystals. Yield 70%. 1H NMR (300MHz, CDCl3) δ 2.92 (s, 6H), 
3.73 (s, 3H), 6.52 (s, 1H), 6.70 (d, J=8.9, 2H), 6.90 (d, J=8.9, 2H), 7.10 (s, 1H), 
7.39 (dd, J1=2.0, J2=9.22, 1H),  7.91 (d, J=9.1, 1H), 8.01 (d, J=9.1, 1H), 8.11 (s, 
1H). 13C NMR (75MHz, CDCl3) δ 41.1, 55.3, 99.9, 113.9, 117.3, 117.4, 119.4, 
121.2, 124.7, 125.0, 127.8, 130.8, 130.9, 134.9, 144.0, 146.8, 147.2, 147.9, 156.0. 
MS (ESI) m/z [M+] 377.7. HPLC: condition B2 tR=1.516min P=99.6%, condition 
B5 tR=1.504min P=99.3%. 
 
N1-(6-Chloro-2-methoxyacridin-9-yl)-N3,N3-diethylbenzene-1,3-diamine 
hydrochloride (8): Orange solid. Yield 41%. 1H NMR (300MHz, CDCl3) δ 1.10 
(t, J= 7.0, 6H) 3.38 (q, J=7.0, 4H) 3.67 (s, 3H) 6.63 (d, J=7.7, 1H) 6.69 (t, J=2.0, 
1H) 6.79 (dd, J1=2.3, J2=8.5, 1H) 7.33 (t, J=8.1, 1H) 7.41 (dd, J1=2.0, J2=9.4, 
1H) 7.56 (d, J=2.5, 1H) 7.64 (dd, J1=2.6, J2=9.3, 1H) 7.82 (d, J=9.3, 1H) 7.88 (d, 
J=1.9, 1H) 8.25 (d, J=9.4, 1H). MS (ESI) m/z [M+] 406.3. Elemental analysis: 
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hydrochloride (9): Orange solid. Yield 60%. 1H NMR (300MHz, CDCl3) δ 1.09 
(t, J=6, 6H) 3.25 (q, J=6, 4H) 6.56 (d, J=9, 2H) 6.84 (d, J=9, 2H) 7.21-7.16 (m, 
2H) 7.57 (t, J=9, 2H) 7.94 (t, J=9, 4H). MS (ESI) m/z [M+] 406.3. Elemental 




Orange solid. Yield 70%. 1H NMR (300MHz, CDCl3) δ 1.99 (t, 4H), 3.28 (t, 4H), 
3.77 (s, 3H), 6.41 (d, J=7.4, 1H), 6.56 (d, J=7.7, 1H), 6.79 (s, 1H), 6.97 (d, J=9.1, 
1H), 7.05 (d, J=9.0, 1H), 7.14 (t, J=8.0, 1H), 7.35 (s, 1H), 7.87 (d, J=9.4, 1H), 
7.97 (d, J=9.3, 1H), 8.12 (s, 1H). 13C NMR (75MHz, DMSO-d6) δ 24.8, 47.2, 
55.3, 102.8, 103.1, 106.6, 106.8, 115.9, 118.7, 123.1, 125.1, 127.6, 129.7 (2C), 
135.3, 141.0, 144.2, 146.4, 147.2, 148.7 (2C), 155.1. MS (ESI) m/z [M+] 404.1. 
HPLC: condition A1 tR=4.275min P=100%, condition A2 tR=3.503min P=100%. 
 
6-Chloro-2-methoxy-N-(3-(piperidin-1-yl)phenyl)acridin-9-amine (11): 
Orange solid. Yield 70%. 1H NMR (300MHz, CDCl3) δ 1.59 (m, 2H) 1.68 (m, 
4H), 3.19 (t, 4H), 3.76 (s, 3H), 6.79 (dd, J1=8.7, J2=11.9, 2H), 7.03 (dd, J1=9.2, 
J2=17.9, 2H), 7.11 (s, 1H), 7.19 (s, 1H), 7.21 (s, 1H), 7.84 (d, J=9.5, 1H), 7.96 (d, 
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J=9.1, 1H), 8.117 (s, 1H). MS (ESI) m/z [M+] 418.1. HPLC: condition A1 
tR=3.568min P=100%, condition A2 tR=3.628min P=100%. 
 
6-Chloro-2-methoxy-N-(4-(piperidin-1-yl)phenyl)acridin-9-amine (12): Red 
solid. Yield 65%. 1H NMR (300MHz, DMSO) δ 1.52 (b, 2H), 1.62 (b, 4H), 3.04 
(b, 4H), 3.72 (s, 3H), 6.65 (s, 1H), 6.86 (b, 4H), 7.32 (d, J=8.7, 1H), 7.42 (s, 1H), 
7.93 (d, J=8.8, 1H), 7.80 (s, 1H), 8.07 (d, J=8.5, 1H), 8.98 (s, 1H).  13C NMR 
(75MHz, CDCl3) δ 24.1, 25.9, 51.3, 55.3, 100.2, 117.3, 117.8, 119.4, 120.6, 
124.9, 125.2, 125.4, 126.8, 129.8, 135.4, 136.7, 144.1, 145.6, 147.0, 148.4, 156.1. 
MS (APCI) m/z [M+] 417.8.  HPLC: condition B3 tR=1.583min P=98.3%, 
condition B6 tR=1.535min P=98.2%. 
 
6-Chloro-2-methoxy-N-(3-morpholinophenyl)acridin-9-amine (13): Orange 
solid. Yield 83%. 1H NMR (300MHz, CDCl3) δ 3.04 (t, J=4.7, 4H), 3.77 – 3.79 
(m, 7H), 6.32-6.41 (m, 2H), 6.52 (d, J=4.6, 1H), 7.14 (t, J=7.8, 2H), 7.31 (d, 
J=10.5, 1H), 7.45 (d, J=9.0, 1H), 7.98 (d, J=9.1, 1H), 8.08 (d, J=9.3, 1H), 8.18 (s, 
1H). 13C NMR (75MHz, DMSO-d6) δ 49.5 (2C), 56.4, 67.1 (2C), 109.4, 109.8, 
119.3, 121.7, 125.6, 126.3, 127.7, 128.6, 130.6, 132.1, 134.7, 144.3, 147.0, 147.9, 
148.0, 148.8, 153.0, 153.1, 156.9. MS (ESI) m/z [M+] 419.5. Elemental analysis: 
found 68.41% C (calcd 68.65%) found 5.11% H (calcd 5.28%) found 9.75% N 
(calcd 10.01%). 
 
6-Chloro-2-methoxy-N-(4-morpholinophenyl)acridin-9-amine (14): Orange 
solid. Yield 69%. 1H NMR (300MHz, CDCl3) δ 3.10 (t, J=4.6, 4H), 3.48(s, 3H), 
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3.87 (t, J=4.5, 4H), 6.46 (s, 1H), 6.86 (b, 4H), 7.09 (s, 1H), 7.42 (d, J=8.0, 1H), 
7.92 (d, J=9.3, 1H), 8.05 (d, J=7.8, 1H), 8.145 (s, 1H). MS (ESI) m/z [M+] 420.1. 
HPLC: condition B1 tR=1.381min P=98.9%, condition B4 tR=1.521min P=96.5%. 
 
6-Chloro-2-methoxy-N-(3-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine 
(15): Red solid. Yield 72%. 1H NMR (300MHz, CDCl3) δ 2.32 (s, 3H), 2.50 (t, 
J=4.4, 4H), 3.11 (t, J=4.5, 4H), 3.78 (s, 3H), 6.30 (d, J=7.6, 1H), 6.39 (s, 1H), 
6.43 (s, 1H), 6.55 (d, J=8.3, 1H), 7.13 (d, J=5.8, 2H), 7.44 (d, J=10.3, 1H), 7.98 
(d, J=8.9, 1H), 8.07 (d, J=9.0, 1H), 8.17 (s, 1H). MS (ESI) m/z [M+] 433.4. 
HPLC: condition B2 tR=1.404min P=98.2%, condition B7 tR=1.578min P=99.1%. 
 
6-Chloro-2-methoxy-N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine 
(16): Red solid. Yield 65%. 1H NMR (300MHz, DMSO) δ 2.33 (s, 3H), 2.56 (t, 
J=4.8, 4H), 3.12 (t, J=4.6, 4H), 3.66 (s, 3H), 6.82 (b, 4H), 7.08 (s, 1H), 7.15 (d, 
J=9.1, 1H), 7.32 (d, J=9.4, 1H), 7.85 (d, J=9.2, 1H), 7.94 (d, J=9.0, 1H), 8.02 (s, 
1H). 13C NMR (75MHz, CDCl3) δ 46.0, 49.6, 55.0, 55.4, 100.5, 116.9, 117.3, 
119.2, 120.7, 125.1, 125.2, 125.6, 125.9, 126.0, 128.9, 135.8, 136.9, 144.7, 146.2, 
147.4, 156.0. MS (ESI) m/z [M+] 431.9. HPLC: condition B3 tR=1.738min 
P=100%, condition B6 tR=1.265min P=98.3%. 
 
6-Chloro-N-(4-(4-ethylpiperazin-1-yl)phenyl)-2-methoxyacridin-9-amine 
(17): Orange solid. Yield 68%. 1H NMR (300MHz, CDCl3) δ 1.14 (t, J=7.2, 3H), 
2.50 (q, J=7.2, 2H), 2.64 (m, 4H), 3.17 (m, 4H), 3.71 (s, 3H), 6.88 (m, 4H), 7.09 
(d, J=2.4, 1H), 7.20 (dd, J1=1.7, J2=9.2, 1H), 7.36 (dd, J1=2.5, J2=9.4, 1H), 7.89 
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(d, J=9.2, 1H), 7.98 (d, J=9.4, 1H), 8.07 (s, 1H). MS (ESI) m/z [M+] 447.5. 
HPLC: condition A1 tR=3.625min P=97.6%, condition A2 tR=3.581min P=98.0%.                                     
 
3-(4-(4-(6-Chloro-2-methoxyacridin-9-ylamino)phenyl)piperazin-1-
yl)propan-1-ol (18): Brown solid. Yield 40%. 1H NMR (300MHz, CDCl3) δ 1.77 
(m, 2H), 2.70 (m, 6H), 3.13 (m, 4H), 3.74 (s, 3H), 3.85 (t, J=15.9, 2H), 6.84 (m, 
4H), 7.08 (d, J=7.7, 1H), 7.28 (s, 1H), 7.40 (dd, J1=7.7, J2=21.6, 1H), 7.90 (d, 
J=9.25, 1H), 8.00 (d, J=9.41, 1H),  8.10 (s, 1H). MS (ESI) m/z [M+] 477.2. 
HPLC: condition A1 tR=3.412min P=98.3%, condition A2 tR=3.267min P=96.5%. 
 
1-(4-(4-(6-Chloro-2-methoxyacridin-9-ylamino)phenyl)piperazin-1-
yl)ethanone (19): Brown solid. Yield 83%. 1H NMR (300MHz, CDCl3) δ 2.14 (s, 
3H), 3.08 (m, 4H), 3.62 (t, 2H), 3.75 (s, 3H), 3.77 (t, 2H), 6.49 (b, 1H), 6.86 (m, 
4H), 7.10 (s, 1H), 7.41 (dd, J1=1.56, J2=9.15, 1H), 7.92 (d, J=9.37, 1H), 8.03 (m, 
1H), 8.15 (s, 1H). MS (ESI) m/z [M+] 461.2. HPLC: condition A1 tR=3.168min 
P=99.7%, condition A2 tR=3.248min P=98.7%. 
 
(4-(4-(6-Chloro-2-methoxyacridin-9-ylamino)phenyl)piperazin-1-
yl)(cyclohexyl)methanone (20): Red solid. Yield 87%. 1H NMR (300MHz, 
CDCl3) δ 1.28 (m, 2H), 1.54 (m, 2H), 1.72 (s, 2H), 1.80 (m, 4H), 2.49 (m, 1H) 
3.08 (m, 4H), 3.66 (m, 2H), 3.73 (s, 3H), 3.76 (m, 2H), 6.87 (m, 4H), 7.10 (d, 
J=2.5, 1H), 7.22 (dd, J1=1.8, J2=9.3, 1H), 7.37 (dd, J1=2.6, J2=9.4, 1H), 7.89 (d, 
J=9.3, 1H) 8.00 (d, J=9.4, 1H), 8.09 (s, 1H). MS (ESI) m/z [M+] 529.3. HPLC: 




yl)(phenyl)methanone (21): Red solid. Yield 80%. 1H NMR (300MHz, CDCl3) δ 
3.12 (m, 4H), 3.62 (m, 2H), 3.74 (s, 3H), 3.92 (m, 2H), 6.88 (t, J=6.5, 4H), 7.12 
(s, 1H), 7.20 (dd, J1=1.5, J2=9.3, 1H), 7.26 (s, 1H), 7.34 (dd, J1=2.4, J2=9.4, 
1H), 7.43 (s, 4H), 7.88 (d, J=9.3, 1H), 7.99 (d, J=9.4, 1H), 8.09 (s, 1H). MS (ESI) 




amine (22): Yellow solid. Yield 74%. 1H NMR (300MHz, CDCl3) δ 2.29 (s, 3H), 
2.47 (b, 8H), 3.45 (s, 2H), 3.75 (s, 3H) 6.44 (s, 1H), 6.76 (d, J=8.2, 2H), 7.09 (s, 
1H), 7.18 (d, J=8.4, 1H), 7.45 (dd, J1=2.0, J2=9.1, 2H), 7.97 (d, J=9.5, 1H), 8.09 
(d, J=9.4, 1H), 8.19 (s, 1H). MS (ESI) m/z [M+] 447.2. HPLC: condition A1 
tR=3.298min P=96.4%, condition A2 tR=3.187min P=97.4%. 
 
(4-(6-Chloro-2-methoxyacridin-9-ylamino)phenyl)(4-methylpiperazin-1-
yl)methanone (23): Yellow solid. Yield 65%. 1H NMR (300MHz, CDCl3) δ 2.30 
(s, 3H), 2.39 (t, 4H), 3.63 (t, 4H), 3.74 (s, 3H), 6.69 (d, J=8.3, 2H), 7.11 (d, J=1.7, 
1H), 7.27 (m, 3H), 7.39 (dd, J1=2.0, J2=9.4, 1H), 7.89 (d, J=9.2, 1H), 7.99 (d, 
J=9.2, 1H), 8.08 (s, 1H). 13C NMR (75MHz, DMSO-d6) δ 46.6, 55.6, 56.4, 101.5, 
116.5, 120.4, 122.7, 126.6, 127.3, 127.8, 128.8, 129.8, 130.1, 132.4, 134.9, 142.9, 
147.8, 148.2, 148.8, 157.4, 170.1. MS (ESI) m/z [M+] 461.5. HPLC: condition A1 




(24): Orange solid. Yield 90%. 1H NMR (300MHz, CDCl3) δ 1.41 (m, 2H), 1.57 
(m, 4H), 2.36 (m, 4H), 3.41 (s, 2H), 3.68 (s, 3H), 6.74 (d, J=8.1, 2H), 7.05 (s, 
1H), 7.17 (d, J=8.1, 2H), 7.24 (m, 1H), 7.36 (d, J=9.4, 1H), 7.90 (d, J=9.1, 1H), 
8.08 (s, 1H). 13C NMR (75MHz, CDCl3) δ 24.3, 25.8, 54.3, 55.2, 63.2, 99.9, 
117.0, 119.3, 121.3, 124.8, 125.4, 125.8, 130.4, 130.6, 131.1, 135.0, 142.1, 142.2, 
144.0, 147.8, 156.4. MS (ESI) m/z [M+] 432.3. HPLC: condition A1 tR=3.647min 
P=97.2%, condition A2 tR=3.589min P=97.0%. 
 
6-Chloro-2-methoxy-N-phenylacridin-9-amine (25): Yellow solid. Yield 96%. 
1H NMR (300MHz, CDCl3) δ 3.72 (s, 3H), 6.80 (d, J=7.9, 2H), 6.95 (t, J=7.3, 
1H), 7.07 (d, J=1.9, 1H), 7.21 (s, 1H), 7.24 (s, 1H), 7.38 (dd, J1=2.3, J2=9.4, 1H), 
7.91 (d, J=9.2, 1H), 8.01 (d, J=9.4, 1H), 8.10 (s, 1H). 13C NMR (75MHz, CDCl3) 
δ 55.4, 99.9, 117.1, 119.4, 121.4, 121.5, 124.8, 125.6, 126.0, 127.6, 129.4, 130.7, 
135.2, 142.0, 145.0, 146.7, 147.6, 156.7. MS (APCI) m/z [M+] 335.2. Elemental 
analysis: found 71.70% C (calcd 71.75%), found 4.34% H (calcd 4.15%), found 
8.13% N, (calcd 8.37%). 
 
4-(6-Chloro-2-methoxy-acridin-9-ylamino)-benzonitrile (26): Orange solid. 
Yield 96%. 1H NMR (300MHz, CDCl3) δ 3.81 (s, 3H), 6.75 (d, J=8.4, 2H), 7.07 
(d, J=2.2, 1H), 7.38 (d, J=9.2, 1H), 7.45 (d, J=10.0, 1H), 7.50 (d, J=8.6, 2H), 7.91 
(d, J=9.2, 1H), 8.06 (d, J=6.8, 1H), 8.17 (s, 1H). 13C NMR (75MHz, dmso-d6) δ 
56.0, 100.4, 100.6, 115.7, 120.2, 120.7, 123.0, 126.3, 126.4, 126.9, 128.4, 131.9, 
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134.1, 134.5, 140.7, 147.7, 148.1, 150.2, 157.4. MS (APCI) m/z [M+] 361.5. 
HPLC: condition A1 tR=3.487min P=98.7%, condition A2 tR=3.385min P=98.5%. 
 
(3-Chloro-acridin-9-yl)-(4-fluoro-phenyl)-amine (27): Yellow solid. Yield 
92%. 1H NMR (300MHz, CDCl3) δ 3.69 (s, 3H), 6.76 (dd, J1=4.5, J2=8.8, 2H), 
6.93 (t, J=8.6, 2H), 7.01 (d, J=1.5, 1H), 7.21 (d, J=9.1, 1H), 7.34 (dd, J1=1.8, 
J2=9.2, 1H), 7.83 (d, J=9.2,  1H), 7.94 (d, J=9.2, 1H), 8.02 (s, 1H). 13C NMR 
(75MHz, CDCl3) δ 55.3, 100.0, 115.9, 116.2, 118.9, 121.0, 124.7, 125.4, 125.7, 
127.2, 130.3, 135.2, 141.4, 142.6, 146.2, 147.3, 156.5, 159.6. MS (APCI) m/z 
[M+H+] 354.4. Elemental analysis found 68.10% C (calcd 68.09%), found 3.90% 
H (calcd 4.00), found 7.60% N (calcd 7.94%). 
 
6-Chloro-N-(3,4-difluorophenyl)-2-methoxyacridin-9-amine (28): Yellow 
solid. Yield 88%. 1H NMR (300MHz, CDCl3) δ 3.84 (s, 3H), 7.09 (dd, J1=2.8, 
J2=9.0, 2H), 7.24 (m, 4H), 7.74 (d, J=9.4, 1H), 7.97 (d, J=9.3, 1H), 8.18 (s, 1H). 
13C NMR (75MHz, dmso-d6) δ 55.5, 103.2, 103.3, 109.6, 114.9, 115.0, 116.8, 
118.0, 118.2, 123.7, 126.2, 127.6, 136.6, 142.3, 142.4, 148.0, 148.2, 151.3, 151.4, 
155.5. MS (ESI) m/z [M+] 372.2. HPLC: condition A1 tR=3.487min P=97.4%, 
condition A2 tR=3.456min P=97.8%. 
 
(6-Chloro-2-methoxy-acridin-9-yl)-(4-methoxy-phenyl)-amine (29): Orange 
solid. Yield 88%. 1H NMR (300MHz, CDCl3) δ 3.72 (s, 3H), 3.78 (s, 3H), 6.83 
(m, 4H), 7.07 (s, 1H), 7.25 (d, J=9.4, 1H), 7.39 (dd, J1=2.1, J2=9.4Hz, 1H), 7.89 
(d, J=9.2, 1H), 8.00 (d, J=7.7, 1H), 8.10 (s, 1H). 13C NMR (75MHz, CDCl3) δ 
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55.3, 55.6, 99.6, 99.7, 114.7, 118.2, 120.0, 120.3, 124.5, 125.3, 125.5, 128.1, 
131.4, 134.9, 138.1, 142.9, 148.1, 155.1, 156.3. MS (APCI) m/z [M+] 365.7. 
Elemental analysis: found 69.13% C (calcd 69.14%), found 4.35% H (calcd 
4.70%), found 7.35% N (calcd 7.68%). 
 
3-(6-Chloro-2-methoxyacridin-9-ylamino)phenol (30): Yellow solid. Yield 
96%. 1H NMR (300MHz, CDCl3) δ 3.73 (s, 3H), 6.29 (t, J=1.9, 1H), 6.41 (dd, 
J1=1.9, J2=8.1, 2H), 7.30 (d, J=9.3, 1H), 7.34 (d, J=2.3, 1H), 7.42 (dd, J1=2.4, 
J2=9.4, 1H), 7.89 (d, J=9.3, 1H), 7.95 (s, 1H), 8.11 (d, J=9.2, 1H). MS (ESI) m/z 
[M+H+] 352.4. Elemental analysis: found 68.64% C (calcd 68.48), found 4.05% 
H (calcd 4.31%), found 7.67% N (calcd 7.99%). 
 
4-(6-Chloro-2-methoxyacridin-9-ylamino)benzene-1,2-diol (31): Yellow solid. 
Yield 46%. 1H NMR (300MHz, MeOD) δ 3.70 (s, 3H), 6.78 (dd, J1=2.3, J2=8.4, 
1H), 6.87 (d, J=2.3, 1H), 7.48 (d, J=8.7, 2H), 7.58 (dd, J1=2.2, J2=9.2, 2H), 7.83 
(s, 1H), 8.12 (d, J=9.3, 1H). 13C NMR (75MHz, MeOD) δ 55.9, 103.0, 110.7, 
114.4, 117.0, 119.2, 125.0, 125.1, 127.0, 127.6, 128.2, 128.3, 137.5, 138.0, 143.6, 
145.2, 147.4, 157.1. MS (ESI) m/z [M+] 368.5. HPLC: condition A1 tR=3.248min 
P=96.5%, condition A2 tR=3.149min P=96.2%. 
 
Group 3 
N-(1-Benzylpiperidin-4-yl)-6-chloro-2-methoxyacridin-9-amine (32): Yellow 
solid. Yield 48%. 1H NMR (300MHz, CDCl3) δ 1.74 (d, J=9.4, 2H), 2.05 (t, 
J=9.4, 4H), 2.90 (d,  J=11.7, 2H), 3.51 (s, 2H), 3.70 (b, 1H), 3.96 (s, 3H), 4.34 (b, 
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1H), 7.19 (s, 1H), 7.30 (s, 4H), 7.37 (d, J=1.96, 1H), 7.44 (dd, J1=2.60, J2=9.41, 
1H), 8.01 (t, J=9.47, 2H), 8.10 (d, J=1.83, 1H). 13C NMR (75MHz, CDCl3) δ 
34.1, 52.4, 55.5, 57.4, 62.9, 99.2, 117.2, 119.3, 124.1, 125.1, 125.2, 127.3, 127.6, 
128.3, 129.1, 130.8, 135.3, 137.8, 147.4, 149.1, 149.2, 156.4. MS (APCI) m/z 
[M+] 432.4. HPLC: condition B2 tR=1.337min P=99.4%, condition B5 
tR=1.278min P=98.2%.  
 
N-(1-(4-Methylbenzyl)piperidin-4-yl)-6-chloro-2-methoxyacridin-9-amine 
dihydrochloride (33): Yellow solid. Yield 51%. 1H NMR (300MHz, CDCl3) δ 
1.77 (d, J=11.20, 2H), 2.05 (t, J=10.6, 4H), 2.33 (s, 3H), 2.90 (d, J=11.2, 2H), 
3.48 (s, 2H), 3.71 (b, 1H), 3.95 (s, 3H), 7.12 (d, J=7.9, 2H), 7.18 (m, 3H), 7.31 
(dd, J1=1.9, J2=9.2, 1H), 7.39 (dd, J1=2.1, J2=9.6, 1H), 7.98 (m, 2H), 8.08 (d, 
J=1.89, 1H). 13C NMR (75MHz, CDCl3) δ 21.1, 34.1, 52.3, 55.5, 57.4, 62.6, 99.0, 
117.3, 119.5, 123.9, 124.9, 125.2, 127.7, 128.9, 129.1, 130.9, 134.7, 135.0, 136.8, 
146.2, 147.6, 148.9, 156.3. MS (ESI) m/z [M+] 446.6. HPLC: condition A1 
tR=3.542min P=97.5%, condition A2 tR=3.425min P=96.9%. 
 
N-(1-(4-Chlorobenzyl)piperidin-4-yl)-6-chloro-2-methoxyacridin-9-amine 
dihydrochloride (34): Yellow solid. Yield 56%. 1H NMR (300MHz, CDCl3) δ 
1.80 (dd, J1=10.6, J2=21.1, 2H), 2.04 (t, J=10.4, 4H), 2.87 (d, J=11.4, 2H), 3.45 
(s, 2H), 3.72 (b, 1H), 3.95 (s, 3H), 7.17-7.28 (m, 5H), 7.30 (d, J=1.9, 1H), 7.37 
(dd, J1=2.4, J2=9.38, 1H), 7.96 (t, J=9.6, 2H), 8.06 (d, J=1.8, 1H). 13C NMR 
(75MHz, CDCl3) δ 34.1, 52.3, 55.5, 57.3, 62.0, 99.2, 116.9, 119.2, 124.0, 125.0, 
125.1, 127.2, 128.3, 130.3, 130.4, 132.8, 135.3, 136.6, 145.5, 147.1, 149.2, 156.3. 
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MS (ESI) m/z [M+] 465.5. HPLC: condition A1 tR=3.426min P=97.2%, condition 
A2 tR=3.412min P=96.4%. 
 
N-(1-(4-Methoxybenzyl)piperidin-4-yl)-6-chloro-2-methoxyacridin-9-amine 
dihydrochloride (35): Yellow solid. Yield 57%. 1H NMR (300MHz, CDCl3) δ 
1.75 (m, 2H), 2.04 (m, 4H), 2.88 (d, J=11.2, 2H), 3.45 (s, 2H), 3.71 (b, 1H), 3.80 
(s, 3H), 3.96 (s, 3H), 6.85 (d, J=8.3, 2H), 7.20 (d, J=8.4, 2H), 7.26 (s, 1H), 7.34 
(dd, J1=0.7, J2=9.2, 1H), 7.43 (dd, J1=1.6, J2=9.4, 1H), 8.00 (m, 2H), 8.09 (s, 
1H). 13C NMR (75MHz, CDCl3) δ 34.1, 52.1, 55.1, 55.3, 57.3, 62.2, 98.8, 113.5, 
117.6, 119.6, 123.8, 124.7, 125.0, 128.2, 129.9, 130.1, 131.4, 134.6, 146.7, 147.9, 
148.5, 156.2, 158.6. MS (ESI) m/z [M+] 461.8. HPLC: condition A1 tR=3.268min 
P=98.6%, condition A2 tR=3.197min P=98.2%. 
 
4-((4-(6-Chloro-2-methoxyacridin-9-ylamino)piperidin-1-
yl)methyl)benzonitrile dihydrochloride (36): Yellow solid. Yield 40%. 1H 
NMR (300MHz, CDCl3) δ 1.74 (dd, J1=10.5, J2=20.9, 2H), 2.06 (dd, J1=9.1, 
J2=18.2, 4H), 2.85 (d, J=11.6, 2H), 3.54(s, 2H), 3.70(b, 1H), 3.97 (s, 3H), 7.19 (d, 
J=2.3, 1H), 7.35 (dd, J1=1.7, J2=9.25, 1H), 7.44 (m, 3H), 7.61(d, J=8.1, 2H), 
8.00 (m, 2H), 8.09 (d, J=1.6, 1H). 13C NMR (75MHz, CDCl3) δ 34.3, 52.6, 55.4, 
57.3, 62.3, 98.9, 110.9, 117.8, 118.9, 119. 9, 123.7, 124.8, 125.4, 128.4, 129.3, 
131.6, 132.1, 134.8, 144.2, 146.9, 148.1, 148.5, 156.4. MS (ESI) m/z [M+] 457.4. 




dihyrochloride (37): Yellow solid. Yield 57%. 1H NMR (300MHz, CDCl3) δ 
1.79 (m, 2H), 2.09 (m, 4H), 2.61 (t, 2H), 2.81 (t, 2H), 3.02 (d, J=11.57, 2H), 3.73 
(b, 1H), 3.97 (s, 3H), 7.20 (m, 3H), 7.27 (d, J=6.5, 2H), 7.35 (d, J=9.2, 1H), 8.01 
(t, J=9.1, 2H), 8.10 (s, 1H). 13C NMR (75MHz, CDCl3) δ 33.6, 34.0, 52.4, 55.2, 
57.1, 60.1, 99.68, 117.6, 119.6, 123.7, 124.6, 125.0, 125.9, 128.1, 128.2, 128.4, 
131.3, 134.5, 139.9, 146.7, 147.8, 148.4, 156.1. MS (ESI) m/z [M+] 445.2. HPLC: 
condition A1 tR=3.185min P=96.8%, condition A2 tR=3.087min P=97.0%. 
 
6-Chloro-2-methoxy-N-(1-(4-methylphenethyl)piperidin-4-yl)acridin-9-amine 
dihyrochloride (38): Yellow solid. Yield 67%. 1H NMR (300MHz, CDCl3) δ 
1.80 (d, J=9.2, 2H), 2.03 (m, 4H), 2.30 (s, 3H), 2.57 (d, J=8.2, 2H), 2.73 (d, 
J=7.8, 2H), 2.98 (d, J=10.4, 2H), 3.66 (d, J=9.1, 2H), 3.93 (s, 3H), 7.07 (s, 4H), 
7.16 (s, 1H), 7.30 (d, J=9.1, 1H), 7.40 (d, J=9.1, 1H), 7.97 (dd, J1=9.2, J2=16.3, 
2H), 8.08 (s, 1H). 13C NMR (75MHz, CDCl3) δ 20.9, 33.1, 33.9, 52.5, 57.3, 60.3, 
98.9, 117.6, 119.7, 123.9, 124.8, 125.1, 127.9, 128.4, 129.0, 131.2, 134.8, 135.5, 
136.8, 146.6, 147.8, 148.8, 156.3. MS (ESI) m/z [M+] 460.3. HPLC: condition A1 
tR=3.562min P=96.0%, condition A2 tR=3.485min P=96.5%. 
 
N-(1-(4-Chlorophenethyl)piperidin-4-yl)-6-chloro-2-methoxyacridin-9-amine 
dihydrochloride (39): Yellow solid. Yield 92%. 1H NMR (300MHz, CDCl3) δ 
1.73 (m, 2H), 2.05 (m, 4H), 2.54 (m, 2H), 2.73 (m, 2H), 2.95 (d, J=10.3, 2H), 
3.66 (b, 1H), 3.94 (s, 3H), 7.08 (d, J=7.9, 2H), 7.14 (s, 1H), 7.22 (d, J=8.0, 2H), 
7.30 (d, J=9.4, 1H), 7.40 (d, J=9.2, 1H), 7.97 (dd, J1=9.3, J2=19.1, 2H), 8.08 (s, 
 261
1H). 13C NMR (75MHz, CDCl3) δ 33.0, 34.1, 52.5, 55.4, 57.2, 59.9, 98.8, 117.6, 
119.7, 123.8, 124.8, 125.2, 128.0, 128.4, 129.8, 131.2, 131.7, 134.7, 138.5, 146.7, 
147.9, 148.6, 156.3. MS (ESI) m/z [M+] 480.4. HPLC: condition A1 tR=3.587min 
P=97.0%, condition A2 tR=3.455min P=96.4%. 
 
N-(1-(4-Methoxyphenethyl)piperidin-4-yl)-6-chloro-2-methoxyacridin-9-
amine dihydrochloride (40): Yellow solid. Yield 90%. 1H NMR (300MHz, 
CDCl3) δ 1.66 (m, 2H), 1.99 (m, 4H), 2.48 (m, 2H), 2.64 (m, 2H), 2.88 (m, 2H), 
3.79 (b, 4H), 3.87 (s, 3H), 6.75 (m, 2H), 7.02 (m, 3H), 7.22 (d, 1H), 7.34 (d, 1H) , 
7.91 (m, 2H), 8.05 (s, 1H). 13C NMR (75MHz, CDCl3) δ 32.6, 33.9, 52.2, 54.9, 
55.0, 57.0, 60.2, 98.6, 113.5, 117.4, 119.5, 123.6, 124.5, 124.8, 128.0, 129.2, 
131.2, 131.8, 134.3, 146.6, 147.7, 148.2, 156.0, 157.6. MS (ESI) m/z [M+H+] 




dihyrochloride (41): Yellow solid. Yield 89%. 1H NMR (300MHz, CDCl3) δ 
1.80 (m, 4H), 1.95 (m, 4H), 2.31 (t, 2H), 2.57 (t, J=7.6, 2H), 2.86 (d, J=11.5, 2H), 
3.64 (b, 1H), 3.89 (s, 3H), 7.12 (m, 4H), 7.24 (m, 3H), 7.36 (dd, J1=2.1, J2=9.4, 
1H), 7.87 (d, J=9.3, 1H), 7.96 (d, J=9.4, 1H), 8.06 (s, 1H). 13C NMR (75MHz, 
CDCl3) δ 28.5, 33.4, 33.8, 52.3, 55.1, 57.1, 57.5, 98.7, 117.3, 119.4, 123.8, 124.6, 
124.8, 125.5, 127.7, 128.0, 128.1, 130.9, 134.5, 141.7, 146.4, 147.6, 148.6, 156.0. 
MS (ESI) m/z [M+] 460.2. HPLC: condition A1 tR=3.358min P=96.4%, condition 




amine (42): Brown solid. Yield 60%. 1H NMR (300MHz, CDCl3) δ 2.28 (m, 4H), 
2.49 (m, 7H), 3.24 (s, 2H), 3.96 (s, 3H), 4.53 (s, 2H), 7.26 (m, 2H), 7.43 (d, 
J=2.1, 1H), 7.81 (d, J=9.3, 1H), 7.95 (s, 1H), 8.19 (d, J=9.3, 1H). 13C NMR 
(75MHz, CDCl3) δ 38.8, 45.7, 47.0, 51.7, 54.6, 55.8, 80.9, 81.0, 100.6, 108.6, 
114.0, 116.8,120.3, 124.6, 125.4, 125.7, 126.6, 137.0, 144.4, 151.0, 156.1. MS 
(APCI) m/z [M+] 409.3. HPLC: condition A1 tR=3.022min P=96.8%, condition 
A2 tR=2.85min P=95.6%. 
 
N-(8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-yl)-6-chloro-2-methoxyacridin-9-
amine (43): Yellow solid. Yield 45%. 1H NMR (300MHz, CDCl3) δ 1.77 (m, 
2H), 1.94 (t, J=11.2, 2H), 2.31 (t, J=6.9, 2H), 2.57 (t, J=7.6, 3H), 2.86 (d, J=11.5, 
2H), 3.64 (m, 1H), 3.89 (s, 3H), 4.44 (s, 2H), 7.11 (d, J=6.3, 3H), 7.23 (d, J=8.3, 
3H),  7.36 (dd, J1=2.1, J2=9.4, 1H), 7.87 (d, J=9.3, 1H), 7.96 (d, J=9.4, 1H), 8.06 
(s, 1H). 13C NMR (75MHz, CDCl3) δ 28.5, 33.4, 33.8, 52.3, 55.1, 57.5, 98.7, 
117.3, 119.4, 123.8, 124.6, 124.8, 125.5, 127.7, 128.0, 128.1, 130.9, 134.5, 141.7, 
146.4, 147.6, 148.6, 156.0. MS (APCI) m/z [M+] 458.5. HPLC: condition A1 
tR=3.871min P=97.5%, condition A2 tR=3.758min P=97.2%. 
 
6-Chloro-2-methoxy-9-phenoxyacridine (44): Light yellow solid. Yield 98%. 
1H NMR (300MHz, CDCl3) δ 3.80 (s, 3H), 6.86 (d, J=8.4, 2H), 7.07 (t, J=7.3, 
1H), 7.16 (s, 1H), 7.30 (t, J=7.7, 2H), 7.37 (d, J=9.2, 1H), 7.48 (d, J=9.5, 1H), 
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7.98 (d, J=9.3, 1H), 8.16 (d, J=9.4, 1H), 8.26 (s, 1H). MS (APCI) m/z [M+] 335.6. 
HPLC: condition A1 tR=3.455min P=96.8%, condition A2 tR=3.42min P=95.8%. 
 
6-Chloro-2-methoxy-N-methyl-N-phenylacridin-9-amine (45): Yellow solid. 
Yield 86%. 1H NMR (300MHz, CDCl3) δ 3.52 (s, 3H), 3.77 (s, 3H), 6.56 (d, 
J=7.2, 2H), 6.78 (t, J=7.3, 1H), 7.01 (d, J=2.6, 1H), 7.18 (t, J=7.8, 2H), 7.35 (dd, 
J1=1.8, J2=9.2, 1H), 7.46 (dd, J1=2.7, J2=9.4, 1H), 7.80 (d, J=9.2, 1H), 8.14 (d, 
J=9.4, 1H), 8.25 (d, J=1.7, 1H). 13C NMR (75MHz, CDCl3) δ 39.2, 55.5, 99.3, 
112.8, 118.1, 123.3, 125.3, 125.8, 126.1, 127.6, 128.6, 129.4, 131.7, 135.0, 147.8, 
148.5, 148.8, 148.9, 157.9. MS (APCI) m/z [M+H+] 349.5. Elemental analysis: 
found 72.06% C (calcd 72.31%), found 4.58% H (calcd 4.91%), found 7.65% N 
(calcd 8.03%). 
 
6-Chloro-2-methoxyacridin-9-amine (46): Yellow solid. Yield 85%. 1H 
NMR (300 MHz, CD3OD) d 8.71–7.20 (m, 6H), 3.96 (s, 3H). MS (ESI, MeOH) 





N1-(Acridin-9-yl)-N4,N4-diethylbenzene-1,4-diamine (48): Brownish red solid. 
Yield 88%. 1H NMR (300MHz, CDCl3) δ 1.09 (t, J=6, 6H), 3.25 (q, J=6, 4H), 
6.56 (d, J=9, 2H), 6.84 (d, J=9, 2H), 7.21-7.16 (m, 2H), 7.57 (t, J=9, 2H), 7.94 (t, 
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J=9, 4H). MS (ESI) m/z [M+] 341.2. HPLC: condition B3 tR=1.353min P=98.9%, 
condition B6 tR=1.368min P=98.9%. 
 
Group 6 
3-Chloro-5,6,7,8-tetrahydroacridin-9-amine (49): Pale yellow solid. Yield 
56%. 1H NMR (300MHz, CDCl3) δ 1.90 (m, 4H), 2.53 (t, J=5.3, 2H), 2.92 (t, 
J=5.3, 2H), 7.37 (dd, J1=1.5, J2=9.0, 1H), 7.62 (d, J=1.4, 1H), 8.13 (d, J=9.0, 
1H). 13C NMR (75MHz, CD3OD) δ 22.2, 22.7, 23.8, 30.1, 111.2, 115.0, 120.3, 
125.7, 126.9, 139.2, 140.6, 154.5, 155.9. MS (APCI) m/z [M+H+] 234.2. HPLC: 
condition A1 tR=3.255min P=97.5%, condition A2 tR=3.147min P=96.8%. 
 
N'-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-yl)-N,N-diethyl-ethane-1,2-
diamine (50): Orange solid. Yield 60%. 1H NMR (300MHz, CDCl3) δ 1.05 (t, 
J=7.1, 6H), 1.88 (t, J=5.5, 4H), 2.58 (q, J=7.1, 4H), 2.67 (t, J=5.6, 4H), 3.01 (m, 
2H), 3.55 (dd, J1=5.2, J2=10.4, 2H), 5.52 (s, 1H), 7.19 (dd, J1=1.9, J2=9.1, 1H), 
7.88 (d, J=1.9, 1H), 7.95 (d, J=9.1, 1H). 13C NMR (75MHz, CDCl3) δ 11.6, 22.4, 
22.7, 24.4, 33.4, 45.4, 45.9, 52.3, 114.6, 117.7, 123.6, 124.7, 126.6, 133.8, 147.4, 
151.1, 158.6. MS (APCI) m/z [M+H+] 333.5. HPLC: condition A1 tR=3.213min 
P=96.6%, condition A2 tR=3.248min P=96.9%. 
 
N-(1-Benzylpiperidin-4-yl)-6-chloro-1,2,3,4-tetrahydroacridin-9-amine (51): 
Orange solid. Yield 56%. 1H NMR (300MHz, CDCl3) δ 1.68 (m, 2H), 1.88 (m, 
4H), 2.00 (d, J=12.4, 2H), 2.12 (t, J=11.4, 2H), 2.67 (m, 2H), 2.89 (d, J=11.8, 
2H), 3.07 (m, 2H), 3.54 (s, 2H), 3.64 (m, 1H), 7.28 (d, J=2.3, 1H), 7.31 (m, 5H), 
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7.83 (d, J=9.0, 1H), 7.97 (d, J=1.8, 1H). 13C NMR (75MHz, CDCl3) δ 22.4, 22.7, 
24.7, 33.7, 34.0, 52.2, 55.6, 62.8, 117.8, 119.2, 124.1, 124.8, 127.0, 127.1, 128.1, 
129.0, 134.1, 137.8, 147.3, 149.9, 159.4. MS (APCI) m/z [M+H+] 407.6. HPLC: 
condition A1 tR=3.358min P=96.9%, condition A2 tR=3.348min P=96.5%. 
 
(6-Chloro-1,2,3,4-tetrahydro-acridin-9-yl)-phenyl-amine (52): Orange solid. 
Yield 80%. 1H NMR (300MHz, CDCl3) δ 1.82 (d, J=5.5, 2H), 1.90 (d, J=5.9, 
2H), 2.68 (t, J=6.0, 2H), 3.09 (t, J=6.3, 2H),  6.66 (d, J=7.8, 2H), 6.90 (t, J=7.3. 
2H), 7.17 (m, 2H), 7.64 (d, J=8.9, 1H), 7.94 (d, J=1.3, 1H). 13C NMR (75MHz, 
CDCl3) δ 22.5, 22.6, 25.1, 33.8, 116.7, 120.9, 121.1, 123.2, 124.9, 125.6, 127.4, 
129.2, 134.3, 143.4, 144.1, 147.6, 161.1. MS (APCI) m/z [M+] 309.7. HPLC: 
condition A1 tR=3.422min P=97.8%, condition A2 tR=3.456min P=98.2%. 
 
N1-(3-Chloro-5,6,7,8-tetrahydroacridin-9-yl)-N4,N4-diethylbenzene-1,4-
diamine (53): Purple solid. Yield 45%. 1H NMR (300MHz, CDCl3) δ 1.14 (t, 
J=7.0, 6H), 1.89 (m, 4H), 2.63 (t, J=3.0, 2H), 3.10 (t, J=3.1, 2H), 3.31 (dd, 
J1=7.0, J2=14.0, 4H), 6.59 (d, J=8.9, 2H), 6.79 (d, J=8.8, 2H), 7.10 (dd, J1=1.9, 
J2=9.1, 1H), 7.62 (d, J=9.1, 1H), 7.99 (s, 1H). 13C NMR (75MHz, CDCl3) δ 12.5, 
22.3, 22.6, 24.7, 33.1, 44.6, 113.0, 117.9, 118.6, 122.2, 124.8, 125.4, 126.1, 132.3, 
134.7, 144.7, 146.5, 146.7, 159.2. MS (APCI) m/z [M+H+] 381.6.  HPLC: 
condition A1 tR=3.585min P=96.4%, condition A2 tR=3.523min P=96.0%. 
 
(6-Chloro-1,2,3,4-tetrahydro-acridin-9-yl)-[4-(4-methyl-piperazin-1-yl)-
phenyl]-amine (54): Gray solid. Yield 52%. 1H NMR (300MHz, CDCl3) δ 1.87 
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(m, 2H), 2.36 (s, 3H), 2.59 (m, 4H), 2.66 (t,2H) 3.08 (m, 2H), 3.14 (m, 2H), 3.63 
(b, 2H), 6.64 (d, J=8.7, 1H), 6.73 (d, J=8.8, 1H), 6.81 (dd, J1=4.6, J2=8.6, 2H), 
7.14 (dd, J1=1.7, J2=9.0, 1H), 7.62 9d, J=9.0, 1H), 7.95 (d, J=1.6, 1H). 13C NMR 
(75MHz, CDCl3) δ22.5, 25.0, 33.6, 45.9, 49.6, 50.6, 55.1, 116.1, 117.2, 118.6, 
119.9, 120.3, 125.1, 127.0, 134.3, 136.7, 140.1, 144.3, 146.7, 160.3. MS (ESI) 





7-Chloroquinolin-4-amine (55): Red solid. Yield 67%. 1H NMR (300MHz, 
DMSO-d6) 6.59 (d, J=5.1, 1H), 7.41 (d, J=8.9, 1H), 7.70 (d, J=8.9, 1H), 7.96 (d, 
J=0.9, 1H), 8.52 (d, J=5.0, 1H). 13C NMR (75MHz, DMSO-d6) δ 104.0, 105.2, 
121.6, 124.7, 125.7, 128.7, 129.0, 151.7, 152.1. MS (APCI) m/z [M+H+] 179.03. 
HPLC: condition A1 tR=2.544min P=98.6%, condition A2 tR=2.444min P=97.6%. 
 
N'-(7-Chloro-quinolin-4-yl)-N,N-diethyl-ethane-1,2-diamine (56): White solid. 
Yield 60%. 1H NMR (300MHz, CDCl3) δ 1.06 (t, J=7.1, 6H), 2.59 (dd, J1=7.0, 
J2=14.1, 4H), 2.79 (t, J=5.4, 2H), 3.24 (t, J=5.2, 2H), 6.32 (d, J=5.3, 2H), 7.32 (d, 
J=7.3, 1H), 7.71 (d, J=8.9, 1H), 7.93 (s, 1H), 8.48 (d, J=5.1, 1H). 13C NMR 
(75MHz, CDCl3) δ 11.7, 39.6, 46.3, 50.4, 99.0, 117.2, 121.3, 125.0, 128.1, 134.6, 
148.6, 149.9, 151.6. MS (APCI) m/z [M+H+] 279.3. Elemental analysis: found 




(1-Benzyl-piperidin-4-yl)-(7-chloro-quinolin-4-yl)-amine (57): Red solid. Yield 
53%. 1H NMR (300MHz, CDCl3) δ 1.62 (dd, J1=10.3, J2=20.3, 2H), 2.07 (d, 
J=11.9, 2H), 2.16 (t, J=11.4, 2H), 2.86 (d, J=11.7, 2H), 3.45 (m, 1H), 3.51 (s, 
2H), 5.24 (d, J=6.6, 1H), 6.36 (d, J=5.5, 1H), 7.24 (m, 2H), 7.30 (m, 3H), 7.66 (d, 
J=9.0, 1H), 7.93 (d, J=1.9, 1H), 8.46 (d, J=5.4, 1H). 13C NMR (75MHz, CDCl3) δ 
31.5, 49.6, 51.9, 62.8, 99.1, 117.0, 121.1, 124.9, 126.9, 128.0, 128.3, 128.9, 134.6, 
137.9, 148.5, 149.0, 151.6. MS (APCI) m/z [M+H+] 353.5. HPLC: condition A1 
tR=3.278min P=96.5%, condition A2 tR=3.335min P=97.0%. 
 
(7-Chloro-quinolin-4-yl)-phenyl-amine (58): White solid. Yield 73%. 1H NMR 
(300MHz, CDCl3) δ 6.96 (d, J=5.3, 1H), 7.22 (t, J=7.4, 1H), 7.30 (d, J=7.5, 2H), 
7.43 (d, J=8.4, 2H), 7.47 (m, 1H), 7.89 (d, J=9.0, 1H), 8.04 (d, J=2.0, 1H), 8.54 
(d, J=5.3, 1H). 13C NMR (75MHz, CDCl3) δ 102.4, 118.0, 121.2, 122.9, 125.1, 
126.2, 128.8, 129.8, 135.4, 139.3, 147.8, 149.4, 151.7. MS (APCI) m/z [M+] 
255.6. HPLC: condition A1 tR=3.784min P=97.0%, condition A2 tR=3.546min 
P=96.5%. 
 
N1-(7-Chloroquinolin-4-yl)-N4,N4-diethylbenzene-1,4-diamine (59): Yellow 
solid. Yield 96%. 1H NMR (300MHz, CDCl3) δ 1.20 (t, J=7.0, 6H), 3.39 (q, 
J=7.0, 4H), 6.62 (d, J=5.5, 1H), 6.73 (d, J=8.9, 2H), 7.14 (d, J=8.8, 2H), 7.43 (dd, 
J1=2.0, J2=9.0, 1H), 7.85 (d, J=8.9, 1H), 8.02 (d, J=2.0, 1H), 8.42 (d, J=5.3, 1H). 
13C NMR (75MHz, DMSO-d6) δ 12.4, 43.7, 100.3, 112.2, 117.6, 124.2, 124.4, 
126.2, 127.0, 127.4, 133.6, 145.4, 149.3, 149.8, 151.7. MS (APCI) m/z [M+H+] 
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326.5. HPLC: condition A1 tR=3.325min P=95.2%, condition A2 tR=3.358min 
P=95.8%. 
 
7-Chloro-N-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-amine (60): Green 
solid. Yield 94%. 1H NMR (300MHz, DMSO-d6) δ 2.22 (s, 3H), 2.45 (t, 4H), 
3.13 (t, 4H), 6.61 (d, J=5.4, 1H), 6.99 (d, J=8.8, 2H), 7.19 (d, J=8.7, 2H), 7.52 
(dd, J1=2.0, J2=9.0, 1H), 7.85 (d, J=2.0, 1H), 8.36 (d, J=5.4, 1H), 8.41 (d, J=9.1, 
1H), 8.92 (s, 1H). 13C NMR (75MHz, DMSO-d6) δ 45.7, 48.2, 54.6, 100.5, 116.1, 
117.7, 124.2, 124.5, 125.1, 127.5, 130.7, 133.7, 148.4, 149.2, 149.4, 151.8. MS 
(APCI) m/z [M+H+] 353.6. Elemental analysis: found 68.34% C (calcd 68.08%), 
found 5.49% H (calcd 6.00%), found 15.50% N (calcd 15.88%).
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Appendix 2: Liquid chromatography tandem mass spectrometry 
 
LC/MS/MS analyses were performed using an Agilent 1100 HPLC system 
(Agilent Technologies, Santa Clara, CA, USA) interfaced with a hybrid triple 
quadrupole linear ion trap mass spectrometer (QTRAP MS) equipped with 
TurboIonSpray ESI source (2000 QTRAP, Applied Biosystems, Foster City, CA, 
USA).  Chromatographic separations were performed on a Luna C18(2) 3 µm 50 x 
2 mm i.d. column (Phenomenex, Torrance, CA, USA). The column heater and 
autosampler were kept at 60oC and 4ºC, respectively. The flow rate was 0.50 
mL/min and the mobile phases consisted of 0.1% formic acid in 10 mM 
ammonium acetate (solvent A) and acetonitrile (solvent B). The optimized elution 
conditions for compound 16 were: 17 to 65% solvent B (0.00–3.00 min), 65 to 
100% solvent B (3.00–3.01 min), isocratic at 100% solvent B (3.01–4.00 min) 
and isocratic at 17% solvent B (4.01–11.00 min). The optimized elution 
conditions for quinacrine were: 0 to 40% solvent B (0.00-2.00min), 40-100% 
solvent B (2.00-2.01min), isocratic at 100% solvent B (2.01-3.00min), isocratic at 
0% solvent B (3.01-8.00min). 
 
All the MS experiments were performed using electrospray positive ionization 
mode (ESI +ve). Multiple reaction monitoring (MRM) experiments using m/z 
433.2 to 348.3 and 400.3 to 327.2 were performed to quantify compound 16 and 
quinacrine, respectively. The MS conditions for the MRM experiment are 
summarized in Table A2 below. All data were acquired at unit resolution and the 
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dwell time was set to 300 ms for both compound 16 and quinacrine. Data 
processing was performed using Analyst 1.4.2 software (Applied Biosystems). 
 




Curtain gas, psi 25 
IonSpray voltage, V 4500 
Temperature, oC 550 
Gas 1, psi 55 
Gas 2, psi 55 
Interface heater ON 
CAD gas Medium 
Entrance potential for compound 16, V 10 
Entrance potential for quinacrine, V 11 
Declustering potential for compound 16, V 87 
Declustering potential for quinacrine, V 31 
Collision energy for compound 16, V 42 
Collision energy for quinacrine, V 40 
Collision cell entrance potential for compound 16, V 22 
Collision cell entrance potential for quinacrine, V 40 
Collision cell exit potential for compound 16, V 5 
Collision cell exit potential for quinacrine, V 4 
 
Figure A2. MRM chromatograms on analysis of compound 16 (A) and 







Appendix 3: ClogP and SlogP values 
Compound EC50 in ScN2a (µM) EC50 in F3 (µM) ClogPa SlogPb 
Quinacrine 0.23 1.88 6.72 3.97 
1 0.021 NDc 6.23 2.81 
2 0.11 NDc 5.51 2.42 
3 0.14 NDc 6.56 3.20 
4 0.15 NDc 6.41 3.59 
5 0.25 NDc 7.12 5.28 
6 0.32 NDc 7.12 5.28 
7 0.51 NDc 7.12 5.28 
8 1.01 NDc 8.18 6.06 
9 0.48 NDc 8.18 6.06 
10 1.06 NDc 7.75 5.81 
11 0.18 NDc 8.31 6.20 
12 4.24 NDc 8.31 6.20 
13 0.9 NDc 6.77 5.05 
14 1.28 NDc 6.77 5.05 
15 0.29 1.49 6.17 3.55 
16 0.1 0.68 6.17 3.55 
17 0.08 NDc 6.87 3.94 
19 0.035 NDc 4.94 4.88 
22 0.06 0.86 7.14 2.39 
23 1.23 4.1 6.15 3.18 
24 0.099 0.64 7.98 5.05 
25 0.54 NDc 6.95 5.21 
32 0.42 0.8 6.82 4.39 
33 0.15 0.63 7.32 4.70 
34 0.28 NDc 7.53 5.05 
35 0.082 NDc 6.74 4.40 
36 0.55 NDc 6.25 4.27 
37 0.13 0.19 6.96 4.17 
38 0.076 0.69 7.46 4.48 
41 0.093 1.04 7.34 4.56 
42 0.027 NDc 5.02 0.30 
43 0.054 0.54 7.13 4.93 
45 2.51 NDc 6.94 5.24 
46 0.13 NDc 4.17 3.05 
48 0.24 NDc 7.09 5.40 
50 0.51 NDc 6.15 2.52 
51 0.54 1.19 6.73 4.11 
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54 0.082 NDc 6.25 3.26 
56 1.56 NDc 4.58 1.64 
57 0.15 1.2 5.16 3.23 
60 0.14 2.04 4.68 2.39 
 
a: determined by ChemDraw version 8.0 
b: determined by Molecular Operating Environment version 2009.10 
c: not determined. 
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Appendix 4: ClustalW2 sequence alignment of TcAChE (PDB 


























































































:*:  *:::.*: .*::*:: **.* *.***:******.**   
 
Note: star denotes conservation, double dot denotes exact match, single dot 
denotes high similarity, and blank means difference. 
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Appendix 5: Superimposing 3D structures of TcAChE and 
hAChE using MOE 
 
In the diagram, 1ACJ  is displayed in blue and 1B41 in pink. RMSD is 4.054Å. 
The amino acid residues at the active site and peripheral site are well-preserved. 
 
 
 
